Alternative blood risk categorization models for South Africa by Leipoldt, Edmund Johann
ALTERNATIVE BLOOD RISK CATEGORIZATION MODELS 
FOR SOUTH AFRICA 
 
by 
EDMUND JOHANN LEIPOLDT 
N.D.: Med. Lab. Tech. (Blood Transfusion Technology) 
N.H.D.: Med. Tech. (Blood Transfusion Technology) 
 
A dissertation submitted in fulfilment of the requirements for the degree 
 
MAGISTER TECHNOLOGIAE: BIOMEDICAL TECHNOLOGY 
in the 
School of Health Technology 
at the 
Central University of Technology 
 
 
Study Supervisor (CUT):  Dr. C. E. Brand, D. Tech. 
Study Co-supervisor (SANBS): Mrs. J. P. Swanevelder, M. Med. Sc. 
 
 
 
 
BLOEMFONTEIN 
April 2008 
 II 
INDEX 
 
CHAPTER / 
SECTION  
CONTENTS PAGE 
    INDEX II 
    LIST OF TABLES VI 
    LIST OF FIGURES VIII 
    DECLARATION OF INDEPENDENT 
WORK 
X 
    ACKNOWLEDGEMENTS XI 
    SUMMARY XII 
    OPSOMMING XV 
1.    INTRODUCTION 1 
 
1.1. 
  
The blood transfusion services in South 
Africa 
3 
 1.2.   The blood collection process 7 
 
1.3. 
  
Determination of the blood group and 
markers for blood transfusion transmissible 
diseases 
10 
 1.4.   Blood processing 11 
 1.5.   The issuing of blood 13 
 1.6.   The broader African context 14 
 1.7.   Motivation for this study 19 
2.    LITERATURE AND HISTORICAL REVIEW 20 
 
2.1. 
  
The early years of HIV risk management in 
the SABTS 
21 
 III 
CHAPTER / 
SECTION  
CONTENTS PAGE 
 
2.2. 
  
The broader base of HIV transmission and 
implementation of HIV testing in the 
SABTS 
25 
 
2.3. 
  
Risk management by donor selection in the 
SABTS / SANBS 
29 
 
2.4. 
  
Risk management by donation risk 
category hierarchy in the SABTS / SANBS 
33 
 
2.5. 
  
The application of the SABTS / SANBS risk 
management system in use since 1999 
39 
 
2.6. 
  
The demerits of the SABTS / SANBS risk 
management system in use since 1999 
43 
 
2.7. 
  
Alternative models for donation risk 
categorization 
45 
3.    AIM OF THE STUDY 53 
 
3.1. 
  
Phase 1: Defining suitable parameters for 
the Age-based Model 
53 
 
3.2. 
  
Phase 2: Comparison of the alternative 
blood risk categorization models with the 
SABTS 1999 Model 
53 
  
3.2.1. 
 
The difference in HIV prevalence within 
each risk category 
54 
  
3.2.2. 
 
The availability of low-risk red blood cells 
for transfusion 
55 
 3.3.   The best model for SANBS 55 
 3.4.   The African potential 56 
4.    METHODOLOGY 57 
 4.1.   Materials used 57 
  
4.1.1. 
 
Phase 1: The development of the 
parameters for the Age-based Model 
58 
 IV 
CHAPTER / 
SECTION  
CONTENTS PAGE 
  
4.1.2. 
 
Phase 2: The comparative analysis of the 
effectiveness of the different suggested 
risk categorization models 
59 
  
4.1.3. 
 
Donations specifically excluded from this 
study 
60 
 4.2.   Methods 62 
  4.2.1.  Collection and entry of donation data 62 
  4.2.2.  Statistical analysis 63 
5.    RESULTS AND DISCUSSION 66 
 
5.1 
  
Phase 1: Results of the analysis of HIV-
positive donations 
67 
  5.1.1.  Male donors 68 
  5.1.2.  Female donors 73 
 
5.2. 
  
Phase 2: Results of the data from the 
collected donations 
79 
  5.2.1.  Potential risk profile of the models 80 
  
5.2.2. 
 
Availability of low-risk blood according to 
the models 
83 
 5.3.   Discussion 85 
  5.3.1.  Potential risk profile of the five models 85 
   5.3.1.1. The SABTS 1999 Model 87 
   5.3.1.2. The Donation Interval Model 91 
   5.3.1.3 The Combination Model 94 
   5.3.1.4. The SANBS 2005 Model 98 
   5.3.1.5. The Age-based Model 102 
 V 
CHAPTER / 
SECTION  
CONTENTS PAGE 
  
5.3.2. 
 
The risk assessment of the donation prior 
to the sero-converted donation 
106 
  5.3.3.  The availability of sufficient blood 107 
   5.3.3.1 The SABTS 1999 Model 107 
   5.3.3.2. The Donation Interval Model 109 
   5.3.3.3. The Combination Model 113 
   5.3.3.4. The SANBS 2005 Model 116 
   5.3.3.5. The Age-based Model 119 
6. 
   
CONCLUSIONS AND 
RECOMMENDATIONS 
122 
 6.1.   Conclusions 122 
 6.2.   Recommendations 125 
7.    REFERENCES 129 
Appendix 1 Ethics Committee letter of approval XVIII 
Appendix 2 HIV-positive donations received by 
SANBS, Inland Region between 1997 and 
2006 
XIX 
Appendix 3 HIV-positive donations received by 
SANBS, Bloemfontein between October 
2004 and September 2005 
XLVII 
Appendix 4 Risk categorization of last donations prior 
to HIV-positive donations received by 
SANBS, Bloemfontein between October 
2004 and September 2005 
XLVIII 
Appendix 5 Risk categorization of donations received 
by SANBS, Bloemfontein between October 
2004 and September 2005 
On CD 
 
 VI 
LIST OF TABLES 
 
TABLE DESCRIPTION PAGE 
1.1 Blood component products prepared from donated whole 
blood 
12 
1.2 Reported adult (aged 15 – 49) HIV prevalence in various 
countries of the world 
16 
2.1 Tests for HIV used by the SABTS and SANBS between 
1985 and 2005 
27 
2.2 Key principles embodied in the SABTS Blood Safety Policy 30 
2.3 HIV-risk assessment lifestyle questions (BTS53E rev. 3) 32 
2.4 Indicators for donation risk category in the SABTS 1999 
Model 
40 
2.5 Risk category application of the SABTS 1999 Model 41 
2.6 SABTS 1999 Model parameters 42 
2.7 Donation Interval Model parameters 46 
2.8 Combination Model parameters 48 
2.9 Risk category application of the SANBS 2005 Model in the 
Inland Region of SANBS 
49 
2.10 SANBS 2005 Model parameters defined for the Inland 
Region 
50 
3.1 Summary of the blood risk categorization models 
investigated 
54 
 
5.1 Summary of the demographic indicators (n=497) included 
in the analysis of HIV-positive donations (Phase 1) 
66 
5.2 Summary of the demographic indicators (n=26664) 
included in the analysis of the collected donations    
(Phase 2) 
67 
5.3 Analysis of donations from regular male donors versus 
HIV-positive donations from regular male donors 
69 
 VII 
TABLE DESCRIPTION PAGE 
5.4 Contribution of age-groups to percentage of donations and 
percentage of HIV-positive donations from regular male 
donors 
73 
5.5 Analysis of donations from regular female donors versus 
HIV-positive donations from regular female donors 
74 
5.6 Contribution of age-groups to percentage of donations and 
percentage of HIV-positive donations from regular female 
donors 
78 
5.7 Age-based Model parameters 79 
5.8 HIV prevalence per donation risk categories according to 
the studied models (n=26664)  
81 
5.9 Summary of the risk categories of the donations prior to 
the HIV-positive donation 
83 
5.10 Availability of blood according to risk category within each 
model 
84 
5.11 Usage of blood products during 2005 in the area served by 
the Bloemfontein branch of SANBS 
85 
 
 
 
 
 
 
 
 
 
 
 
 
 VIII 
LIST OF FIGURES 
 
FIGURE DESCRIPTION PAGE 
1.1 Map of South Africa indicating the area served by 
SANBS 
5 
1.2 Approximate area served by the Bloemfontein Branch of 
SANBS 
6 
1.3 Blood packs used for blood collection during 2004 and 
2005 
9 
1.4 World HIV prevalence 17 
2.1 Schematic diagram of the relationship between the 
development of the p24 antigen and anti-HIV antibodies 
28 
5.1 Graphic representation of relationship between donations 
from regular male donors (n=14603) and HIV-positive 
donations from regular male donors (n=259) 
72 
5.2 Graphic representation of relationship between donations 
from regular female donors (n=8838) and HIV-positive 
donations from regular female donors (n=238) 
77 
5.3 Percentage of HIV-positive donations by risk category 
using the SABTS 1999 Model 
89 
5.4 HIV prevalence per risk category using the SABTS 1999 
Model 
90 
5.5 Percentage of HIV-positive donations by risk category 
using the Donation Interval Model 
92 
5.6 HIV prevalence per risk category using the Donation 
Interval Model 
93 
5.7 Percentage of HIV-positive donations by risk category 
using the Combination Model 
96 
5.8 HIV prevalence per risk category using the Combination 
Model 
97 
5.9 Percentage of HIV-positive donations by risk category 
using the SANBS 2005 Model 
100 
 IX 
FIGURE DESCRIPTION PAGE 
5.10 HIV prevalence per risk category using the SANBS 2005 
Model 
101 
5.11 Percentage of HIV-positive donations by risk category 
using the Age-based Model 
104 
5.12 HIV prevalence per risk category using the Age-based 
Model 
105 
5.13 Percentages of whole blood donations by risk category 
using the SABTS 1999 Model 
108 
5.14 Percentages of whole blood donations by risk category 
using the Donation Interval Model 
111 
5.15 Percentage of whole blood donations by risk category 
using the Combination Model 
115 
5.16 Percentage of whole blood donations by risk category 
using the SANBS 2005 Model 
117 
5.17 Percentage of whole blood donations by risk category 
using the Age-based Model 
120 
 
 
 
 
 
 
 
 
 
 
 
 
 
 X 
DECLARATION OF INDEPENDENT WORK 
 
I, Edmund Johann Leipoldt, hereby declare that this project submitted for 
the degree MASTER TECHNOLOGIAE: BIOMEDICAL TECHNOLOGY in 
the SCHOOL OF HEALTH TECHNOLOGY at the CENTRAL UNIVERSITY 
OF TECHNOLOGY, FREE STATE, is my own independent work that has 
not been submitted before to any institution, by me or anyone else as part of 
any qualification. 
 
 
 
 
____________________     _____________ 
Edmund Johann Leipoldt     DATE 
 
 
 
 
 
 
 
 
 
 
 
 XI 
ACKNOWLEDGEMENTS 
 
I would like to express my gratitude to all the people who supported me and 
who provided assistance in the course of this study. In particular I want to 
thank the following people: 
Mr Dave Brown, whose suggestion for a model started the ball rolling, 
My wife Bertie, who provided support and understanding through many late 
nights and weekends, 
The administrative staff of the Bloemfontein Branch of SANBS, who assisted 
in the collection of the data used in my research, in a way which I could 
apply with ease, 
The management of SANBS, who were prepared to allow me to undertake a 
study on an extremely sensitive issue from a socio-political point of view, 
And my study supervisors Dr C. E. Brand and Mrs J. P. Swanevelder, for 
their invaluable contribution to the quality of this research. 
 
 
 
 
 
 
 
 
 
 
 XII 
SUMMARY 
 
Blood transfusions carry a number of risks, one of which is transmitting 
HIV/AIDS from an infected donor. Since HIV is sexually and parenterally 
transmitted, the initial HIV risk management of donated blood in the early 
1980‟s consisted of screening by visual assessment and completion of a 
lifestyle questionnaire, followed by deferral of practicing homosexual and 
bisexual male donors and intravenous drug addicts. The visual assessment 
was replaced by tests for antibodies directed against HIV, from the middle 
1980‟s. In the early 1990‟s HIV was increasingly found in the black 
population of South Africa, particularly among black women. By 1998 0.26% 
of the received donations returned a positive test for HIV-1. In 1999 the 
South African Blood Transfusion Service (SABTS) Blood Safety Policy was 
introduced, including a donation HIV-risk categorization model which used 
the donor ethnic group, gender and donation history as indicators of the risk 
of exposure to HIV. 
 
The unacceptable use of the donor ethnic group as an indicator was the 
motivation to seek a suitable alternative donation risk categorization model 
which excludes the donor‟s ethnic group. The use of a more acceptable 
model with a high level of accuracy in predicting the risk of exposure to HIV 
has the potential of contributing to the reduced risk of HIV transmission 
through blood transfusion in South Africa. 
 
 XIII 
The aim of this study was to compare the suitability of four alternative 
models based on the information obtained from donors. Donations from new 
and lapsed donors were categorized in the highest applicable risk category 
in each model. The study was divided into two phases to achieve the aim. 
The first phase needed to determine suitable parameters for a model which 
uses the donor‟s age as an indicator. For this phase the ages of the regular 
donors returning an HIV-positive test result, were analysed. The second 
phase was to evaluate the effectiveness of the four suggested alternative 
blood donation risk categorization models against the model introduced by 
the SABTS in 1999. During this phase the donor demographic data and 
donation histories of donors who made donations at the Bloemfontein 
branch of the South African National Blood Service (SANBS) between 
October 2004 and September 2005, were analysed statistically. This phase 
honed in on two aspects to evaluate the effectiveness of the alternative 
models. Firstly the percentages of HIV-positive donations found in each risk 
category of each model, were determined as indicators of the residual risk of 
HIV-positive donations within the window period. Secondly the percentages 
of the collected blood donations allocated to each risk category within each 
model, were analysed to give an indication of the availability of “safe” blood 
associated with each of the models. 
 
The first phase of the study highlighted the difference in the age-group 
prevalence between male and female regular donors who returned an HIV-
positive test result. Potentially suitable parameters for an Age-based Model 
were formulated by comparing this data with the ages of the donors who 
 XIV 
donated in Bloemfontein during the twelve months covered by this study. 
The second phase compared a Donation Interval Model, a Combination 
Model (using donation interval, gender and ethnic group as indicators), the 
SANBS 2005 Model (using age and gender as indicators) and an Age-
based Model (using age and gender as indicators) with the SABTS 1999 
Model (using gender and ethnic group as indicators). 
 
This study has shown that each of the models analysed has its advantages 
and disadvantages. The SANBS 2005 Model proved the best model without 
an ethnic indicator, for SANBS. Several recommendations regarding further 
investigation emanating from the results of this study were made. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 XV 
OPSOMMING 
 
Bloedoortappings is onderhewig aan „n aantal risikos waaronder die oordrag 
van MIV/VIGS vanaf „n geïnfekteerde skenker. Aangesien MIV seksueel en 
parenteraal oordraagbaar is, het die aanvanklike MIV risiko-bestuur van 
geskenkte bloed in die vroeë 1980‟s bestaan uit ‟n visuele beoordeling en 
die voltooiing van ‟n lewensstyl vraelys met gepaardgaande wegwysing van 
praktiserende homoseksuele en biseksuele manlike skenkers en 
intraveneuse dwelmverslaafdes. Die visuele beoordeling is gedurende die 
middel 1980‟s vervang met toetse om teenliggame teen MIV op te spoor. 
Gedurende die vroeë 1990‟s is MIV toenemend onder die swart bevolking 
van Suid-Afrika gevind, veral onder swart vrouens. Teen 1998 is 0.26% van 
die skenkings ontvang positief getoets vir MIV-1. In 1999 is die Suid-
Afrikaanse Bloedoortappingsdiens (SABOD) Bloed Veiligheidsbeleid 
geïmplementeer, insluitende ‟n skenking MIV-risiko kategoriseringsmodel 
wat die skenker se etniese groep, geslag en vorige geskiedenis van 
bloedskenkings gebruik het as aanwyser van die risiko van blootstelling aan 
MIV. 
 
Die onaanvaarbare gebruik van die skenker se etniese groep as aanwyser 
was die beweegrede vir ‟n alternatiewe skenking risiko 
kategoriseringsmodel wat die skenker se etniese groep uitsluit. Die gebruik 
van ‟n meer aanvaarbare model, met ‟n hoë akkuraatheid ten opsigte van 
die voorspelling van die risiko van blootstelling aan MIV, het die potensiaal 
 XVI 
om by te dra tot die verminderde risiko van MIV oordrag deur middel van 
bloedoortapping in Suid-Afrika. 
 
Die doel van die studie was om die geskiktheid van vier alternatiewe 
modelle, gebaseer op die inligting ontvang van gereelde bloedskenkers, te 
vergelyk. Skenkings van nuwe en voormalige skenkers is gekategoriseer in 
die hoogste toepaslike risiko kategorie in elke model. Die studie is in twee 
fases verdeel om dié doel te bereik. Die eerste fase moes geskikte  
parameters identifiseer vir ‟n model gebaseer op die skenker se ouderdom. 
Tydens hierdie fase is die ouderdomme van die gereelde skenkers met ‟n 
positiewe MIV toetsresultaat, geanaliseer. Die tweede fase moes die 
effektiwiteit van die vier voorgestelde alternatiewe bloedskenking risiko 
kategoriseringsmodelle opweeg teen die model wat by die SABOD in 1999 
geimplementeer is. Tydens hierdie fase is die demografiese inligting en 
skenkingsgeskiedenis van skenkers wat by die Bloemfonteintak van die 
Suid-Afrikaanse Nasionale Bloeddiens (SANBD) tussen Oktober 2004 en 
September 2005 geskenk het, statisties geanaliseer. Die effektiwiteit van die 
alternatiewe modelle is volgens twee maatstawe beoordeel. Eerstens is die 
persentasies van die MIV-positiewe skenkings gevind in elke risiko 
kategorie vir elke model, bepaal ter aanduiding van die residuele risiko van 
MIV-positiewe skenkings in die venster-periode. Tweedens is die 
persentasies van die bloedskenkings soos toegeken aan die onderskeie 
risiko kategorieë in elke model, geanaliseer. Daarvolgens kan die 
beskikbaarheid van “veilige“ bloed ten opsigte van elk van die modelle 
bepaal word. 
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In die eerste fase is die verskil in ouderdomsgroep prevalensie tussen MIV-
positiewe manlike en vroulike gereelde skenkers uitgelig. Potensieël 
geskikte parameters vir ‟n Ouderdom-gebaseerde Model is geformuleer 
deur hierdie inligting te vergelyk met die ouderdomme van die skenkers wat 
in Bloemfontein geskenk het gedurende die twaalf maande bestek van 
hierdie studie. Die tweede fase het ‟n Skenking Interval Model, ‟n 
Kombinasie Model (met skenking interval, geslag en etniese groep as 
aanwysers), die SANBD 2005 Model (met ouderdom en geslag as 
aanwysers) en ‟n Ouderdom-gebaseerde Model (met ouderdom en geslag 
as aanwysers) vergelyk met die SABOD 1999 Model (met geslag en etniese 
groep as aanwysers). 
 
Hierdie studie het getoon dat daar voor- en nadele verbonde is aan elk van 
die vier modelle wat geanaliseer is. Die SANBD 2005 Model het geblyk die 
beste model, sonder etniese aanwyser, te wees vir die SANBD. Etlike 
aanbevelings voortspruitend uit die resultate van hierdie studie is gemaak 
aangaande verdere navorsing. 
 
 
 
 
 
 
 
 1 
CHAPTER 1: INTRODUCTION 
 
Throughout the world, blood transfusion services collect and distribute blood 
donations on the premise of these donations being made available to 
patients to save their lives in the face of life-threatening blood loss or 
haematological disease. The South African National Blood Service (SANBS) 
is no different in this respect. SANBS is obligated by the South African 
Department of Health (DoH) through its “Policy with regard to blood 
transfusion in South Africa” (South Africa: Department of Health, 1998), to 
ensure that an adequate supply of safe (low risk) blood is provided to all 
people resident in South Africa. The National Blood Transfusion Council of 
South Africa through its “Policy to protect the safety of the blood supply 
against the HIV/AIDS pandemic” (National Blood Transfusion Council of 
South Africa, 2000) provides more specific guidance in this respect to the 
blood transfusion services and the DoH. Being an organization situated in 
Africa and dependant on blood donations from the population of South 
Africa with an HIV prevalence of 16.2% in 2005 (UNAIDS, 2007) and a 
reported official infection rate or incidence of 11.4% (Williamson, 2006), the 
HIV pandemic poses a serious threat to the stated aim of providing blood 
which will save patients’ lives. This is even more relevant in the light of the 
efficiency of the transmission of HIV from infected blood donors to patients 
through blood transfusions. Swanevelder (1994) reported that the World 
Health Organization (WHO) at that time already estimated the risk of HIV 
infection following an HIV-infected transfusion to be more than 90%. The 
study by Shisana, Rehle et al (2005) under the auspices of the South 
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African Human Sciences Research Council, also indicates that 29% of 
individuals, who believed that they were at risk of being infected with HIV, 
believed that the source of the infection would be through a blood 
transfusion. 
 
The issue of finding, collecting and ultimately providing blood in sufficient 
quantities, which is safe enough to actually save each patient’s life and not 
ring the patient’s death-knell, remains a major challenge in Africa. Many 
methods of managing the risk of HIV transmission, ranging from pre-
donation donor education campaigns, to initiatives supporting the 
appropriate clinical use of blood, and covering all the various phases in the 
collection, testing, processing, issuing and transfusion stages, have been 
applied to this challenge. Some success has been achieved by the 
application of these diverse methods as shown by the lower prevalence of 
HIV in blood donors when compared to the HIV prevalence in the general 
South African population, indicated in Table 1.2. However, some risk still 
remains. It is therefore clear that a multifaceted approach will probably 
always be needed. This study will investigate the application potential of five 
alternative models with regard to one of the tools which can be applied to 
the management of the risk of transfusion transmitted HIV. The tool in this 
case being the categorization of blood donations in a hierarchy of risk, to 
allow the use of blood products with the lowest risk available, at all times. 
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1.1. The blood transfusion services in South Africa 
The DoH considers itself as being “… ultimately accountable to the 
citizens of South Africa for all aspects of blood transfusion” as cited in 
its Policy with regard to blood transfusion in South Africa (South Africa: 
Department of Health, 1998). The practice of blood transfusion in 
South Africa is therefore regulated by the Health Act of 2003. In terms 
of this Act any organization undertaking the collection, processing, 
testing and issuing of blood for transfusion to patients is required to be 
licensed by the DoH and to fulfil the obligations stipulated in the Health 
Act of 2003, the Regulations Pertaining to Blood Transfusion and the 
Standards for the Practice of Blood Transfusion in South Africa. 
SANBS was, and still is (as of April 2008), one of two blood services 
licensed by the DoH in the period covered by this study (October 2004 
to September 2005) for the collection, processing and issuing of 
voluntarily donated blood, the other service being the Western 
Province Blood Transfusion Service (WPBTS). 
 
SANBS owes its existence to the DoH’s aim as stated in its Policy with 
regard to Blood Transfusion in South Africa (South Africa: Department 
of Health, 1998) to de-fragment the provision of blood transfusion 
services in South Africa as advocated by the WHO WHA728.7 
resolution, through the voluntary amalgamation of the various blood 
transfusion services which existed in South Africa prior to 2000. The 
services which amalgamated in the course of 1998 to 2000 and 
ultimately formed SANBS, were the South African Blood Transfusion 
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Service (SABTS), the Northern Blood Transfusion Service (NoBTS), 
the Natal Blood Transfusion Service (NBTS), the Border Blood 
Transfusion Service (BBTS), the Eastern Province Blood Transfusion 
Service (EPBTS) and a small organisation operating in Durban under 
the name of Medimatch. Figure 1.1 shows a map of South Africa on 
which the approximate geographical areas served by these services 
can be identified. The SABTS with its head office in Johannesburg 
served the Mpumalanga, Gauteng, North West, Northern Cape and 
Free State provinces. The NoBTS with its head office in Pietersburg 
(now known as Polokwane) served the Limpopo province. The NBTS 
with its head office in Pinetown near Durban served Kwazulu-Natal. 
The BBTS with its head office in East London served the eastern half 
of the Eastern Cape. The EPBTS with its head office in Port Elizabeth 
served the western half of the Eastern Cape. Although participating in 
the initial amalgamation discussions, the WPBTS withdrew prior to the 
final amalgamation which brought about the creation of SANBS in April 
2000. The WPBTS with its head office in Cape Town continues to 
serve the Western Cape. Figure 1.1 also indicates the boundaries of 
the area served by SANBS and the location of Bloemfontein within this 
area. The area covered by the map in Figure 1.2 which shows the area 
served by the Bloemfontein Branch of SANBS, is also indicated. It 
should be noted that Lesotho is excluded from the area served by 
SANBS due to the fact that it is an independent sovereign country with 
its own blood transfusion service. 
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Figure 1.1: Map of South Africa indicating the area served by SANBS 
(modified from SA PLACES) 
 
At the time of this study, SANBS was operationally managed as two 
regions, namely the East Coast Region and the Inland Region. The 
East Coast Region consisted of the areas served by the former NBTS, 
BBTS, EPBTS and Medimatch, with regional head-office located in 
Pinetown, Natal. The Inland Region consisted of the areas served by 
the former SABTS and NoBTS, with regional head-office located in 
Roodepoort, Gauteng. At the next lower level, the Inland Region was 
managed through 21 branches (each under the control of a Branch 
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Manager) located in the larger centres, with each branch serving a 
particular geographical area within the Inland Region. Since the 
process of amalgamation of the services had not been completed at 
the time of this study, the operational management structure and many 
of the operational practices still differed between the two regions in 
terms of the details of the practices, specific procedures and specific 
tests. It should therefore be noted that this study is based on the 
practices, specific procedures and tests as prescribed in the Inland 
Region of SANBS during this period because the whole blood 
donations analysed in this study were obtained in the blood collection 
area of the Bloemfontein branch. Figure 1.2 shows the area served by 
the Bloemfontein branch of SANBS.  
 
 
 
Figure 1.2: Approximate area served by the Bloemfontein Branch of SANBS 
(modified from SA PLACES) 
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The mission statement of SANBS is as follows: “The mission of the 
South African National Blood Service (SANBS), an association of 
voluntary, non-remunerated blood donors, is to provide all patients with 
sufficient, safe, quality blood products and medical services related to 
blood transfusion in an equitable, cost effective manner.” (BTS53E rev. 
3, 2004). To achieve this, SANBS collects human blood from voluntary 
blood donors, determines the blood group and performs an array of 
tests for presence of transmissible diseases, processes the blood into 
different components and distributes it for transfusion to patients with 
acute blood loss or diseases resulting in a severe lack of one or more 
of the components which make up whole blood in the body. A broad 
overview of these processes, as prescribed by the Inland Region of 
SANBS, is given below. Only the processes implicated in this study will 
be discussed in greater detail in the following chapters. 
 
1.2. The blood collection process 
The blood collection process starts with the recruitment of potential 
donors whose blood is anticipated to be suitable for transfusion to 
patients. The National Blood Transfusion Council of South Africa 
(1999) lays down the minimum requirements which voluntary blood 
donors need to meet in order for their blood donations to be 
considered suitable for transfusion to patients. The basic criteria 
include the following: donor age, donation interval, general health, drug 
therapy, haemoglobin concentration or haematocrit value, pulse and 
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blood pressure, pregnancy and donor weight. All potential donors are 
medically evaluated by a physician or nursing sister prior to donation to 
ensure that the donation of blood would not harm the donor and that 
the donated blood is not expected to harm the recipient. The method of 
evaluation consists of the completion and assessment of a health 
questionnaire, a haemoglobin screening test, a blood pressure 
determination and a pulse rate determination. 
 
If the potential donor is deemed fit to donate, approximately 450ml of 
blood is taken into a container containing 70ml of an anticoagulant-
preservative solution. Various containers have been used over time as 
dictated by technology and processing requirements. During 2004 and 
2005 the choice was limited to single blood packs used for blood not 
intended for blood component preparation, and OPTI-system triple 
blood packs for blood intended for blood component preparation. 
Figure 1.3 provides a schematic diagram of these two types of blood 
packs. The whole blood donations are then sent to the branch 
Components Laboratory for processing into their main constituent 
blood components as described in 1.4. 
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Figure 1.3: Blood packs used for blood collection during 2004 and 2005 
 
In addition, two blood specimens are drawn from the pack of donated 
blood at the end of the donation process. These specimens are then 
sent to the SANBS Donor Serology and Donor Virology laboratories in 
Roodepoort for testing. One specimen is used for blood group 
determination and antibody screening, and the other for blood 
transfusion transmissible disease marker screening, as indicated in 1.3 
below.  
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1.3. Determination of the blood group and markers for blood 
transfusion transmissible diseases 
The National Blood Transfusion Council of South Africa has laid down 
very specific requirements with regard to the determination of the blood 
groups of the donations, and tests to determine the presence of 
markers for blood transfusion transmissible diseases (National Blood 
Transfusion Council of South Africa, 1999). The routine testing 
requirements for all donations prior to release as prescribed are as 
follows. One of the blood specimens taken at the end of the donation 
process is used to determine the ABO type, the Rho (D) type, the anti-
A and / or anti-B titre, and the presence of irregular blood group 
antibodies by the SANBS Donor Serology Laboratory in Roodepoort. 
This laboratory also carries out the VDRL test for antibodies to syphilis. 
 
The other specimen is tested for the presence of the hepatitis B 
surface antigen (HBsAg), the hepatitis C virus (HCV) and the human 
immunodeficiency virus (HIV) using the ELISA methodology. In the 
case of HCV, the specimens are tested for antibodies to HCV as 
indicated in SOP-DON-68 rev. 0 (1999). For HIV, the specimens are 
tested for the HIV-1.2.O antibodies as well as the HIV-1 and -2 p24 
antigens as indicated in SOP-DON-44 rev. 1 (2003). These tests are 
carried out at the SANBS Donor Virology Laboratory in Roodepoort. 
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1.4. Blood processing 
The donated unit of whole blood can be processed into a number of 
blood component products for transfusion into patients. Due to the 
scarcity of donated blood relative to the demand, virtually all whole 
blood donations are processed into their main constituent components 
of red cells, platelets and plasma. Each of these component products 
have their specific roles in the body; red cells provide the oxygen 
transport capacity, platelets play a vital role in the control of 
haemorrhage, and plasma provides coagulation factors and circulatory 
volume. Transfusions of red cell concentrates are therefore generally 
indicated in situations of severe haemorrhage or haematological 
disease affecting the patient’s red cells. Platelet concentrates are 
generally indicated in situations of haematological disease affecting the 
patient’s platelets or excessive platelet consumption during 
haemorrhagic episodes. Plasma (thawed fresh frozen plasma or 
reconstituted lyophilised [dried] plasma) is generally indicated in 
situations of circulatory volume loss without red cell loss (e.g. 
generalized burns) or excessive coagulation factor consumption due to 
haemorrhagic episodes. The storage conditions and shelf-life of each 
of these products differ, red cell concentrates are stored at 1 – 6ºC for 
a maximum of 35 days, platelet concentrates are stored at 20 – 24ºC 
for a maximum of five days, and fresh frozen plasma is stored at less 
than -18ºC for a maximum of one year. 
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This practice allows the transfusion of the specific blood component 
product indicated by a patient’s condition, leaving the remaining 
products available for other patients. The advantage of this practice 
lies in the ability to provide sufficient blood from a scarce resource to a 
greater number of patients. The disadvantage of this practice lies in the 
fact that a single donation from a donor infected with a transfusion 
transmissible disease, could transmit the disease to as many as 5 
different patients, depending on the number of component products 
prepared from that donation and transfused. The products generally 
prepared in the Components Laboratory in Bloemfontein are indicated 
in Table 1.1. 
 
Table 1.1: Blood component products prepared from donated whole blood 
PARENT 
PRODUCT 
1st LEVEL DAUGHTER 
PRODUCT 
2nd LEVEL DAUGHTER PRODUCT 
Whole Blood 
(525 ml) 
Red Cell Concentrates 
(300ml) 
Paediatric Red Cell Concentrates (3 x 75ml) 
Leuco-depleted 
Red Cell Concentrates (250ml) 
Fresh Frozen Plasma* 
Donor-retested Fresh Frozen Plasma (260ml) 
Plasma frozen for the  National Bioproducts Institute* 
Plasma for Processing* Pooled Random Donor Platelet Concentrates (250ml) 
[Prepared from 1 x Plasma for Processing + 5 x Buffy 
Coats] Buffy Coats* 
* Intermediate products 
 
 
A considerable amount of the fresh frozen plasma prepared in 
Bloemfontein is sent to the National Bioproducts Institute (NBI) in 
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Pinetown for the preparation of a number of virus-inactivated plasma 
products (e.g. factor VIII concentrates, factor IX concentrates and 
lyophilised plasma) and fractionated products (e.g. 20% albumin) for 
SANBS. This process requires the pooling of the plasma obtained 
from no more than 100 donations per pool. The NBI makes use of the 
solvent-detergent method of virus inactivation. Their difficulty, while 
the prevalence of HIV is high, lies in the fact that the viral load of an 
unknown number of donations in a given batch, which tested negative 
for HIV but were within the window period could exceed the amount of 
inactivation achieved with the amount of inactivating reagents that is 
added. 
 
1.5. The issuing of blood 
Once the blood has been processed into the required components and 
the results of the blood grouping tests and disease marker tests have 
been received, the units considered safe for transfusion to patients are 
appropriately labelled and sent to the cross-match laboratories. At the 
cross-match laboratories specimens of blood from patients requiring 
blood transfusions, are received. The ABO and Rho(D) type of the 
patient, and the presence of irregular blood group antibodies is 
determined as prescribed in SOP-BBK-002 rev. 4 (2004). Blood of an 
appropriate ABO and Rho(D) type and any other required quality 
characteristics such as the lowest risk category available, is then 
selected, checked, and a compatibility test performed according to 
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SOP-BBK-002 rev. 4 (2004) prior to the issuing of blood for transfusion 
to the patient.  
 
1.6. The broader African context 
Lachman (1995) reported that in some areas of sub-Saharan Africa the 
prevalence of HIV in sexually active adults varied between 10% and 
33%. UNAIDS (2007) indicates that South Africa has the largest 
number of people living with HIV/AIDS in the world, estimated by the 
WHO (2008) to have been approximately 5.5 million in 2005. This 
translates to an adult (aged 16 – 49) prevalence of 16.2%. However, a 
high HIV prevalence is not limited to South Africa. Most of sub-
Saharan Africa suffers from this pandemic. Tapko, Sam and Diarra-
Nama (2007) reported that globally more than 60% of people living 
with HIV or approximately 22.5 million people (UNAIDS, 2007) were 
concentrated in the little more than 10% of the total world population 
living in sub-Saharan Africa. The WHO estimated in 2002 that 
approximately 5% to 10% of all HIV transmissions occur through 
infected blood transfusions (United States of America: Department of 
State, 2006). The magnitude of the problem is echoed by the HIV/AIDS 
Survey Indicators Database (2008) which states that the risk of 
transfusion-associated HIV transmission is highest in this area 
although doubt is expressed regarding the usefulness of donor 
screening policies in countries with a high HIV prevalence where more 
than one adult in five is infected. The statistics quoted by the United 
States of America: Department of State (2006) are largely based on 
 15 
assumptions regarding the HIV prevalence in the individual countries 
and each country’s donation screening procedures. Initiatives such as 
the United States of America (USA) President’s Emergency Plan for 
AIDS Relief (PEPFAR) are intended to contribute considerably towards 
reducing the prevalence of HIV by funding suitable projects. Blood 
transfusion services can also obtain funding from PEPFAR to finance 
projects intended to limit the transmission of HIV through blood 
transfusions. Table 1.2 provides a summary of the recently reported 
prevalence of HIV in the populations of a number of countries in sub-
Saharan Africa and in the blood donations collected and tested in 
those countries. Table 1.2 also provides the same information for a 
number of other countries to highlight the magnitude of the challenge 
in sub-Saharan Africa. It is particularly noticeable and alarming that the 
statistics on the prevalence of HIV in the general population and in 
blood donors for Europe and North America are usually quoted per 
100,000, whereas the equivalent statistics for most countries in sub-
Saharan Africa are usually quoted as percentages in the literature. 
Figure 1.4 provides a global overview of HIV prevalence and highlights 
the fact that sub-Saharan Africa has a much greater challenge in 
identifying blood donors not at HIV exposure risk, in sufficient numbers 
to serve the needs of patients requiring blood transfusions. 
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Table 1.2: Reported adult (aged 15 – 49) HIV prevalence in various 
countries of the world 
 Country 
Reported HIV  
prevalence in the 
general 
population 1 
Year 
Source 
(see 
notes 
below) 
Reported 
prevalence in 
blood 
donations 
Year 
Source 
(see note 
below) 
1 Botswana 25.2% 2004 UN 4.00% 2005 U 
2 Ethiopia 1.4% 2005 UN 3.40% 2005 U 
3 Kenya 6.7% 2003 UN 1.80% 2005 U 
4 Mozambique 16.1% 2005 W 6.43% 2005 U 
5 Namibia 19.6% 2005 W 0.50% 2005 U 
6 Nigeria 3.9% 2005 W 4.40% 2005 U 
7 Rwanda 3.0% 2005 UN 1.10% 2005 U 
8 South Africa 16.2% 2005 UN 0.09% 2005 U 
9 Tanzania 7.0% 2004 UN 5.70% 2005 U 
10 Uganda 7.1% 2005 UN 1.60% 2005 U 
11 Zambia 15.6% 2002 UN 8.00% 2005 U 
12 Kazakhstan 0.1% 2005 W 0.0088% 2003 L 
13 Ukraine 1.4% 2005 W 0.1284% 2004 L 
14 Russian Federation 1.1% 2005 W 0.0234% 2004 L 
15 Romania <0.1% 2005 W 0.0077% 2004 L 
16 Turkey <0.2% 2005 W 0.0055% 2004 L 
17 Hungary 0.1% 2005 W 0.0006% 2004 L 
18 Poland 0.1% 2005 W 0.0017% 2004 L 
19 France 0.4% 2005 W 0.0014% 2004 L 
20 Germany 0.1% 2005 W 0.0012% 2004 L 
21 Spain 0.6% 2005 W 0.0058% 2004 L 
22 United Kingdom 0.2% 2005 W 0.0006% 2004 L 
23 India 0.9% 2005 W 0.54% 2 2002 S 
24 Canada 0.3% 2005 W 0.0004% 2000 C 
25 
United States of 
America 
0.6% 2005 W 0.0097% 3 2001 D 
Notes: 
1 The HIV prevalence figures in the general population are estimates. The figures attributed to 
UNAIDS are derived from population-based surveys. The figures attributed to WHO are derived 
from the 2006 Report on the global AIDS epidemic. 
2 Based on a study of blood donors in Delhi including blood replacement donors, which is not 
necessarily an accurate reflection of the whole of India. 
3 Prevalence among new donors, prevalence in the total donor population is not cited. 
UN: UNAIDS. 2007 
W: WHO. 2008 
U: United States of America: Department of State. 2006 
L: Likatavičius, Hamers, et al. 2007 
S: Singh, Verma, et al. 2005 
C: Chiavetta, Escobar, et al. 2003 
D: Dodd, Notari IV, Stramer. 2002 
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Figure 1.4: World HIV prevalence (modified from Wikipedia, http://en.wikipedia.org) 
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In 1994 the Regional Committee of the World Health Organization 
African Region, through Resolution AFR/RC44/R12 (1994) urged the 
member states to, among others, enact blood safety policies for the 
attainment of HIV-free blood transfusions. Tapko (2002), in a 
presentation at the 4th Arab Congress and 3rd African Congress of 
Blood Transfusion in Tunis in 2002, estimated that at the time over 
25% of the approximately 2.3 million units of blood transfused in sub-
Saharan Africa, were still not tested for HIV resulting in an estimated 
5% to 10% cases of HIV infection due to the transmission of HIV by 
blood transfusion. This situation, as reported by Tapko (2002), is 
primarily brought about by the shortage of financial, physical and 
trained human resources in many African countries, which particularly 
impacts on their ability to implement highly sensitive tests for HIV. 
Collier and Oxford (1993) also note that the similar prevalence of HIV 
in males and females in Africa is indicative of a heterosexual 
transmission, in contrast to the primarily male homosexual and 
intravenous drug abuse transmission modes apparent in the USA and 
Europe. 
 
In African countries other than South Africa, extremely small white and 
Asian populations in relation to the total population make the use of the 
SABTS 1999 Model or the Combination Model, with their racial 
indicators, impractical. Although doubt has been expressed regarding 
the feasibility of donor screening in countries with a high HIV 
prevalence and per implication possibly also donation risk 
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categorization, this tool may provide a measure of safety for patients 
receiving blood transfusions at a relatively low operational cost. Most 
sub-Saharan African countries are unable to provide sufficient blood 
for transfusion from voluntary blood donors. However, the author’s 
experience indicates that the times of peak supply and peak demand 
of certain ABO and Rhesus blood groups, seldom coincide. The value 
of the risk categorization system would therefore lie in the ability to 
ensure that if units of blood should expire due to insufficient demand at 
any particular point in time, they would ideally be donations from 
donors exhibiting indicators of the highest risk of possible window-
period HIV transmission. 
 
1.7. Motivation for this study 
Many countries in sub-Saharan Africa have limited HIV-testing 
infrastructure and expertise in respect of the routine testing of all 
donations for the HI-virus. The use of a more acceptable model, with a 
high potential of accurately predicting the risk of exposure to HIV as a 
point of departure, has the potential of contributing to the reduced risk 
of HIV transmission in those countries at minimal additional operational 
cost. In contrast to the reservation expressed by the HIV/AIDS Survey 
Indicators Database, the author believes that the management of the 
risk of HIV transmission through transfusion, by the application of a 
suitable donation risk categorization model, is of even greater 
importance in those countries. 
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CHAPTER 2: LITERATURE AND HISTORICAL REVIEW 
 
Although blood transfusions are intrinsically intended to be life-saving 
medical interventions, the procedure also carries a number of risks, some of 
which can even threaten the life of the patient. In 1981 acquired immuno-
deficiency syndrome (AIDS) was identified in previously healthy male 
homosexuals based on the unusual prevalence of Pneumocystis carinii 
pneumonia (PCP) and Kaposi’s sarcoma. Both of these conditions were 
very rare in otherwise healthy persons (Collier and Oxford, 1993). Since 
December 1982 the transmission of the unidentified agent associated with 
certain risk behaviours such as male homosexual intercourse and intra-
venous drug abuse by the donors, causing AIDS, has been added to the list 
of risks to which blood transfusion recipients could be exposed. By 1983 the 
agent suspected to cause AIDS had been identified as a retrovirus, initially 
called the Human T-lymphocyte Virus III (HTLV III) in the United States of 
America or Lymphadenopathy-associated Virus (LAV) in France until 1986. 
After it was shown that the two viruses were the same, they were renamed 
the Human Immuno-deficiency Virus (HIV) in 1986 by the International 
Committee for the Taxonomy of Viruses (Swanevelder, 1994). In 1990, HIV 
was further subdivided into two identified species of virus in the family of 
Retroviridae and sub-family of Lentivirinae, namely HIV-1 and HIV-2 as 
defined in the National Library of Medicine – Medical Subject Headings 
(2007). 
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As summarised by Lachman (1995), HIV infection leads to functional 
abnormalities and depletion of a group of cells associated with a person’s 
normal immune response, known as the CD4+ T-lymphocytes. These 
T-lymphocytes play a cardinal role in the immune surveillance of the body 
for infectious agents by the processing of the “foreign” antigens of the 
infectious agents for presentation to the B-lymphocytes which effect the 
antigen-specific immunoglobulin production. The CD4+ T-lymphocytes also 
control the auto-immune tendencies of the immune system in conjunction 
with the CD8 T-lymphocytes. Increasing functional abnormalities and 
depletion of the CD4+ T-lymphocytes lead to opportunistic infection by a 
variety of pathogens, ultimately leading to the death of the infected person. 
According to Lachman (1995) approximately 2.5% of cases of AIDS 
reported to the Centre for Disease Control (CDC) in the USA, were 
associated with blood transfusions. Furthermore Lachman (1995) reported 
that approximately 95% of recipients of HIV-infected blood became 
seropositive, and approximately 50% of these patients developed AIDS 
symptoms within 7 years of the implicated transfusion. 
 
2.1. The early years of HIV risk management in the SABTS 
It should be noted that, of the practices discussed in this section, little 
documentation has survived. Thus pertinent references are not 
possible. The information given in this section is primarily based on the 
recollection of the author and other staff members of the SABTS at the 
time, as well as deductions from surviving donor records and the few 
surviving circulars of the relevant period to which references are made. 
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In keeping with the observed epidemiology in the USA and Europe up 
to 1993, the development of AIDS could be associated with 
intravenous drug use, or male-to-male sexual intercourse (Collier and 
Oxford, 1993). Once the risk posed by overtly healthy persons 
engaging in male-to-male sexual intercourse or intravenous drug 
abuse was recognized in 1982, the blood transfusion services in South 
Africa initiated pre-donation screening of all its donors at every 
donation. Initially this screening consisted of the deferral of prospective 
donors at the discretion of donor clinic staff based on visible indicators 
of the possible high-risk activities stated above. This deferral followed 
a similar ban on the acceptance of donations from males who had 
recently engaged in homosexual intercourse, as was enforced in 
Europe and North America. The visible signs most commonly sought 
included needle-prick lesions in the case of intravenous drug users 
and, depending on the opinion of the staff-member dealing with the 
donor, the wearing of ear-rings and certain mannerisms considered 
effeminate, in the case of homosexual and bi-sexual men. This method 
of screening for practicing homosexual and bi-sexual men was highly 
subjective and depended largely on the preconceptions of the staff-
member dealing with the donor at the time.  
 
By October 1988 this method of screening was replaced by the first 
version of a questionnaire aimed at educating potential new donors. 
Life-style risk factors, as known at the time, which could place the 
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potential donor at risk of being exposed to the causative agent, as 
prescribed in the Bloemfontein Branch circular A10/88 (1988), were 
highlighted. It was envisaged that potential new donors who 
recognised elements of their own life-styles in the questionnaire, would 
exclude themselves voluntarily from donating blood. By September 
1991 a questionnaire aimed at regular donors, asked for confirmation 
that the donor deemed his / her blood was safe for transfusion. This 
new questionnaire was implemented as prescribed in a protocol issued 
by the SABTS head office and numbered at the Bloemfontein Branch 
for reference purposes as S18/91 (1991). The various versions of the 
questionnaire successively in use from 1991 also attempted to achieve 
a more objective evaluation by requesting new donors to record 
answers to a number of specific questions with regard to known high-
risk activities.  
 
By October 1985 the SABTS instituted testing of all donations for the 
antibody to the HI virus, as subsequently prescribed by the National 
Blood Transfusion Council of South Africa (1990). This alleviated some 
of the risk of HIV transmission posed by donors who had been infected 
by HIV, through the transfusion of their donated blood. The risk posed 
by the transfusion of a unit of blood donated while the donor was in the 
window period of infectivity i.e. the period between the donor’s 
infection by the virus and the first time that a test could provide a 
positive result, remained. By June 1986, management of the risk of 
HIV transmission was also implemented with regard to the process of 
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issuing blood through a directive requiring the preferential issue of 
blood from donors with the highest number of previous HIV tests as 
indicated on the blood pack label (the number of HIV tests on record 
prefixed by an “H”). Until 1988 fresh whole blood and fresh red cell 
concentrates were routinely requested for certain procedures and 
treatments, notably where the physicians felt the need for platelets and 
the labile coagulation factors. The HIV test results for these products, 
to be transfused less than 48 hours after collection, were generally not 
yet available at the time of issue, which gave the “H” number a very 
particular importance. This is evidenced by the Bloemfontein Branch 
circular B2/88 issued in January 1988, which prohibited the 
unauthorised issue units of blood marked “H0”, “H1” or “H2”. Only units 
marked “H3” or higher were considered acceptable for issue prior to 
the availability of the HIV test result. However, during June 1988 the 
Bloemfontein Branch of the SABTS discontinued the practice of 
routinely providing fresh whole blood and fresh red cell concentrates to 
patients. This decision was brought about by the identification of a 
probable transmission of HIV to a patient through the transfusion of a 
unit of fresh whole blood subsequently found to be HIV positive. Areas 
in the SABTS close to Johannesburg could still continue to provide 
these products due to the much reduced time associated with the 
transport of the specimens drawn during the blood collection process, 
to the Donor Virology Laboratory, resulting in HIV test results routinely 
being available within 18 to 36 hours of collection of the donation.  
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2.2. The broader base of HIV transmission and implementation of HIV 
testing in the SABTS 
By the early 1990’s it had been conclusively shown that HIV was 
infecting a substantial portion of the South African population through 
heterosexual transmission. Annual national surveys undertaken by the 
South African Department of Health in women attending antenatal 
clinics since 1990 have shown a steady increase in the prevalence of 
this sentinel group from 0.74% in 1990 to 30.2% in 2005. Estimates of 
HIV in the general South African population between the ages of 15 
and 49 years had grown to 16.2% in 2005, as reported by Shisana et 
al (2005).  
 
As already mentioned, it was known that a window period of infectivity 
existed between the time of infection with the HI virus and the 
development of antibodies that could be identified by means of a 
screening test for the first time. The poor sensitivity of these first-
generation test systems resulted in an estimated window period of 45 
days. As indicated by Heyns and Swanevelder (2005), donated blood 
or blood products collected within this period would be infective 
although the test used would provide a negative result. By the same 
token, the WHO estimated the risk of HIV infection following an HIV-
infected blood transfusion to be more than 90% (Swanevelder, 1994). 
Since the initial test system was used in 1985 to determine the 
presence of the HI virus, more sensitive and specific reagents and test 
protocols for more viral markers have been developed, reducing the 
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length of the window period, but not eliminating it. This statement is 
supported by the Haemovigilance Annual Report: 2003 (Heyns and 
Nel, 2004), which indicates that in the period between 2000 and 2003, 
nine possible transmissions of HIV from transfused blood products 
prepared from eight blood donations which returned a negative test for 
HIV, were reported. This calculates to a risk of approximately 1:390000 
transfused donations. Table 2.1 indicates the sequence of test systems 
used by the SABTS and SANBS since 1985, together with the 
estimated remaining window periods associated with these test 
systems.  
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Table 2.1: Tests for HIV used by the SABTS and SANBS between 1985 and 
2005 
TEST 
TEST TRADE-
NAME 
TEST 
SUBSTRATE 
MARKER 
IDENTIFIED 
DATE 
IMPLEMENTED 
SCREEN / 
CONFIRMATORY 
TEST 
ESTIMATED 
WINDOW 
PERIOD 
1st generation 
Enzyme-linked 
Immunosorbant-
assay (12-unit pool 
test) 
Organon Technika: 
HTLV-III, Uniform I, 
Uniform II 
Viral lysate 
Anti-HIV 
antibody 
Oct 1985 Screen 45 days 
2nd generation 
Enzyme-linked 
Immunosorbant-
assay (individual unit 
test) 
Dade-Behring: 
Enzygnost 
Synthetic 
peptide 
Anti-HIV-1+2 
antibody 
1991 Screen 33 days 
3rd generation 
Enzyme-linked 
Immunosorbant-
assay 
Ortho Clinical 
Diagnostics: HIV-1 
/ HIV-2 Ab-capture 
ELISA test system 
Recombinant 
antigen 
Anti-HIV-1+2 
antibody 
Before 1996 
(archived SOP 
effective 
5/12/1997) 
Screen  22 days 
3rd generation 
Enzyme-linked 
Immunosorbant-
assay 
Ortho Clinical 
Diagnostics: HIV-1 
p24 antigen ELISA 
test system 
Recombinant 
antibody 
HIV-1 p24 
antigen 
Jun 1996 Screen 16 days 
3rd generation 
Enzyme-linked 
Immunosorbant-
assay 
Organon Technica: 
Vironostika HIV-1 
antigen test 
Recombinant 
antibody 
HIV-1 p24 
antigen 
Dec 1999 Screen 16 days 
3rd generation 
Enzyme-linked 
Immunosorbant-
assay 
Murex HIV-1.2.O 
Recombinant 
antigen 
Anti-HIV-1+2+O 
antibody 
Feb 2000 Screen 16 days 
3rd generation 
Enzyme-linked 
Immunosorbant-
assay 
Genscreen: HIV-1 / 
2 version 2 
Recombinant 
antigen 
Anti-HIV-1+2+O 
antibody 
Jun 2001 Confirmatory 16 days 
3rd generation 
Enzyme-linked 
Immunosorbant-
assay 
Organon Technica: 
Vironostika HIV-1 
antigen 
neutralization test 
Recombinant 
antibody 
HIV-1 p24 
antigen 
Jun 2001 Confirmatory 16 days 
3rd generation 
Enzyme-linked 
Immunosorbant-
assay 
Innogenetics: 
Inotest HIV antigen 
mAb test 
Recombinant 
antibody 
HIV-1+2 p24 
antigen 
Jan 2002 Screen 16 days 
3rd generation 
Enzyme-linked 
Immunosorbant-
assay 
Abbott: Prism 
Recombinant 
antigen 
Anti-HIV-1+ 
2+O antibody 
Apr 2002 Screen 16 days 
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Since June 1996, third generation enzyme-linked immunosorbant 
assay (ELISA) tests for the anti-HIV-1, -2 and -O(ther) antibodies as 
well as the third generation ELISA tests for the HIV-1 and -2 p24 
antigen were used concurrently. The reason for this is that initially only 
the viral antigen occurs in sufficient quantity to provide a positive result 
in a test for HIV soon after infection by the virus. The amount of free 
virus, however, soon reduces to undetectable levels, while the anti-HIV 
envelope and anti-HIV core antibody levels (or antibody titres) 
concurrently increase to easily detectable levels. Once the viral antigen 
level has become undetectable, only the antibody test is effective; a 
period usually lasting for several years. Only in the final symptomatic 
stages of the disease would the viral antigen levels again become 
detectable. Figure 2.1 indicates this relationship graphically. 
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Figure 2.1: Schematic diagram of the relationship between the development 
of the p24 antigen and anti-HIV antibodies (after Collier and 
Oxford, 1993) 
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2.3. Risk management by donor selection in the SABTS / SANBS 
The introduction of an operational computer system (Meditech, $T 
version) during November 1992 by the SABTS enabled the real time 
electronic capturing of information regarding the blood donations 
received, processed and tested. Prior to issuing the blood product to a 
patient the full set of information regarding the donor and the results of 
the blood group serology and virology screening tests are evaluated by 
the system to determine the safety and compatibility of the blood 
selected for that patient. The blood product issue process is completed 
by the capture of relevant patient and hospital data, ensuring full 
traceability of the donation. If the blood product was not used prior to 
its expiry date, the product is incinerated and those details are also 
captured. The electronic capture of donor data, has also allowed 
information on the donation history to be freely available to authorized 
staff in order to ensure that persons known to be at risk of being 
exposed to transfusion-transmissible diseases would be identifiable at 
all the clinics of the SABTS. In addition, blood / blood product issue 
rules were defined in the programme which prevented the computer-
issue of untested donations and donations flagged on the system as 
unsuitable for transfusion. 
 
The continued existence of the window period as seen in Figure 2.1 
together with increasing prevalence of HIV (0.26% of donations 
confirmed HIV-1 positive in 1998) as reported by Heyns, Benjamin, et 
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al (2006), forced the SABTS to develop and adopt a structured Blood 
Safety Policy in 1999 (SPMED001 rev. 0, 2003). This policy as quoted 
by Heyns and Swanevelder (2005) encompassed a number of key 
principles as shown in Table 2.2. 
 
Table 2.2: Key principles embodied in the SABTS Blood Safety Policy 
1. A coordinated programme to procure sufficient safe blood from low-risk voluntary, non-
remunerated blood donors. 
2. A programme that aims to be nationally self-sufficient for low-risk blood products. 
3. Issuing blood according to a hierarchy of risk. 
4. Recognizing the right to privacy of the individual donor. 
5. Protecting the health of blood donors, recipients of blood products and staff members. 
6. Educating blood donors, particularly learners, on the importance of donating blood, the 
spread and pathogenesis of HIV / AIDS, and the effect of a safe healthy lifestyle on the 
quality and safety of the blood supply. 
 
 
In practice this policy covered a number of aspects of the day-to-day 
operations of the SABTS as reported by Williamson (2006). Blood 
donor clinics in areas of high HIV prevalence were discontinued, a 
programme for targeting donors for regular repeat donations was 
instituted, donor education was escalated with regard to the activities 
leading to increased risk of exposure to HIV, and considerable 
improvements to the donor health / self-exclusion questionnaire 
coupled with the institution of the donor interview were initiated. 
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One of the outcomes of this policy was that the SABTS and 
subsequently SANBS continued to refine and apply the pre-donation 
assessments of all prospective donors, both new and existing, to 
minimise the risk of a window period blood donation entering the blood 
supply, and through its subsequent transfusion to a patient, from 
transmitting HIV. The first step in the process in use at the time of this 
study consisted of the evaluation of the health of the prospective donor 
in respect of potential risks of donation to the donor as well as to the 
patient based on a health questionnaire (BTS53E rev. 3) completed by 
the donor as prescribed by SOP-DON-24 rev. 2 (2002). The health 
questionnaire also included the questions in Table 2.3 regarding the 
donor’s life-style which could place him / her at risk of being exposed 
to the HI virus. It should be noted that this procedure is carried out 
every time a prospective donor presents himself / herself to donate 
blood, irrespective of the number of previous donations made or any 
other possible circumstance which may exist. 
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Table 2.3: HIV-risk assessment lifestyle questions (BTS53E rev. 3) 
1. Do you have AIDS or are you HIV positive? 
2. Is your main reason for donating blood to undergo an HIV test? 
3. In the past 6 months: 
a. Have you had more than one sex partner, had casual sex, or had sex with someone whose 
sexual background you don’t know? 
4. In the past 12 months: 
a. Have you been a victim of sexual assault? 
5. In the past 5 years: 
a. Have you had sex with a male or female prostitute, escort or sex worker, or exchanged 
money, drugs, goods or favours in return for sex? 
b. Have you had male to male sex? 
c. Have you suffered from a sexually transmitted disease (STD) e.g. syphilis, gonorrhoea, 
genital herpes, genital ulcer, VD or “drop”? 
6. Have you ever injected yourself, or been injected, with any drugs or any other substance 
(including steroids) that were not prescribed for you by a doctor? 
7. To your knowledge do any of the above questions apply to your sex partner? 
8. Do you consider your blood safe for transfusion to a patient? 
 
 
 The evaluation of the answers provided on the questionnaire was 
supported by a discussion between the prospective donor and one of 
the SANBS staff to determine whether the donor had a satisfactory 
understanding of the questions asked in the questionnaire and also an 
understanding of the implications of the window period for the HIV test 
as prescribed in SOP-DON-32 rev. 2 (2002). If the prospective donor 
was deemed to have no overt risks to himself or the patient by 
donating, a unit of 450ml of blood as well as two 5ml specimens of 
blood for virology and serology tests were collected. In the event of any 
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risks becoming apparent through the assessment of the questionnaire 
or the discussion, normal procedure dictated that the prospective 
donor be deferred from donating for a period of time as determined by 
the nature of the risk and defined in PM-MED-001 rev. 0 (2003).  This 
procedure was also applied to the life-style questions unless the 
deferral could not be made without public embarrassment to the 
potential donor. In such cases the donation process was completed as 
with any other donor but the blood donation was immediately taken 
aside and privately marked for incineration. 
 
2.4. Risk management by donation risk category hierarchy in the 
SABTS / SANBS 
In 1998 the WHO issued a report which included the recommendation 
that populations at low risk for transfusion-transmissible infections 
should be identified (WHO, 1998) for recruitment of voluntary blood 
donations. This document, in common with other documents on the 
subject emanating from the WHO and its regional offices, makes little 
attempt to define possible low-risk populations other than the 
requirement that blood donations should be obtained from voluntary, 
non-remunerated and regular blood donors who have been educated 
in some way regarding life-styles and behaviours which could enhance 
exposure to transfusion transmissible infections such as HIV. No 
further attempt is made to suggest avenues of research which could 
possibly lead to an acceptable set of parameters defining low-risk 
populations of blood donors.  
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In the United States of America and Canada prospective blood donors 
from many sub-Saharan African countries are regarded as high-risk 
donors in respect of the potential transmission of HIV. The Food and 
Drug Administration (FDA) of the United States of America put a 
requirement in place in 1998 whereby persons who were born or lived 
in a number of central African states after 1977 were barred from 
donating blood due to the risk of HIV type O transmission as stated on 
the website of the American Red Cross (2005). The Canadian Blood 
Services have a similar bar, described as a “geographic deferral” as 
indicated on their website (Canadian Blood Services, 2006).  
 
Statistical analyses published by the Department of National Health 
and Population Development in various issues of Epidemiological 
Comments during the early 1990’s (South Africa: Department of 
National Health and Population Development, 1993; South Africa: 
Department of National Health and Population Development, 1994) 
showed a strong race and gender association in respect of the 
prevalence of HIV, both in antenatal surveys as well as in data 
obtained from the various blood transfusion services. In addition, the 
data from the blood transfusion services showed a strong association 
with the previous donation history of the donors. 
 
During 1998 the Natal Blood Transfusion Service started importing 
blood from the Netherlands to mitigate the escalating risk of HIV 
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transmission by the transfusion of blood donations collected from a 
donor base with an increasing HIV incidence in Natal as reported in the 
print media (Correspondent, 1999). 
 
An important outcome of the Blood Safety Policy was therefore the 
development of a four-tiered HIV risk categorization hierarchy for all 
blood donations, described in this study as the SABTS 1999 Model 
(Tables 2.4, 2.5 and 2.6). The four tiers of this risk categorization 
hierarchy were labelled “I”, “II”, “III” and “IV” in order of increasing risk. 
Once the various blood products had been prepared from the blood 
donations, the risk categories were carried onto the blood products as 
issue priorities which were labelled as “A1”, “A2”, “A3” and “A4” 
respectively. For the purposes of this study, no distinction has been 
made between the HIV risk categorization hierarchy and the blood 
issue priority, and therefore the “A1” to “A4” labels are used throughout 
to describe the risk categories of the SABTS 1999 Model. In respect of 
the other models, the same principle has been applied and the blood 
issue priority labels have been used to describe the risk categories. 
 
This HIV risk categorization hierarchy was implemented to augment 
the already existing risk management procedures. The upgrading of 
the operational computer system to the NPR version of the Meditech 
programme during 1998 and the introduction of a SQL Database data 
repository enabled the real time analysis of the data entered. The 
adoption of the Blood Safety Policy in 1999 relied on the improved 
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functionality of the NPR version of the Meditech programme being 
applied to the risk management of all blood donations received, by 
electronically evaluating each donation according to certain 
predetermined criteria in order to allocate a risk category classification 
to each donation. The electronic issuing routine on Meditech was also 
modified to limit the electronic issuing of higher-risk categorized blood 
products under routine circumstances and by issuing a warning on 
which an audit trail was kept, to staff authorized to allow the electronic 
issue of such blood products in situations of extreme shortage. 
 
This meant that not all donations were considered equally acceptable 
for the preparation of the various blood products and for freely issuing 
to patients. Therefore, until February 2005 the choice of blood pack 
into which the blood was drawn and which ultimately determined the 
potential usability of the blood was prescribed by SOP-DON-043 rev. 2 
(2003). This choice was determined by the normally acceptable usage 
of the donations as applied in the SABTS 1999 Model, as can be seen 
in Table 2.5. In essence this meant that donations in risk category “A1” 
could be taken in OPTI-system triple blood packs for processing into 
plasma products, red cell concentrates and platelet concentrates. 
Donations in risk category “A2” could be taken in OPTI-system triple 
blood packs for processing into plasma products and red cell 
concentrates (except for paediatrics and immune-compromised 
patients). Until June 2004 donations in risk category “A3” and “A4” 
could only be taken into single blood packs for the use of the red cell 
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concentrate in situations of extreme shortage. After June 2004 the NBI 
was sufficiently satisfied that the disease marker incidence in 
donations of risk category “A3” was low enough to avoid compromising 
the efficacy of the virus-inactivating reagents. These donations could 
now also be collected into OPTI-system triple blood packs for 
processing into virus-inactivated plasma products while the red cell 
concentrates would only be used in situations of extreme shortage. 
 
Concurrent to donation testing, initial processing of the donation was 
undertaken to prepare red cell concentrates, plasma and the buffy-coat 
concentrates (for the processing of pooled platelet concentrates). Once 
the virology tests had been completed, the results were sent via an 
interface from the automated test systems into the Meditech 
programme. These results were then accessed by the technicians in 
the Components Laboratory prior to the second phase processing to 
determine which units were suitable for the preparation of specialized 
products. In addition, the virology and serology test results were used 
to determine whether the blood or blood products could be included 
into the blood supply to be transfused as prescribed by the SOP-COM-
71 rev. 2 (2003). 
 
The implementation of the HIV risk categorization hierarchy made 
certain decisions in the components laboratories and in the cross-
match laboratories considerably easier. In the components laboratories 
an easier choice could be made regarding the identification of low HIV 
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risk donations from which to prepare special products such as infant 
fresh frozen plasma, pooled platelet concentrates, leucocyte-depleted 
red cell concentrates and paediatric red cell concentrates as 
prescribed in SOP-COM-104 rev. 0 (2001), SOP-COM-100 rev. 2 
(2003) and SOP-COM-76 rev. 0 (1999). In the cross-match 
laboratories the technologists and technicians selecting blood for 
cross-matching and issuing to patients were in a position to exercise 
the requirement contained in SOP-BBK-2 rev. 3 (2003) and in SOP-
BBK-9 rev. 3 (2002) which stated that units of the lowest risk category 
available, needed to be selected for cross-matching. 
 
During 1999 the SABTS also embarked on a plasma quarantining 
procedure in order to ensure a greater level of safety when transfusing 
fresh frozen plasma. According to SOP-COM-114 rev. 0 (2003), all 
fresh frozen plasma from risk category “A1” and “A2” donations 
returning a negative test result for the disease marker tests and 
intended for transfusion to patients, needed to be retained in 
quarantine. Only after the donor’s subsequent donation (made 
between 56 and 100 days later) had been tested and found negative 
for all the tested disease markers, could the plasma be released for 
patient use as “donor-retested fresh frozen plasma” as prescribed by 
SOP-COM-126 rev. 0 (2003). In the event of any of the donor’s 
subsequent donation tests for the disease markers returning a positive 
result, the quarantined unit of plasma (together with all the products 
prepared from the donation returning the positive test) would be 
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changed to “Contaminated” status on the Meditech programme to 
prevent computer issuing procedures, and all the above-mentioned 
physical units would be disposed of according to SOP-COM-7 rev. 1 
(2003). Quarantined plasma not released after four months in 
quarantine, due to the donor not having been retested for the disease 
markers, was sent to NBI as a separate batch for production of 20% 
albumin. After June 2004, the same procedure applied to fresh frozen 
plasma from risk category “A3” donations. This procedure could only 
be applied to the fresh frozen plasma due to its one year shelf-life. Red 
cell products with a shelf-life of 35 days and platelets with a shelf-life of 
five days could not be held in quarantine. 
 
2.5. The application of the SABTS / SANBS risk management system 
in use since 1999 
The intention of the risk management system in a country like South 
Africa with a high HIV prevalence is to protect the recipients of blood 
transfusions from being infected by this virus. The risk categorization is 
therefore intended as an aid to limit the possibility of window period 
transmission of HIV during transfusions by defining low-risk issue 
parameters. The use of the risk management system as an aid in 
issuing the lowest risk blood was implemented in July 1999 when the 
Blood Safety Policy was adopted. It was also used as an aid for 
targeting low risk donors during recruitment efforts in order to reduce 
the collection of donations from populations with higher HIV prevalence 
levels. The categorization system needed to be based on sound 
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scientific analysis and objectively applicable by the staff of the service 
as described in SOP-MLD-002 rev. 0 (2003). As mentioned previously, 
statistical analyses showed a large difference in HIV prevalence 
between new donors and regular donors, as well as a strong race and 
gender association. 
 
The risk categorization in use until 30 September 2005 (SABTS 1999 
Model) was based on relatively easily identifiable indicators provided 
by the donors and captured on Meditech as prescribed in SOP-DON-
60 rev. 2 (2003), as well as previous donation data captured on the 
computer as described in SOP-DON-043 rev. 2 (2003). The indicators 
are shown in Table 2.4. 
 
Table 2.4: Indicators for donation risk category in the SABTS 1999 Model 
INDICATOR DEFINING ALTERNATIVES 
Previous donations 
New donor (no previous donations on computer record) 
Old donor (previous donations on computer record) 
Interval since last donation 
Regular donor (<12 months since last donation) 
Lapsed donor (>12 months since last donation) 
Gender 
Male 
Female 
Race 
White 
Asian 
Coloured 
Black 
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According to this risk management system the donations were 
categorized into issue priorities ranging from “A1” to “A4” in order of 
increasing HIV risk as shown in Table 2.5. The risk model from which 
the system is derived defines the HIV prevalence limits for the four risk 
categories and the normally acceptable usage of the blood after the 
donor screening processes proved sufficiently effective to consistently 
remain within the HIV prevalence limits over an extended time period. 
 
Table 2.5: Risk category application of the SABTS 1999 Model 
RISK 
CATEGORY 
ISSUE 
PRIORITY 
HIV PREVALENCE 
LIMITS 
NORMALLY 
ACCEPTABLE USAGE 
BLOOD PACK 
USED 
I A1 <0.0100% 
All products for infant 
and adult immune-
compromised patients 
OPTI-system 
triple blood 
pack 
II A2 
0.0100% – 
0.0999% 
All products for adult 
immune-competent 
patients 
OPTI-system 
triple blood 
pack 
III A3 
0.1000% – 
0.9999% 
Quarantined or virus-
inactivated plasma 
OPTI-system 
triple blood 
pack 
IV A4 
1.0000% and 
greater 
Incinerated 
Single blood 
pack 
 
 
The specific risk allocation of each individual cohort of donors, as 
determined by combinations of defining alternatives for the four 
indicators shown in Table 2.4 above, was determined by statistical 
analysis of the HIV test results obtained from donation testing between 
1996 and 1997 (coinciding with the introduction of p24 antigen testing). 
In the absence of incidence estimates in first-time donors, the 
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incidence of HIV in the donations was assumed to have a directly 
proportionate relationship to the number of units anticipated to be 
within the window period. The parameters of the SABTS 1999 Model 
are summarised in Table 2.6. 
 
Table 2.6: SABTS 1999 Model parameters 
RISK 
CATEGORY 
NEW DONORS (includes 
donors not previously 
recorded on Meditech) 
REGULAR DONORS 
(<365 days since 
previous donation) 
LAPSED DONORS 
(>365 days since 
previous donation) 
A1  
Asian male 
 
Asian female 
White male 
White female 
A2 
Asian male 
Coloured male 
Asian male 
Asian female Asian female 
White male 
Coloured female 
White male 
White female White female 
A3 Coloured male 
Black male Coloured male 
Black female Coloured female 
A4 
Coloured female 
 
Black male 
Black male 
Black female 
Black female 
 
 
By selecting blood for transfusion from cohorts of donors exhibiting a 
very low prevalence of HIV, it was anticipated that the risk of a window 
period transfusion would be correspondingly low. This risk 
 43 
categorization model, however, allowed very limited progression for 
donors’ donations through the various risk categories, resulting in the 
situation where a considerable number of very regular black donors 
could only reach an “A3” risk category. This meant that their donations 
were only used in processes where additional safety measures 
entailing virus inactivation could be put in place, such as fractionated 
blood products (albumin and factor VIII concentrate) or dried plasma 
products. Only in very exceptional emergency circumstances could 
blood products such as red cell concentrates be used. 
 
2.6. The demerits of the SABTS / SANBS risk management system in 
use since 1999 
Over the past years this situation has resulted in declining blood 
donations from the black population, primarily as a result of the 
discontinuation of active recruitment and reminder programmes in 
respect of donors whose last donation had an “A3” and “A4” risk 
categorization as calculated by the SABTS 1999 Model (see Table 
2.6). This made the approximately 80% of the geographical area of 
South Africa served by SANBS almost totally dependant for its blood 
supply on the second largest and smallest population groups, namely 
the white and Asian population groups. These two population groups 
only constitute 20% of the population in this area. The steadily 
increasing number of black staff in the lower to middle management 
positions and in positions in the donor clinics and blood processing 
laboratories, where the risk categorization needed to be applied, also 
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placed a strain on their relationship with the higher management 
levels. This was highlighted in the Commission for Conciliation, 
Mediation and Arbitration (CCMA) case no FS5169/04 when Hospersa 
(the trade union which represents the majority of the staff) filed a 
dispute on behalf of a staff member against SANBS in November 2004 
(CCMA, 2004; O’Connor, 2004; Correspondent, 2004). This dispute 
revolved around the withdrawal of an offer of a permanent position in 
the Bloemfontein Branch due to the fact that the staff member had 
inconclusively expressed an unwillingness to work for an institution 
which used race as part of its risk categorization system. Many of the 
staff questioned the moral ethics of continuously accepting donations 
from black donors in order to improve screening techniques and to 
obtain continually updated statistics while incurring the financial burden 
of the collection of the blood and knowing that it was highly unlikely 
that the blood would be transfused to a patient. Finally, the general 
public, particularly as represented by the media, had difficulty 
understanding and accepting a rigid risk categorization system which 
allows the blood of a regular donor with a considerable history of 
donations with a negative test for HIV, to be almost automatically 
incinerated based solely on the fact that the race of the donor 
precludes progression to risk categories “A2” or “A1”, as shown in 
Table 2.6, which is commonly used for transfusions (Pienaar and 
Rossouw, 2004; Dladla, 2004). Even the medical fraternity was divided 
on the question as to whether a risk categorization model using the 
race of the donor as one of the indicators, was acceptable when 
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measured against the safety of blood transfusions for the patient 
(Bateman, 2005). 
 
Mikkelsen (2006) subsequently in an article highlighting donor rights 
and expectations, states that “…the patient’s right to safe blood 
(stemming from his right to health) competes with the right of the donor 
not to be discriminated against.” He concedes that a patient’s right to 
safe blood may prevail, but maintains that the donor still retains a right 
to a proper explanation for his / her deferral. He therefore suggests 
that, in order to avoid undue discrimination, all donor deferrals must be 
based on scientific evidence. The experience of SANBS with the public 
reaction to the SABTS 1999 Risk Categorization Model has also 
proven that scientific evidence is not always a match for public socio-
political sentiments. 
 
2.7. Alternative models for donation risk categorization 
Given the issues above, there has since 2002, been a regular call from 
the branch managers of SANBS for the institution of a new risk 
categorization system, or the modification of the existing system, 
although no specific suggestions were made. As SANBS was the only 
blood transfusion service in the world using donation risk 
categorization beyond the distinction between new donors and regular 
donors, no other existing models could be investigated. During the 
southern area branch managers’ meeting in April 2004, the Kimberley 
branch manager (Mr D H Brown) suggested that a risk management 
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model based entirely on the interval since the last donation be 
investigated. In this study this model is referred to as the Donation 
Interval Model. The suggested parameters for the model entailed that 
all donations from new donors and donors whose previous donation 
had been made more than 365 days (one year) previously, are 
categorized at the highest risk level of a four-tiered system. With each 
successive donation made by the donor within a period of 121 days 
(four months) the risk category of the donation drops by one level till 
the lowest risk category level is reached. Any donation made by the 
donor between 122 and 182 days (four to six months) after the 
previous donation, would result in the risk categorization of that 
donation remaining the same as that of the previous donation. Any 
donation made by the donor between 183 and 365 days (six months to 
one year) after the previous donation, would result in the risk 
categorization of that donation increasing by one level until the highest 
risk categorization level is reached. The parameters of the Donation 
Interval Model are summarised in Table 2.7. 
 
Table 2.7: Donation Interval Model parameters 
RISK CATEGORY / CHANGE DONATION  / TEST INTERVAL 
Category DI4 
>365 days 
New donors 
Previous donation category +1 level 183 – 365 days 
Previous donation category 122 – 182 days 
Previous donation category –1 level 0 – 121 days 
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However, the author felt that the Donation Interval Model could place 
severe strains on the total low risk (“A1” and “A2”) blood supply due to 
the limited regularity of donations by voluntary blood donors. A second 
alternative model is suggested by this author. This alternative model 
uses the parameters of the SABTS 1999 risk categorization model as a 
base-line which is then augmented by the parameters of the Donation 
Interval Model, and is described as the Combination Model in this 
study. The parameters of the Combination Model are summarised in 
Table 2.8.  The defining difference between this model and the SABTS 
1999 Model is the fact that regular donations at intervals of not more 
that 121 days (4 months)  by a donor, would result in following 
donations being categorized at the lowest risk level irrespective of the 
donor’s ethnic group or gender. On the other hand the difference 
between this model and the Donation Interval Model lies in the fact that 
donations made by a donor at extended intervals greater than 182 
days (six months) would result in a progressive increase of the risk 
categorization level to the maximum risk category as determined by 
the SABTS 1999 Model for donors of the specific ethnic group and 
gender. 
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Table 2.8: Combination Model parameters 
RISK CATEGORY / 
CHANGE 
DONATION / TEST INTERVAL 
COHORT 
New 
donors 
>365 
days 
183 – 365 
days 
122 – 182 
days 
0 – 121 days 
Asian male Cb2 Cb2 
Prev. cat. -1; 
max = Cb2 
Prev. cat. 
Prev. cat. +1; 
min = Cb1 
Asian female Cb2 Cb2 
Prev. cat. -1; 
max = Cb2 
Prev. cat. 
Prev. cat. +1; 
min = Cb1 
White male Cb2 Cb2 
Prev. cat. -1; 
max = Cb2 
Prev. cat. 
Prev. cat. +1; 
min = Cb1 
White female Cb2 Cb2 
Prev. cat. -1; 
max = Cb2 
Prev. cat. 
Prev. cat. +1; 
min = Cb1 
Coloured male Cb3 Cb3 
Prev. cat. -1; 
max = Cb3 
Prev. cat. 
Prev. cat. +1; 
min = Cb1 
Coloured female Cb4 Cb3 
Prev. cat. -1; 
max = Cb3 
Prev. cat. 
Prev. cat. +1; 
min = Cb1 
Black male Cb4 Cb4 
Prev. cat. -1; 
max = Cb4 
Prev. cat. 
Prev. cat. +1; 
min = Cb1 
Black female Cb4 Cb4 
Prev. cat. -1; 
max = Cb4 
Prev. cat. 
Prev. cat. +1; 
min = Cb1 
 
 
Before a study of the implications of the suggested alternative models 
could be launched, the arbitration and mediation of the labour dispute 
between the staff member and SANBS took place. As a result of the 
media coverage of the case and the risk categorization system used by 
SANBS, unpublished discussions were held between SANBS and the 
Department of Health during November and December 2004, 
regarding possible alternative risk categorisation models which would 
also be in keeping with the South African constitution. At a further 
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meeting in February 2005 between SANBS and the Department of 
Health, a model was proposed which is based on the number of 
donations made by a donor within the previous 24 months, officially 
designated as the “Donor Status Risk Management Model” by Heyns, 
Swanevelder, et al (2006) and described as the SANBS 2005 Model in 
this study. This proposal was implemented on 1 October 2005 together 
with nucleic acid amplification testing (NAT) (Hill, 2000) in place of the 
HIV p24 test. This model provides for the risk categories and usually 
appropriate usage of the donations collected in the Inland Region as 
indicated in Table 2.9. In the East Coast Region of SANBS, this model 
was implemented with modified criteria based on the specific HIV 
prevalence statistics of the region. 
 
Table 2.9: Risk category application of the SANBS 2005 Model in the Inland 
Region of SANBS 
RISK CATEGORY NORMALLY ACCEPTABLE USAGE CRITICAL SHORTAGE USAGE 
C 
Red cell products for adults and infants, 
platelet products and plasma products 
 
R 
Red cell products for adults and plasma 
products 
Platelet products 
PLR1 Plasma products Red cell products for adults 
PLR2 Plasma used 
Red cell products for adults if no 
PLR1 red cells available 
PLR3 Plasma used 
Red cell products for adults if no 
PLR2 red cells available 
P Plasma used  
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An unpublished predictive statistical analysis carried out by the SANBS 
data analyst, which was presented at a branch managers’ meeting in 
March 2005, indicated that this model, coupled with the implementation 
of NAT, appeared potentially safer than the SABTS 1999 Model. An 
informal predictive statistical analysis of the donation frequency of the 
donors on the panel, as carried out at the branch managers’ meeting in 
March 2005, indicated that 85% to 90% of donations received would 
be expected to fall in the “C” and “R” risk categories, which 
represented a considerable decrease in routinely available blood when 
compared to the 94% of donations which fell in the “A1” and “A2” risk 
categories. The parameters of the SANBS 2005 Model are 
summarised in Table 2.10. 
 
Table 2.10: SANBS 2005 Model parameters defined for the Inland Region 
RISK CATEGORY DONATIONS IN 24 MONTHS DONOR AGE DONOR SEX 
C 4 and more All ages Male & female 
R 2 to 3 All ages Male & female 
PLR1 1 All ages Male & female 
PLR2 New donors 16 – 25 years Male 
PLR3 New donors 16 – 25 years Female 
P New donors >25 years Male & female 
 
 
During a discussion between the Chief Executive Officer (CEO) of 
SANBS and the author at the branch managers’ meeting in March 
2005, the CEO made a suggestion that consideration be given to the 
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use of the donor age as a possible indicator for a more effective risk 
categorization model. The intention of the suggestion was to find a 
model combining the anticipated safety of the SANBS 2005 Model with 
an increased availability of blood categorized as low risk. However, an 
informal unpublished pilot study of the HIV-positive donations received 
at the Bloemfontein branch of SANBS since October 1997, which was 
undertaken prior to the start of this study, showed very little correlation 
with specific age groups among new donors and is therefore not 
reported in this study. This can probably be attributed to the fact that 
the HIV-positivity rate is more reflective of the HIV prevalence in the 
potential donor population than of the incidence of new HIV infections. 
A similar situation exists in respect of existing donors who have not 
donated for more than 24 months (lapsed donors) where the time of 
seroconversion is poorly defined. The finding in this pilot study did not 
correspond with the results of Shisana et al (2005) when applied to 
new and lapsed donors. This discrepancy may have been the result of 
the informality of the pilot study or the ethnic bias inherent in the donor 
population at the time of this study when compared to the study by 
Shisana et al (2005). In the case of “regular” donors (previous donation 
within 24 months) the time of seroconversion is more closely defined, 
resulting in rates of HIV positivity which may more closely approach 
the incidence of new HIV infections. Analysis of the data obtained in 
this informal pilot study by the author showed that in the case of 
“regular” donors there were noticeable differences in the prevalence of 
HIV-positive donations among the donors of differing ages and 
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therefore forms the basis of a 5th model. Data published by Shisana et 
al (2005) also shows an unequal prevalence of HIV among different 
age-groups, similar to the results obtained in the pilot study with regard 
to “regular” donors. In addition, the study by Shisana et al (2005) 
shows a marked difference in HIV prevalence between males and 
females within individual age-groups.  
 
The model which is primarily based on the donor age at the time of the 
donation is described as the Age-based Model in this study. The 
determination of the final parameters for this model forms the first 
phase of this study. 
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CHAPTER 3: AIM OF THE STUDY 
 
This study has the ultimate aim of evaluating the effectiveness of four 
alternative blood donation risk categorization models against the model in 
use at the time of this study, namely the SABTS 1999 Model. As stated in 
Chapter 2, no parameters have been defined for the Age-based Model. The 
first phase of the study would be the definition of the parameters of this 
model before the effectiveness of this model can be evaluated in the second 
phase. 
 
3.1. Phase 1: Defining suitable parameters for the Age-based Model 
The parameters of the Age-based Model were not predefined by 
SABTS or SANBS policies as was the case with the SABTS 1999 
Model and the SANBS 2005 Model, or through the precise suggestions 
of individuals as was the case with the Donation Interval Model and the 
Combination Model. This means that in order to fulfil the ultimate 
purpose of this study as stated above, the first phase of this study was 
to determine potentially suitable parameters for the Age-based Model.  
 
3.2. Phase 2: Comparison of the alternative blood risk categorization 
models with the SABTS 1999 Model 
The success of any blood risk categorization model, from a patient 
safety point of view, is determined by two outcomes, namely the 
maximum availability of low-risk red blood cells for transfusion and the 
lowest incidence of HIV within the window period in those categories of 
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blood considered suitable for transfusion. The ultimate purpose of this 
study, through this phase of the study, is to compare the five risk 
categorization models, namely the SABTS 1999 Model; the Donation 
Interval Model; the Combination Model; the SANBS 2005 Model and 
the Age-based Model in terms of these two outcomes using the 
SABTS 1999 Model as benchmark. Table 3.1 shows the models 
together with the indicators used in each model. 
 
Table 3.1: Summary of the blood risk categorization models investigated 
MODEL INDICATORS USED DETAILS 
1 SABTS 1999 Model 
Donor ethnic group 
See Table 2.6 Donor sex 
Donation interval 
2 Donation Interval Model Donation interval See Table 2.7 
3 Combination  Model 
Donor ethnic group 
See Table 2.8 Donor sex 
Donation interval 
4 SANBS 2005 Model 
Donation interval 
See Table 2.10 Donor sex 
Donor age 
5 Age-based Model To be determined See Section 5.1 
 
 
3.2.1. The difference in HIV prevalence within each risk category 
The purpose of this comparison is to ensure that any suggested 
alternative would not place patients at any greater risk of a window 
period transfusion than the SABTS 1999 Model. For this reason the 
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risk model limits of the SABTS 1999 Model, as indicated in Table 2.5, 
are accepted as the benchmarks for the purposes of this study. The 
outcome is the prevalence of HIV-positive donations expressed as a 
percentage of the total number of donations allocated to each risk 
category. 
 
3.2.2. The availability of low-risk red blood cells for transfusion 
The purpose of this aspect of the study is to determine whether the 
donor population, as extant in the period October 2004 till September 
2005 with their actual donation frequency, would be sufficiently large 
to provide all the patients with sufficient safe blood as per the normal 
usage indications applicable for each of the risk categories. The 
outcome is the number of donations allocated to each risk category 
and also expressed as a percentage of the total number of donations 
collected. For this analysis the availability of low-risk red blood cells 
according to the SABTS 1999 model, is used as the benchmark since 
this model was the risk management system in use during the period 
that the donation data was collected. 
 
3.3. The best model for SANBS 
The final outcome of this study would be to provide an indication to the 
management of SANBS, as to which of the studied models is likely to 
be the best suited to the needs of the patients served by SANBS, given 
the need for “sufficient safe blood” as stated in the service’s mission 
statement referred to in Chapter 1.  
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3.4. The African potential 
 
The same challenges to identify safe blood for transfusion purposes 
exist throughout sub-Saharan Africa due to the high prevalence of HIV 
in the general population as reported in Chapter 1. It is intended that 
the final outcome of this study could provide indications of possible 
avenues of research to mitigate the impact of the HIV-pandemic on 
recipients of blood transfusions throughout sub-Saharan Africa. 
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CHAPTER 4: METHODOLOGY 
 
This study consisted of two distinct phases. The first phase required the 
collection of the donor demographic data and donation histories of the HIV-
positive donors, as recorded during routine operations throughout the Inland 
Region of SANBS, to determine suitable parameters for the Age-based 
Model. The second phase required the collection of donor demographic data 
and donations histories as recorded at the Bloemfontein branch of SANBS 
in respect of all the voluntary whole blood donations received between 1 
October 2004 and 30 September 2005, for the comparative study of the five 
models. The routine confirmed HIV virology test data for all the specific 
donations used in both aspects of the study was recorded. 
 
4.1. Materials used 
The following data associated with the whole blood donations received 
from the voluntary donors, as originally captured in the Meditech 
computer programme, was used for both phases of this study: 
 The donor ethnic group as recorded (Asian, black, coloured or 
white). 
 The donor gender as recorded (male or female). 
 The blood group of the donor. 
 The collection dates of the specimens associated with the previous 
tests for HIV markers to a maximum of eight if the donor had 
made eight or more donations. 
 Date of the donation under investigation. 
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 The age of the donor at the time of the donation under 
investigation. 
 The confirmed HIV marker test results for the donation under 
investigation. 
 
The specific donations, for which the above-mentioned data was 
obtained, were determined by the requirements of the two aspects of 
the study as defined in 4.1.1 and 4.1.2 below. 
 
4.1.1. Phase 1: The development of the parameters for the Age-
based Model 
The demographic data and donation histories mentioned above, 
of all the obtainable HIV-positive donations collected by the 
SANBS, Inland Region were used. The geographic area 
covered by the source of these donations is indicated in 
Chapter 1 and comprises Mpumalanga, Gauteng, Limpopo, 
North West, the Free State and the Northern Cape. The 
identifying records for HIV-positive donations collected at the 
Bloemfontein branch of SANBS were obtained from hard-copy 
records kept at the Bloemfontein branch. Records were 
available of HIV-positive donations collected since 1997. The 
identifying records for HIV-positive donations collected in the 
rest of the SANBS, Inland Region were obtained from the 
SANBS SQL Database managed by the SANBS Data Analyst. 
Records were available of HIV-positive donations collected 
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since 2000. The demographic data and donation histories 
pertaining to the donors were drawn from records archived in 
the Meditech computer programme in use by SANBS at the 
time of the study.  
 
4.1.2. Phase 2: The comparative analysis of the effectiveness of 
the different suggested risk categorization models 
The donors’ demographic data, donation histories and the test 
results of all the voluntary whole blood donations collected by 
the Bloemfontein Branch of the SANBS, Inland Region during 
the 12-month period from 1 October 2004 till 30 September 
2005, as recorded in the Meditech computer programme, were 
used in this study. The length of the study period (12 months) 
was intended to ensure that short-term and seasonal 
fluctuations in donation regularity were effectively included. At 
the same time campaigns to recruit new donors and re-recruit 
lapsed donors, with an extended, irregular periodicity, were 
effectively included to the extent of their actual annual 
contribution to the available blood stock. The choice of the 
specific time period, although initially arbitrary, ultimately 
coincided with the last twelve months of use of the SABTS 1999 
risk categorization model. This meant that the effect of NAT 
testing was not included in this study, thereby obviating the 
impact of the inclusion of an additional test sensitivity variable 
partway during the course of the study. The geographic area 
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which served as the source of the donations included in this 
aspect of the study is indicated in Figure 1.2. The HIV tests on 
all the donations included in this study were carried out by the 
Donor Virology Laboratory of the SANBS, Inland Region. In the 
process all four recorded ethnic groups, both sexes, new 
donors, lapsed donors and regular donors with varying donation 
intervals, all corresponding to the actual relative proportions 
were included in the study.  
 
4.1.3. Donations specifically excluded from this study 
Data from the following types of donations was specifically 
excluded from both aspects of this study: 
 Autologous, directed and paid therapeutic blood collections 
were not included. They were not considered purely 
voluntary donations made without the likelihood of coercion 
and were therefore never placed in the general blood 
inventory. 
 Aphaeresis platelet and plasma donations were not 
included. The donors of these products are a specialized 
group of voluntary donors who are not treated and assessed 
in exactly the same way as voluntary whole blood donors. 
The routine handling of these donors is characterized by an 
extended interaction between the donor and the clinic staff 
of up to 2 hours at any single session in contrast to the 10 to 
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15 minutes interaction during a voluntary whole blood 
donation. 
 “Specimen donations” taken for test purposes when donors 
could not donate for health reasons were not included. 
These “specimen donations” are recorded in the Meditech 
programme in a similar way as the actual donations and 
also contribute to the donors’ total donation count but do not 
constitute a unit of blood which can potentially be 
transfused. The test results of these “specimen donations” 
are used by the Meditech programme to allow or prevent the 
release of plasma prepared from the previous donation and 
kept in quarantine till the results of the following donation 
are known. 
 
In all instances the results of the previous tests carried out in 
respect of the above types of donations were included in this 
study since the data was used by the Meditech programme 
when calculating the risk category of each subsequent donation. 
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4.2. Methods 
Both phases of this study consisted of the following two main activities 
relating to the data specifically required for each phase: 
 
4.2.1. Collection and entry of donation data 
The required donation data was obtained and entered on 
Microsoft Excel spreadsheets. During the first phase for the 
development of the parameters for the Age-based Model, data 
of 497 regular donors returning a confirmed HIV-positive result 
was entered. During the second phase for the comparative 
study of the five different models, data from 26664 consecutive 
unselected voluntary whole blood donations collected at the 
blood donation clinics served by the Bloemfontein branch of the 
SANBS, Inland Region between 1 October 2004 and 30 
September 2005 was entered. In both cases the four ethnic 
groups as recorded, the sexes, new donors, lapsed donors and 
regular donors with varying donation intervals, all corresponding 
to the actual relative proportions were included in the study.  
 
For the comparative study the risk category of each donation, 
based on the parameters of each of the five risk categorization 
models, was then calculated and recorded. The final HIV test 
result of each donation was also recorded on the spreadsheet. 
In order to be able to assess the sufficiency of the collected 
blood within each risk category, the requirement needed to be 
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analysed. Unpublished internal statistics have been obtained for 
this purpose. Since this study only encompassed voluntary 
whole blood donations, only the products prepared from these 
donations were used as reference points for determining the 
degree of sufficiency allowed by each risk categorization model. 
 
4.2.2. Statistical analysis 
The spreadsheets were set up to generate the following 
information from the data entered: 
 A unique serial number to represent each individual entered 
donation. This number was needed to replace the official 
donation unit number as recorded in the Meditech 
programme, in order to ensure that the individual results 
pertaining to the donors and donations remain confidential. 
 The age of the donor at the time of the donation under 
investigation. 
 The time period between successive disease marker tests 
expressed as the number of days. 
 The risk category of the donation being studied according to 
the parameters for each of the five models being analysed 
in the case of the comparative study. 
 
For the determination of the parameters of the Age-based 
Model, the donors were grouped according to the sex and the 
age of the donor when his / her donation returned a confirmed 
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positive HIV test result. Counts of the number of donors falling 
within each sex and age combination were done and 
tabulated. This information was also plotted on graphs and 
polynomial trend lines developed using the Microsoft Excel 
trend line function. The R2 goodness of fit correlation ratios for 
the trend lines were determined and also recorded. Empirical 
parameters were determined from the graphs for application in 
the Age-based Model. 
 
For the comparative study the prevalence of HIV-positive 
donations within the collected blood was recorded, as well as 
the availability of blood considered safe for transfusion. In 
respect of the prevalence of HIV-positive donations the 
collected and calculated data was analysed to provide totals of 
HIV-positive donations, totals of all donations and percentages 
of HIV-positive donations within each risk category of each 
model studied. Since the study was based on the calculation of 
the risk category of each donation for each of the models 
under investigation, further pertinent conclusions could be 
made regarding the level of effectiveness of each model based 
on the calculated risk category of each of the individual HIV-
positive donations. An analysis was also done on the 
calculated risk category of the donation prior to the HIV-
positive donation where applicable, in order to assess the 
effectiveness of each model from this vantage point. 
 65 
 
With regard to the availability of platelet concentrates and red 
cell concentrates prepared from whole blood donations 
considered safe for transfusion, the collected and calculated 
data was analysed to provide totals of donations received per 
risk category and the percentage of the donations attributable 
to each risk category within each model.  
 
Standard statistical techniques, using the Microsoft Excel 
statistical functions, were used for this purpose. This included 
the determination of the following information: 
 The percentage of the donations received, allocated to each 
risk category within each model. 
 The percentage of units with a positive HIV marker test 
result within each risk category in each model. 
 The determination of the R2 correlation ratios for the trend 
lines of the percentage of donors returning an HIV-positive 
result per age interval. 
 The assessment of the statistical significance of the 
differences in the above percentages for the alternative 
models when compared with the results of the SABTS 1999 
Model, using the F Test. 
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CHAPTER 5: RESULTS AND DISCUSSION 
 
In the first phase covering the analysis of HIV-positive donations the donor 
demographics of 497 donations from “regular” donors with at least one 
donation in the preceding two years, were analysed. The data is shown in 
Appendix 1 and can also be found on the enclosed compact disc in the 
Microsoft Excel file titled CatStudyPr3.xls. Table 5.1 summarises the 
numbers of the demographic indicators represented in this phase. 
 
Table 5.1: Summary of the demographic indicators (n=497) included in the 
analysis of HIV-positive donations (Phase 1) 
DONOR DATA PROFILE TOTAL PERCENTAGE 
GENDER 
MALE 259 52.11% 
FEMALE 238 47.89% 
ETHNIC GROUP 
ASIAN 6 1.21% 
BLACK / AFRICAN 324 65.19% 
COLOURED 43 8.65% 
WHITE / CAUCASIAN 124 24.95% 
DONATION 
HISTORY 
REGULAR a  497  
LAPSED b Not noted  
NEW c Not noted  
DONOR AGE 
AGE SPECTRUM 16 – 69 years  
AVERAGE AGE 31 years  
a Previous donation recorded on Meditech ≤ 730 days prior to the present donation 
b Previous donation recorded on Meditech > 730 days prior to the present donation  
c No previous donation recorded on Meditech 
 
 
During the second phase, covering the analysis of the donations collected 
between 1 October 2004 and 30 September 2005, the donor demographics 
of 26664 donations were analysed. The data can be found on the enclosed 
compact disc in the Microsoft Excel file titled CatStudyPr4.xls. Table 5.2 
summarises the demographic indicators represented in this phase. 
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Table 5.2: Summary of the demographic indicators (n=26664) included in 
the analysis of the collected donations (Phase 2) 
DONOR DATA PROFILE TOTAL PERCENTAGE 
GENDER 
MALE 16320 61.21% 
FEMALE 10344 38.79% 
ETHNIC GROUP 
ASIAN 89 0.33% 
BLACK / AFRICAN 996 3.74% 
COLOURED 790 2.96% 
WHITE / CAUCASIAN 24789 92.97% 
DONATION 
HISTORY 
REGULAR a  23441 87.91% 
LAPSED b 1290 4.84% 
NEW c 1933 7.25% 
DONOR AGE 
AGE SPECTRUM 15 – 87 years  
AVERAGE AGE 37 years  
a Previous donation recorded on Meditech ≤ 730 days prior to the present donation 
b Previous donation recorded on Meditech > 730 days prior to the present donation  
c No previous donation recorded on Meditech 
 
 
5.1. Phase 1: Results of the analysis of HIV-positive donations 
The donor age distribution of HIV-positive donations received at the 
Bloemfontein branch of SANBS since October 1997 and HIV-positive 
donations received throughout the rest of the SANBS, Inland Region 
since January 2000, was analysed (n=497). Inspection of the results 
indicated that the relationship between donor age and the number of 
HIV-positive donations differed for male and female donors. The 
parameters were therefore separately determined for regular male and 
female donors. This data is shown in Appendix 1 and also recorded on 
the enclosed compact disc in Microsoft Excel file CatStudyPr3.xls. The 
term “regular”, in this context, referred to a donor who had made a 
donation within the 24 months prior to the date of the donation which 
returned a positive result for the HIV test. 
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The age distribution of the donors included in the comparative study 
(encompassing all the voluntary donations made at the various blood 
collection clinics of the Bloemfontein branch between October 2004 
and September 2005) was also separately determined for regular male 
and female donors. The choice of 24 months as a limit to the “regular 
donation” category for this phase of the study was determined by the 
higher of the two values defined in the risk models applied by SANBS 
up to the time of publication of this study, namely the SABTS 1999 
Model with a 12-month limit, and the SANBS 2005 Model with a 24-
month limit. It should be noted that three donations were received from 
15-year old donors during this period. Since the legal minimum age to 
make voluntary blood donations in South Africa is sixteen years, these 
donations were not included in the analysis of the results. The 
acceptance of these donations at the time was based on the provision 
of an incorrect date of birth, which had since been corrected. The 
following discussion does not make provision for persons younger than 
sixteen years making voluntary blood donations.  
 
5.1.1. Male donors 
The data used to analyse the relationship between the ages of male 
regular blood donors (n=14603) and the ages of male regular blood 
donors returning a confirmed HIV-positive test result (n=259) is 
summarised in Table 5.3. 
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Table 5.3: Analysis of donations from regular male donors versus HIV-
positive donations from regular male donors 
 
DONOR 
AGE 
DONATIONS 
% 
DONATIONS 
HIV-POS. 
DONATIONS 
% HIV-POS. 
DONATIONS 
DIFFERENCE IN 
% HIV-POS. 
DONATIONS AND 
% DONATIONS 
15 2 0.01% 0 0.00% Unacceptable age 
16 191 1.31% 1 0.39% -0.92% 
17 397 2.72% 1 0.39% -2.33% 
18 432 2.96% 6 2.32% -0.64% 
19 405 2.77% 10 3.86% 1.09% 
20 322 2.21% 5 1.93% -0.28% 
21 333 2.28% 7 2.70% 0.42% 
22 281 1.92% 6 2.32% 0.40% 
23 300 2.05% 14 5.41% 3.36% 
24 293 2.01% 13 5.02% 3.01% 
25 257 1.76% 9 3.47% 1.71% 
26 219 1.50% 8 3.09% 1.59% 
27 268 1.84% 10 3.86% 2.02% 
28 301 2.06% 9 3.47% 1.41% 
29 263 1.80% 11 4.25% 2.45% 
30 302 2.07% 12 4.63% 2.56% 
31 308 2.11% 7 2.70% 0.59% 
32 369 2.53% 13 5.02% 2.49% 
33 326 2.23% 5 1.93% -0.30% 
34 340 2.33% 10 3.86% 1.53% 
35 309 2.12% 6 2.32% 0.20% 
36 332 2.27% 14 5.41% 3.14% 
37 328 2.25% 3 1.16% -1.09% 
38 287 1.97% 6 2.32% 0.35% 
39 229 1.57% 6 2.32% 0.75% 
40 242 1.66% 5 1.93% 0.27% 
41 308 2.11% 5 1.93% -0.18% 
42 355 2.43% 2 0.77% -1.66% 
43 322 2.21% 6 2.32% 0.11% 
44 279 1.91% 8 3.09% 1.18% 
45 277 1.90% 3 1.16% -0.74% 
46 323 2.21% 5 1.93% -0.28% 
47 299 2.05% 2 0.77% -1.28% 
48 341 2.34% 3 1.16% -1.18% 
49 346 2.37% 2 0.77% -1.60% 
50 315 2.16% 3 1.16% -1.00% 
51 251 1.72% 3 1.16% -0.56% 
52 295 2.02% 4 1.54% -0.48% 
53 238 1.63% 3 1.16% -0.47% 
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DONOR 
AGE 
DONATIONS 
% 
DONATIONS 
HIV-POS. 
DONATIONS 
% HIV-POS. 
DONATIONS 
DIFFERENCE IN 
% HIV-POS. 
DONATIONS AND 
% DONATIONS 
54 254 1.74% 2 0.77% -0.97% 
55 250 1.71% 0 0.00% -1.71% 
56 233 1.60% 2 0.77% -0.83% 
57 224 1.53% 1 0.39% -1.14% 
58 220 1.51% 1 0.39% -1.12% 
59 270 1.85% 0 0.00% -1.85% 
60 187 1.28% 1 0.39% -0.89% 
61 186 1.27% 0 0.00% -1.27% 
62 155 1.06% 0 0.00% -1.06% 
63 161 1.10% 0 0.00% -1.10% 
64 141 0.97% 0 0.00% -0.97% 
65 100 0.68% 0 0.00% -0.68% 
66 77 0.53% 3 1.16% 0.63% 
67 94 0.64% 0 0.00% -0.64% 
68 81 0.55% 2 0.77% 0.22% 
69 72 0.49% 1 0.39% -0.10% 
70 40 0.27% 0 0.00% -0.27% 
71 30 0.21% 0 0.00% -0.21% 
72 46 0.32% 0 0.00% -0.32% 
73 38 0.26% 0 0.00% -0.26% 
74 48 0.33% 0 0.00% -0.33% 
75 39 0.27% 0 0.00% -0.27% 
76 18 0.12% 0 0.00% -0.12% 
77 17 0.12% 0 0.00% -0.12% 
78 8 0.05% 0 0.00% -0.05% 
79 1 0.01% 0 0.00% -0.01% 
80 10 0.07% 0 0.00% -0.07% 
81 8 0.05% 0 0.00% -0.05% 
82 4 0.03% 0 0.00% -0.03% 
83 4 0.03% 0 0.00% -0.03% 
84 0 0.00% 0 0.00% 0.00% 
85 0 0.00% 0 0.00% 0.00% 
86 0 0.00% 0 0.00% 0.00% 
87 2 0.01% 0 0.00% -0.01% 
88 0 0.00% 0 0.00% 0.00% 
89 0 0.00% 0 0.00% 0.00% 
TOTAL 14603 100.00% 259 100.00%  
TREND LINE 
R
2  0.8273  0.8133  
See Table 5.4 for the definition of the colour legend 
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Analysis of the data using the Microsoft Excel polynomial trend line 
function showed that the HIV-positive donations peaked in the age-
group of 21 to 34 years with a contribution of more than 3.00% for 
each year of donor age, as indicated in Figure 5.1 below. The trend 
lines showed a reasonably good fit as indicated by the coefficients of 
determination (R2) for the male donor age percentages and the male 
HIV-donor age percentages indicated in Table 5.3. 
 
In the case of regular male donors the trend line of the percentage 
HIV-positive donations for each year of age, rose above the trend line 
of the percentage donations for each year of age between the ages 
of 19 and 41 years. This indicated a higher percentage contribution of 
HIV-positive donations to the total number of donations than the 
overall percentage contribution of the donations by the particular age-
group of male donors. This would be indicative of a failure on the part 
of the donor education campaign and the pre-donation screening 
system. The donations from regular male donors within these age-
groups should be considered to be within elevated HIV-risk 
categories. Further analysis of this peak showed that regular male 
donors in the age-group 21 to 34 years accounted for 51.74% of the 
HIV-positive donations obtained from regular male donors (more than 
3% for each year of donor age) compared to the 28.49% contribution 
by this age-group to the total number of donations received from 
regular male donors as shown in Table 5.4 below.
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Figure 5.1: Graphic representation of relationship between donations from regular male donors (n=14603) and HIV-positive 
donations from regular male donors (n=259)
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Based on the trend line analysis in Figure 5.1, empirical 
categorizations of donations from male regular donors were set up. 
The categories applied to all the donations from male donors and 
their specific rationales are indicated in Table 5.4. 
 
Table 5.4: Contribution of age-groups to percentage of donations and 
percentage of HIV-positive donations from regular male donors 
 
CATEGORY 
RATIONALE 
AGE-
GROUP 
RISK 
CATEGORY 
% 
DONATIONS 
% HIV-
POSITIVE 
DONATIONS 
HIV % trend line 
below donation % 
trend line 
16 – 18 Yrs 
41+ Yrs 
AC1 54.69% 27.03% 
HIV % trend line 
above donation % 
trend line but <3% 
contribution to total 
HIV % 
19 – 20 Yrs 
35 – 40 Yrs 
AC2 16.80% 21.24% 
HIV % trend line 
above donation % 
trend line and 3% to 
5% contribution to 
total HIV % 
21 – 34 Yrs AC3 28.49% 51.74% 
HIV % trend line 
above donation % 
trend line and >5% 
contribution to total 
HIV % 
Not 
applicable 
AC4 0.00% 0.00% 
New donors & donors 
<1 per 24 months 
New / lapsed 
donors 
AC5 
New / lapsed 
donors 
New / lapsed 
donors 
 
 
5.1.2. Female donors 
The data used to analyse the relationship between the ages of 
female regular blood donors (n=8838) and the ages of female regular 
blood donors returning a confirmed HIV-positive test result (n=238) is 
summarised in Table 5.5. 
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Table 5.5: Analysis of donations from regular female donors versus HIV-
positive donations from regular female donors 
 
DONOR 
AGE 
DONATIONS 
% 
DONATIONS 
HIV-POS. 
DONATIONS 
% HIV-POS. 
DONATIONS 
DIFFERENCE IN 
% HIV-POS. 
DONATIONS AND 
% DONATIONS 
15 1 0.01% 0 0.00% Unacceptable age 
16 189 2.14% 8 3.36% 1.22% 
17 324 3.67% 21 8.82% 5.15% 
18 282 3.19% 14 5.88% 2.69% 
19 326 3.69% 24 10.08% 6.39% 
20 332 3.76% 12 5.04% 1.28% 
21 338 3.82% 11 4.62% 0.80% 
22 325 3.68% 8 3.36% -0.32% 
23 252 2.85% 8 3.36% 0.51% 
24 194 2.20% 12 5.04% 2.84% 
25 211 2.39% 7 2.94% 0.55% 
26 203 2.30% 6 2.52% 0.22% 
27 161 1.82% 6 2.52% 0.70% 
28 198 2.24% 5 2.10% -0.14% 
29 179 2.03% 8 3.36% 1.33% 
30 191 2.16% 10 4.20% 2.04% 
31 206 2.33% 5 2.10% -0.23% 
32 205 2.32% 5 2.10% -0.22% 
33 222 2.51% 6 2.52% 0.01% 
34 167 1.89% 5 2.10% 0.21% 
35 184 2.08% 6 2.52% 0.44% 
36 177 2.00% 7 2.94% 0.94% 
37 212 2.40% 3 1.26% -1.14% 
38 189 2.14% 4 1.68% -0.46% 
39 152 1.72% 5 2.10% 0.38% 
40 140 1.58% 2 0.84% -0.74% 
41 195 2.21% 4 1.68% -0.53% 
42 167 1.89% 3 1.26% -0.63% 
43 170 1.92% 1 0.42% -1.50% 
44 181 2.05% 4 1.68% -0.37% 
45 203 2.30% 3 1.26% -1.04% 
46 164 1.86% 3 1.26% -0.60% 
47 157 1.78% 1 0.42% -1.36% 
48 167 1.89% 0 0.00% -1.89% 
49 160 1.81% 3 1.26% -0.55% 
50 152 1.72% 1 0.42% -1.30% 
51 128 1.45% 0 0.00% -1.45% 
52 149 1.69% 2 0.84% -0.85% 
53 160 1.81% 0 0.00% -1.81% 
54 147 1.66% 1 0.42% -1.24% 
55 97 1.10% 0 0.00% -1.10% 
56 88 1.00% 1 0.42% -0.58% 
57 128 1.45% 1 0.42% -1.03% 
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DONOR 
AGE 
DONATIONS 
% 
DONATIONS 
HIV-POS. 
DONATIONS 
% HIV-POS. 
DONATIONS 
DIFFERENCE IN 
% HIV-POS. 
DONATIONS AND 
% DONATIONS 
58 106 1.20% 0 0.00% -1.20% 
59 90 1.02% 0 0.00% -1.02% 
60 61 0.69% 0 0.00% -0.69% 
61 77 0.87% 0 0.00% -0.87% 
62 68 0.77% 1 0.42% -0.35% 
63 31 0.35% 0 0.00% -0.35% 
64 30 0.34% 0 0.00% -0.34% 
65 31 0.35% 0 0.00% -0.35% 
66 17 0.19% 0 0.00% -0.19% 
67 27 0.31% 1 0.42% 0.11% 
68 21 0.24% 0 0.00% -0.24% 
69 22 0.25% 0 0.00% -0.25% 
70 16 0.18% 0 0.00% -0.18% 
71 20 0.23% 0 0.00% -0.23% 
72 4 0.05% 0 0.00% -0.05% 
73 9 0.10% 0 0.00% -0.10% 
74 9 0.10% 0 0.00% -0.10% 
75 2 0.02% 0 0.00% -0.02% 
76 6 0.07% 0 0.00% -0.07% 
77 5 0.06% 0 0.00% -0.06% 
78 9 0.10% 0 0.00% -0.10% 
79 3 0.03% 0 0.00% -0.03% 
80 0 0.00% 0 0.00% 0.00% 
81 0 0.00% 0 0.00% 0.00% 
82 1 0.01% 0 0.00% -0.01% 
83 0 0.00% 0 0.00% 0.00% 
84 0 0.00% 0 0.00% 0.00% 
85 0 0.00% 0 0.00% 0.00% 
86 0 0.00% 0 0.00% 0.00% 
87 0 0.00% 0 0.00% 0.00% 
88 0 0.00% 0 0.00% 0.00% 
89 0 0.00% 0 0.00% 0.00% 
TOTAL 8838 100.00% 238 100.00%  
TREND LINE 
R
2  0.8893  0.7298  
See Table 5.6 for the definition of the colour legend 
 
 
Analysis of the data using the Microsoft Excel polynomial trend line 
function showed that in the case of regular female donors the HIV-
positive donations peaked in the age-group of 16 to 20 years with a 
contribution of more than 5% for each year of donor age, as indicated 
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in Figure 5.2 below. The trend lines showed a reasonably good fit as 
indicated by the coefficients of determination (R2) for the female 
donor age percentages and the female HIV-donor age percentages 
indicated in Table 5.5. 
 
In the case of regular female donors the trend line of the percentage 
HIV-positive donations for each year of age, rose above the trend line 
of the percentage donations for each year of age between the ages 
of 16 and 34 years. This indicated a higher percentage contribution of 
HIV-positive donations to the total number of donations than the 
overall percentage contribution of the donations by the particular age-
group of female donors. This would be indicative of a failure on the 
part of the donor education campaign and the pre-donation screening 
system. The donations from regular female donors within these age-
groups should be considered to be within elevated HIV-risk 
categories. An analysis of this peak indicated that regular female 
donors in the age-group 16 to 20 years accounted for 33.18% of the 
HIV-positive donations obtained from regular female donors 
compared to the 16.44% contribution by this age-group to the total 
number of donations received from regular female donors as shown 
in Table 5.6. 
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Figure 5.2: Graphic representation of relationship between donations from regular female donors (n=8838) and HIV-positive 
donations from regular female donors (n=238) 
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Based on the trend line analysis in Figure 5.2 empirical 
categorizations of donations from female regular donors were set up. 
The categories applied to all the donations from female donors and 
their specific rationales are indicated in Table 5.6. 
 
Table 5.6: Contribution of age-groups to percentage of donations and 
percentage of HIV-positive donations from regular female 
donors 
 
CATEGORY 
RATIONALE 
AGE-
GROUP 
RISK 
CATEGORY 
% 
DONATIONS 
% HIV-
POSITIVE 
DONATIONS 
HIV % trend line 
below donation % 
trend line 
34+ Yrs AC1 50.91% 26.08% 
HIV % trend line 
above donation % 
trend line but <3% 
contribution to total 
HIV % 
28 – 33 Yrs AC2 13.59% 16.38% 
HIV % trend line 
above donation % 
trend line and 3% to 
5% contribution to 
total HIV % 
21 – 27 Yrs AC3 19.06% 24.36% 
HIV % trend line 
above donation % 
trend line and >5% 
contribution to total 
HIV % 
16 – 20 Yrs AC4 16.44% 33.18% 
New donors & donors 
<1 per 24 months 
New / lapsed 
donors 
AC5 
New / lapsed 
donors 
New / lapsed 
donors 
 
From the information in Tables 5.4 and 5.6 the parameters of the Age-based 
Model can be summarized as indicated in Table 5.7. These parameters 
were subsequently applied in the study of the donations collected between 
October 2004 and September 2005 as reported in Section 5.2 below. 
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Table 5.7: Age-based Model parameters 
RISK 
CATEGORY 
MINIMUM  DONATIONS PER 
PERIOD 
DONOR AGE GROUPS 
MALE DONORS FEMALE DONORS 
AC1 1 / 24 months <19 & > 40 Yrs > 33 Yrs 
AC2 1 / 24 months  
19 – 20 &  35 – 40 
Yrs 
28 – 33 Yrs 
AC3 1 / 24 months  21 -  34 Yrs 21 – 27 Yrs 
AC4 1 / 24 months  Not applied <21 Yrs 
AC5 <1 / 24 months & new donors All ages All ages 
 
 
5.2. Phase 2: Results of the data from the collected donations 
A total of 26664 donations of whole blood were received by the 
Bloemfontein branch of SANBS in the period from 1 October 2004 till 
30 September 2005.  
 
The data collected in respect of these donations is recorded on the 
enclosed compact disc in the Microsoft Excel file titled 
CatStudyPr4.xls. The calculated risk category for each donation 
according to each of the five risk management models is also recorded 
in the file. These results are summarised below in terms of the 
potential risk associated with each model, based on the number of 
HIV-positive donations found within each risk category, and in terms of 
the relative numbers of donations available for use according to the 
criteria defined in Chapter 2 and section 5.1. Of the 26664 donations, 
17 were found to be HIV-positive. Although the data collected in 
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respect of the HIV-positive donations is also included in the Microsoft 
Excel file titled CatStudyPr4.xls, the data has been duplicated as a 
separate table in Appendix 2 and on the enclosed compact disc in 
Microsoft Excel file titled CatStudyPr5.xls for reference ease. 
 
5.2.1. Potential risk profile of the models 
The risk limits, as applied by the SABTS in its SABTS 1999 Model, 
are indicated in Table 5.8 and also applied to the other four models in 
this study, with the exponential extrapolation required for the SANBS 
2005 Model and the Age-based Model. The extrapolation consists of 
the subdivision of the “A3” risk category of the SABTS 1999 Model 
into three sub-categories (“PLR1”, “PLR2” and “PLR3”) in the case of 
the SANBS 2005 Model.  In the case of the Age-based Model the 
“A3” risk category of the SABTS 1999 Model was subdivided into two 
subcategories (“AC3” and “AC4”). 
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Table 5.8: HIV prevalence per donation risk categories according to the 
studied models (n=26664) 
Risk limits based on 
SABTS 1999 Model 
<0.0100% 
0.0100% 
-  
0.0999% 
0.1000% - 0.9999% 
1.0000% 
and 
greater 
 
0.100% -
0.2149% 
0.215% - 
0.4639% 
0.464% - 
0.9999% 
0.100% - 
0.2999% 
0.3000% - 0.9999% 
USAGE* 
Generally 
acceptable 
All products 
Adult red 
cell 
products 
&  
plasma 
products 
Adult 
plasma 
products 
Adult 
plasma 
products 
Adult 
plasma 
products 
Frac-
tionated 
plasma 
products 
 
Severe 
shortage 
All products 
Adult red 
cell 
products 
&  
plasma 
products 
Adult red 
cell 
products 
& adult 
plasma 
products 
Adult red 
cell 
products 
& adult 
plasma 
products 
Adult red 
cell 
products 
& adult 
plasma 
products 
Frac-
tionated 
plasma 
products 
 
SABTS 
1999 
Model 
RISK 
CATEGORY 
A1 A2 A3 A4 TOTAL 
TOTAL 
TESTED 
21246 4225 740 453 26664 
TOTAL 
HIV-POS. 
0 6 3 8 17 
% HIV-POS. 0.0000% 0.1420% 0.4054% 1.7660% 0.0638% 
Donation 
Interval 
Model 
RISK 
CATEGORY 
DI1 DI2 DI3 DI4 TOTAL 
TOTAL 
TESTED 
15019 2808 2922 5915 26664 
TOTAL 
HIV-POS. 
1 0 0 16 17 
% HIV-POS. 0.0067% 0.0000% 0.0000% 0.2705% 0.0638% 
Combin-
ation 
Model 
RISK 
CATEGORY 
Cb1 Cb2 Cb3 Cb4 TOTAL 
TOTAL 
TESTED 
19273 6454 360 577 26664 
TOTAL 
HIV-POS. 
1 5 3 8 17 
% HIV-POS. 0.0052% 0.0775% 0.8333% 1.3865% 0.0638% 
SANBS 
2005 
Model 
RISK 
CATEGORY 
C R PLR1 PLR2 PLR3 P TOTAL 
TOTAL 
TESTED 
16621 6817 1293 732 584 617 26664 
TOTAL 
HIV-POS. 
2 1 7 2 0 5 17 
% HIV-POS. 0.0120% 0.0147% 0.5414% 0.2732% 0.0000% 0.8104% 0.0638% 
Age- 
based 
Model 
RISK 
CATEGORY 
AC1 AC2 AC3 AC4 AC5 TOTAL 
TOTAL 
TESTED 
12488 3654 5844 1454 3224 26664 
TOTAL 
HIV-POS. 
2 0 1 0 14 17 
% HIV-POS. 0.0160% 0.0000% 0.0171% 0.0000% 0.4342% 0.0638% 
* Based on the requirements for the SABTS 1999 Model and the SANBS 2005 Model 
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The last donations received from each donor prior to the HIV-positive 
donation, which may have been in the window period, were also 
analysed to provide an additional indication of the effectiveness of the 
alternative models. Of the seventeen confirmed HIV-positive 
donations received during this study, seven donations were made by 
new donors, previous potential window-period donations therefore did 
not exist. The remaining ten donations were made by donors who 
had a record of previous donations. SANBS in SOP-DON-44 rev. 1 
(2003) requires a look-back investigation to be undertaken on the 
previous donation if the donation was made within five years of an 
anti-HIV 1.O.2 positive test result, or if it was made within one year of 
an HIV 1 p24 antigen positive and anti-HIV 1.O.2 negative test result. 
All the donations collected from HIV-positive donors in this study who 
had donated previously and now tested anti-HIV 1.O.2 positive were 
also subjected to the risk categorization calculation for each of the 
five models analysed. The data collected and the risk category 
calculation for these donations are shown in Appendix 3 and 
recorded on the enclosed compact disc in the Microsoft Excel file 
titled CatStudyPr6.xls. For this purpose the donations were 
subdivided into 2 groups, namely donations made more than five 
years prior to the HIV-positive donation and donations made five 
years and less prior to the HIV-positive donation. The results of this 
analysis are shown in Table 5.9.  
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Table 5.9: Summary of the risk categories of the donations prior to the HIV-
positive donation 
MODEL 
RISK 
CAT. 
DONORS 
 >5 YEARS TILL 
HIV-POSITIVE 
DONATION 
% DONORS  
>5 YEARS TILL 
HIV-POSITIVE 
DONATION 
DONORS <5 
YEARS INTERVAL 
TILL  
HIV-POSITIVE 
DONATION 
% DONORS <5 
YEARS INTERVAL 
TILL  
HIV-POSITIVE 
DONATION 
NEW DONORS 7     
SABTS 1999 
MODEL 
A1 2 40.00% 0 0.00% 
A2 1 20.00% 1 20.00% 
A3 1 20.00% 4 80.00% 
A4 1 20.00% 0 0.00% 
DONATION 
INTERVAL 
MODEL 
DI1 3 60.00% 2 40.00% 
DI2 1 20.00% 0 0.00% 
DI3 0 0.00% 3 60.00% 
DI4 1 20.00% 0 0.00% 
COMBINATION 
MODEL 
Cb1 4 80.00% 2 40.00% 
Cb2 0 0.00% 1 20.00% 
Cb3 0 0.00% 2 40.00% 
Cb4 1 20.00% 0 0.00% 
SANBS 2005 
MODEL 
C 3 60.00% 2 40.00% 
R 1 20.00% 3 60.00% 
PLR1 0 0.00% 0 0.00% 
PLR2 0 0.00% 0 0.00% 
PLR3 1 20.00% 0 0.00% 
P 0 0.00% 0 0.00% 
AGE-BASED 
MODEL 
AC1 2 40.00% 2 40.00% 
AC2 0 0.00% 1 20.00% 
AC3 2 40.00% 2 40.00% 
AC4 0 0.00% 0 0.00% 
AC5 1 20.00% 0 0.00% 
 
 
5.2.2. Availability of low-risk blood according to the models 
The donations available after disposal of the HIV-positive donations, 
were analysed to determine the relative number of donations which 
would be available within each of the risk categories associated with 
each of the models studied. The results of this analysis are given in 
Table 5.10. 
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Table 5.10: Availability of blood according to risk category within each model 
MODEL 
RISK 
CATEGORY 
NUMBER OF 
DONATIONS 
CUMULATIVE 
NUMBER OF 
DONATIONS 
PERCENTAGE 
OF 
DONATIONS 
CUMULATIVE 
% OF 
DONATIONS 
SABTS 
1999 Model 
A1 21246 21246 79.73% 79.73% 
A2 4219 25465 15.83% 95.56% 
A3 737 26202 2.77% 98.33% 
A4 445 26647 1.67% 100.00% 
Donation 
Interval 
Model 
DI1 15018 15018 56.36% 56.36% 
DI2 2808 17826 10.54% 66.90% 
DI3 2922 20748 10.97% 77.87% 
DI4 5899 26647 22.14% 100.00% 
F ratio 0.3985    
Combination 
Model 
Cb1 19272 19272 72.32% 72.32% 
Cb2 6449 25721 24.20% 96.52% 
Cb3 357 26078 1.34% 97.86% 
Cb4 569 26647 2.14% 100.00% 
F ratio 0.8641    
SANBS 
2005 Model 
C 16619 16619 62.37% 62.37% 
R 6816 23435 25.58% 87.95% 
PLR1 
2600 
1286 24721 4.83% 92.78% 
PLR2 730 25451 2.74% 95.52% 
PLR3 584 26035 2.19% 97.71% 
P 612 26647 2.30% 100.00% 
F ratio 0.6055    
Age-based 
Model 
AC1 12486 12486 46.86% 46.86% 
AC2 3654 16140 13.71% 60.57% 
AC3 
7297 
5843 21983 21.93% 82.50% 
AC4 1454 23437 5.46% 87.96% 
AC5 3210 26647 12.05% 100.00% 
F ratio 0.2047    
 
 
The amount of blood needed for transfusion to patients was obtained 
from unpublished internal statistics and summarized in Table 5.11. 
Since this study only encompassed voluntary whole blood donations, 
only the products prepared from these donations were used as 
reference points for determining the degree of sufficiency allowed by 
each risk categorization model. 
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Table 5.11: Usage of blood products during 2005 in the area served by the 
Bloemfontein branch of SANBS 
DONATION TYPE 
USED 
SOURCE 
COMPONENT 
PRODUCT 
UNITS 
ISSUED 
% OF TOTAL 
DONATION TYPE 
Voluntary whole blood 
donation 
Red Cells 
Whole Blood 19 0.07% 
Red Cell Concentrate 14341 55.84% 
Filtered Red Cell 
Concentrate 
8568 33.71% 
Paediatric Filtered Red Cell 
Concentrate 
2756 10.73% 
Total red cells required 25684 100% 
Platelets 
Pooled Platelet Concentrate 458 1.78% 
Total platelets required 458 1.78% 
Plasma 
Adult Fresh Frozen Plasma 4092 15.93% 
Infant Fresh Frozen Plasma 176 0.69% 
Frozen Cryoprecipitate 130 0.51% 
Total plasma products 
required 
4398 17.12% 
Total voluntary whole blood donations 
required 
25684  
Voluntary aphaeresis 
donation 
Platelets 
Paediatric Platelet 
Concentrate 
141 9.02% 
Adult Platelet Concentrate 1422 90.88% 
Autologous & directed 
whole blood donation 
Red Cells 
Autologous Whole Blood 50 30.86% 
Directed Red Cell 
Concentrate 
112 69.14% 
 
 
5.3. Discussion 
 
5.3.1. Potential risk profile of the five models 
Table 5.8 clearly highlights the difficulty in applying an objective and 
effective risk categorization hierarchy in terms of the blood donations 
received, while simultaneously steering clear of pitfalls based on 
peoples’ perceptions of discrimination. It is assumed that the relative 
prevalence of donations within the window period corresponds with 
the relative prevalence of donations testing HIV-positive. According to 
the SANBS blood risk management policy applied till 2005, the 
primary focus of the risk categorization is on the identification of safe 
sources of platelets and red cells for paediatrics and other immuno-
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compromised patients from donors statistically exhibiting a risk of HIV 
prevalence less than 0.0100%, and red cells for immuno-competent 
adults which could also be sourced from donors statistically exhibiting 
a risk of HIV prevalence between 0.0100% and 0.0999%. The 
relative risks associated with the use of donations falling in higher risk 
categories, with a risk of HIV prevalence up to 0.9999%, as occurs in 
situations of extreme blood shortage, will also be discussed. Since 
plasma is quarantined till the next donation has been made and 
tested, before being released for transfusion, the merits of the 
different models in terms of this product are not discussed. 
 
Due to the exceedingly small numbers of HIV-positive donations 
collected during this study, the HIV prevalence of the individual risk 
categories, as determined in this study, is not considered to be 
statistically significant. These figures, particularly where they are 
derived from multiple HIV-positive donations, still constitute a 
meaningful guide to possible HIV-risk pitfalls. In addition, the potential 
impact of NAT has not been considered in this study. Unpublished 
data, in respect of the donations received in the area served by the 
Bloemfontein branch, indicates an increase in the number of HIV-
positive donations received since October 2005 when compared to 
the equivalent period before 30 September 2005. This change 
should, however, not only be attributed to the increased sensitivity of 
NAT. Additional factors such as new and lapsed donor recruitment 
drives and regular donor reminder systems without an ethnic target 
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element may also be playing a role due to the still-existing higher HIV 
prevalence in the racial groups previously considered to be high-risk 
populations, as well as limitations in the pre-donation screening 
system. In spite of the possibility of increased risk in the donations 
collected, and very possibly due to the increased sensitivity of NAT, 
unpublished data also suggests that no identified instance of HIV 
transmission has been reported till March 2008, through the 
transfusion of donations subjected to NAT after September 2005 
throughout SANBS (representing approximately 1,500.000 transfused 
donations over this period). 
 
5.3.1.1. The SABTS 1999 Model 
Of the five models studied, the SABTS 1999 Model provided the 
greatest level of protection against HIV-transmission by the 
transfusion of platelet concentrates and paediatric red cell 
concentrates, since these are exclusively prepared from donations 
falling within the lowest risk category (“A1”). No HIV-positive 
donations accepted routinely within the ambit of this study were 
categorized as “A1”. 
 
In terms of red cell concentrates prepared for transfusion to 
adults, this model proved considerably less superior. The risk limit 
defined for risk category “A2” is less than 0.1000%. In the course 
of this study, six HIV-positive donations occurred among the 4221 
donations that fell in risk category “A2” giving this category a 
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0.1420% prevalence. An analysis of these donations showed that 
two of the donations (33.33%) came from white male new donors, 
one of the donations (16.67%) came from a white female new 
donor, two of the donations (33.33%) came from lapsed white 
male donors who had made their previous donations more than 
seven years previously, and one donation (16.67%) had been 
accepted from a regular coloured female donor who had made 
her previous donation six months previously. This last donation is 
the most serious cause for concern, particularly since it was typed 
as an O Rho-negative and therefore the previous donation, which 
may have been in the window-period, would probably have been 
used for transfusion to a patient. 
 
In times of extreme blood shortage, when donations of the next 
lower risk category are used, the 0.4054% prevalence of HIV-
positive donations in risk category “A3” was found to be 
comfortably within the set risk limits of less than 1.0000%. The 
three HIV-positive donations which fell in this risk category were 
identified as being a new donor, a lapsed donor whose previous 
donation had been made almost eight years previously, and one 
very regular donor whose previous donation had been made 2 
months previously. The fact that this donation was typed as a 
group O Rho-positive would have increased the possibility that the 
previous donations may have been transfused, due to serious 
blood shortages. 
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The categories within which the HIV-positive donations fell in 
respect of the SABTS 1999 Model are illustrated graphically in 
Figure 5.3.  
 
P E R C E N T A G E  H IV - P O S IT IV E  D O N A T IO N S :
S A B T S  1 9 9 9  M o d e l
A 3 ;  1 7 . 6 5 %
A 2 ;  3 5 . 2 9 %
A 1 ;  0 . 0 0 %
A 4 ;  4 7 . 0 6 %
A 1
A 2
A 3
A 4
 
Figure 5.3: Percentage of HIV-positive donations by risk category using the 
SABTS 1999 Model 
 
The performance of the SABTS 1999 Model against the set risk 
limit standards is graphically illustrated in Figure 5.4. 
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Figure 5.4: HIV prevalence per risk category using the SABTS 1999 Model 
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5.3.1.2. The Donation Interval Model 
The Donation Interval Model provided the next best level of 
protection against HIV-transmission by the transfusion of platelet 
concentrates and paediatric red cell concentrates. One of the 17 
HIV-positive donations collected would have been considered 
suitable for transfusion prior to the receipt of the HIV test results of 
the donation due to its “DI1” risk categorization. An investigation 
of the results showed that this was the same donation from a very 
regular donor whose donation was categorized as “A3” in the 
SABTS 1999 Model. If this model had been in use, the previous 
donation, which has a high probability of having been in the 
window-period, would most probably have been used for 
transfusion to a patient since the blood was typed as group O 
Rho-positive. The prevalence of HIV-positive donations in risk 
category “DI1” is 0.0067% and, in spite of the HIV-positive 
donation mentioned, the risk category still falls comfortably within 
the set risk limit of less than 0.0100%. 
 
At the next risk level, the Donation Interval Model is superior, with 
its HIV prevalence of 0.0000%, compared to the SABTS 1999 
Model with a prevalence of 0.1420%. All the HIV-positive 
donations categorized as “A2” in the SABTS 1999 Model were 
categorized as “DI4” in the Donation Interval Model. 
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A similar situation exists when red cells for transfusion to adults 
need to be found in situations of extreme shortage. There were no 
HIV-positive donations categorized as “DI3” in the Donation 
Interval Model. 
 
Sixteen of the HIV-positive donations fell within the highest risk 
category (“DI4”) in the Donation Interval Model, which is 
considered the almost ideal categorization from a risk elimination 
perspective. The categories within which the HIV-positive 
donations fell in respect of the Donation Interval Model are 
illustrated graphically in Figure 5.5.  
 
P E R C E N T A G E  H IV - P O S IT IV E  D O N A T IO N S :
D o n a t io n  In t e r v a l  M o d e l
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D I2 ;  0 . 0 0 %
D I3 ;  0 . 0 0 %
D I1 ;  5 . 8 8 %
D I1
D I2
D I3
D I4
 
Figure 5.5: Percentage of HIV-positive donations by risk category using the 
Donation Interval Model 
 
The performance of the Donation Interval Model against the risk 
limit standards set for the SABTS 1999 Model is graphically 
illustrated in Figure 5.6. 
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Figure 5.6: HIV prevalence per risk category using the Donation Interval 
Model 
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5.3.1.3. The Combination Model 
The Combination Model provided a similar level of protection 
against HIV-transmission by the transfusion of platelet 
concentrates and paediatric red cell concentrates. One of the 17 
HIV-positive donations collected would have been considered 
suitable for transfusion prior to the receipt of the HIV test results of 
the donation due to its “Cb1” risk categorization. An investigation 
of the results showed that this was the same donation from a very 
regular donor whose donation was categorized as “A3” in the 
SABTS 1999 Model. If this model had been in use, the previous 
donation, which has a high probability of having been in the 
window-period, would most probably have been used for 
transfusion to a patient since the blood was typed as group O 
Rho-positive. The prevalence of HIV-positive donations in risk 
category “Cb1” is 0.0052% and, in spite of the HIV-positive 
donation mentioned, the risk category still falls comfortably within 
the set risk limit of less than 0.0100%. 
 
At the next risk level, the Combination Model has an HIV-positive 
donation prevalence of 0.0775%, which is poorer than the 
equivalent risk category in the Donation Interval Model, but a 
slight improvement on the equivalent category in the SABTS 1999 
Model. The five HIV-positive donations which were categorized as 
“Cb2”, constituted three new donors and two lapsed donors who 
had made their previous donations more than seven years 
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previously. These were the same donors classified as “A2” in the 
SABTS 1999 Model. The Combination Model succeeded in 
categorizing the single regular donor from “A2” in the SABTS 
1999 Model to “Cb3” in the Combination Model. The prevalence of 
these HIV-positive donations in the Combination Model is, 
however, still within the suggested risk limit of less than 0.1000% 
for risk category “Cb2”. 
 
A similar situation exists when red cells for transfusion to adults 
need to be found in situations of extreme shortage. The three 
HIV-positive donations which fell into the “Cb3” category of the 
Combination Model consisted of a donation from a new donor, a 
donation from a lapsed donor who had made his previous 
donation almost 8 years previously, and a donation from a regular 
donor who had made his previous donation six months previously. 
The 0.8333% prevalence in risk category “Cb3” remains within the 
suggested risk limit of less than 1.0000%. 
 
The categories within which the HIV-positive donations fell in 
respect of the Combination Model are illustrated graphically in 
Figure 5.7.  
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Figure 5.7: Percentage of HIV-positive donations by risk category using the 
Combination Model 
 
The performance of the Combination Model against the risk limit 
standards set for the SABTS 1999 Model is graphically illustrated 
in Figure 5.8 
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Figure 5.8: HIV prevalence per risk category using the Combination Model 
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5.3.1.4. The SANBS 2005 Model 
The SANBS 2005 Model was implemented by SANBS following 
the directive by the South African Department of Health to 
discontinue the use of the SABTS 1999 Model due to its use of 
race as an indicator. This model proved to be one of the models 
with the poorest safety factor when donations required for the 
preparation of platelet concentrates and paediatric red cell 
concentrates needed to be identified. In this model two donations 
returning an HIV-positive result were categorized as “C”. These 
two HIV-positive donations were made by two regular donors who 
had respectively made their previous donations two months and 
twelve months previously. The donation collected two months 
previously (the same donation categorized as “DI1” in the 
Donation Interval Model) was typed as group O Rho-positive and 
would most likely have been transfused if the SANBS 2005 Model 
had been applied at the time of this study. The “C” categorized 
donation from the donor whose last donation had been made 
twelve months previously was categorized as “A4”, “DI4” and 
“Cb4” within their respective models. The performance of this 
model in terms of the risk limits set for the SABTS 1999 Model 
was unsatisfactory at 0.0120%, compared to the set standard of 
less than 0.0100 %. 
 
In terms of donations allocated to the preparation of red cell 
concentrates for transfusion to adults, the SANBS 2005 Model, 
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although returning one HIV-positive donation in risk category “R”, 
recorded a prevalence of 0.0147%, which was well within the 
suggested risk limit standards. This donation was an HIV-positive 
donation accepted from the group O Rho-negative regular donor 
whose previous donation had been made six months earlier and 
whose present donation was categorized as “A2” according to the 
SABTS 1999 Model. 
 
The safety factor according to the SANBS 2005 Model, associated 
with donations to be considered for the preparation of red cell 
concentrates for adults in situations of extreme shortage, proved 
disappointing with seven, two and no HIV-positive donations 
respectively for the “PLR1”, “PLR2” and “PLR3” categories. The 
ideal model should have allocated categories to these donations 
in reverse order. With an extrapolated risk limit of less than 
0.2150% for “PLR1”, this category, at 0.5414%, did not meet the 
required standard. All seven HIV-positive donations were donated 
by donors who had made their previous donations more than 3½ 
years earlier. The HIV prevalence in the “PLR2” and “PLR3” risk 
categories proved well within the suggested limits of less than 
0.4640% and less than 1.0000% respectively. Both the “PLR2” 
HIV-positive donations were accepted from new donors. 
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The categories within which the HIV-positive donations fell, in 
respect of the SANBS 2005 Model, are illustrated graphically in 
Figure 5.9. 
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Figure 5.9: Percentage of HIV-positive donations by risk category using the 
SANBS 2005 Model 
 
The performance of the SANBS 2005 Model against the 
extrapolated risk limit standards set for the SABTS 1999 Model is 
graphically illustrated in Figure 5.10. 
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Figure 5.10: HIV prevalence per risk category using the SANBS 2005 Model 
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5.3.1.5. The Age-based Model 
The Age-based Model also proved to be a model with a poor 
safety factor when donations for the preparation of platelet 
concentrates and paediatric red cell concentrates needed to be 
identified. Two donations which returned an HIV-positive result 
were categorized as “AC1”. The two HIV-positive donations 
categorized as “AC1” in the Age-based Model were donated by 
two regular donors who had made their previous donations two 
months and six months earlier. The donation collected two months 
previously (the same donation categorized as “DI1” in the 
Donation Interval Model) was typed as group O Rho-positive and 
would most likely have been transfused if the Age-based Model 
had been applied. The other HIV-positive donation to be 
categorized as “AC1” in the Age-based Model was a donation 
from a group O Rho-negative donor who had made his previous 
donation six months previously (the same group O Rho-negative 
donation categorized as “A2” in the SABTS 1999 Model). The 
performance of the Age-based model in terms of the risk limits set 
for the SABTS 1999 Model is poor at 0.0160%, compared to the 
set standard of less than 0.0100 %. 
 
In terms of donations allocated to the preparation of red cell 
concentrates for transfusion to adults, the Age-based Model 
recorded no HIV-positive donations, which places the “AC2” risk 
category on par with the “DI2” risk category of the Donation 
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Interval Model and represents an improvement over the other 
three models. 
 
The safety factor, according to the Age-based Model, associated 
with donations to be considered for the preparation of red cell 
concentrates for adults in situations of extreme shortage proved a 
safer option than the SABTS 1999 Model, the Combination Model 
and the SANBS 2005 Model. The prevalence in the “AC3” 
category was 0.0171% compared to the suggested limit of less 
than 0.3000%, and the prevalence in the “AC4” category was 
0.0000% compared to the suggested limit of less than 1.0000%. 
One HIV-positive donation was allocated to the “AC3” category, 
this being the donation accepted from a regular donor who had 
last donated twelve months previously. This was the same 
donation categorized as “C” in the SANBS 2005 Model.  
 
The categories within which the HIV-positive donations fell in 
respect of the Age-based Model are illustrated graphically in 
Figure 5.11.  
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Figure 5.11: Percentage of HIV-positive donations by risk category using the 
Age-based Model 
 
The performance of the Age-based Model against the 
extrapolated risk limit standards set for the SABTS 1999 Model is 
graphically illustrated in Figure 5.12. 
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Figure 5.12: HIV prevalence per risk category using the Age-based Model 
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5.3.2. The risk assessment of the donation prior to the sero-converted 
donation 
The real risk of HIV transmission does not lie with the seventeen 
identified HIV-positive donations, but with unidentified HIV-positive 
donations still in the window period of infection. The donations 
received from donors prior to their HIV-positive donations, could 
potentially have been in the window period. Since the subgroup of 
donations made five years or less prior to the HIV-positive donation, 
was the group on which a look-back investigation needed to be done, 
this would then have been the subgroup providing the potential of 
HIV transmission to patients. Although the total donations in this 
group, namely five, are extremely small, there was a marked 
difference between the SABTS 1999 Model and the other four 
models at the level of the two lowest risk categories for each of the 
models constituting the source of red cell concentrates available for 
routine use for patients. The SABTS 1999 Model allowed 1 donation 
(20%) into the “A2” risk category compared to the other models which 
allowed between 40% (the Donation Interval Model) and 100% (the 
SANBS 2005 Model) into these risk categories. According to this 
criterion the SABTS 1999 Model would be the preferred model for the 
risk categorization of whole blood donations.  
 
 
 
5.3.3. The availability of sufficient blood 
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The analysis of the categorization of the 26647 HIV-negative 
collected donations includes another dimension of risk categorization, 
namely the availability of sufficient donated units, since the ideal of 
sufficient, safe blood needs to be attained. This aspect of the study 
also used the SABTS 1999 Model as a benchmark. The numbers of 
donations contained within each risk category are high enough so 
that the percentages can be considered statistically significant. The 
degree of significance to which the availability of blood, according to 
each model, varied, was determined using the F ratio and is indicated 
in Table 5.10. In all the models investigated in this study, the 
precedent set by SANBS in the application of its SABTS 1999 Model 
and maintained in the SANBS 2005 Model, where the two lowest risk 
categories are considered suitable sources of red blood cells for 
routine transfusion, has been applied as indicated in Table 5.8. 
 
5.3.3.1. The SABTS 1999 Model 
As shown in Table 5.10, the relative amount of risk category “A1” 
blood available for the preparation of platelet concentrates and 
paediatric red cell concentrates amounts to almost 80% of the 
blood collected. This compares with the 12.5% demand for these 
products in the area served by the Bloemfontein branch of 
SANBS. Subject to quality limitations, this allows a very easy 
choice of donated whole blood for the preparation of these 
products with the remainder being available for the preparation of 
other blood products requiring less stringent selection criteria from 
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the HIV risk management perspective. The cumulative percentage 
of risk category “A1” and “A2” blood, amounting to over 95%, is 
about 400 donations short of the number needed to serve the 
demands of the patients for all the red cell requirements which 
amounted to (25684 during 2005) as indicated in Table 5.10. This 
shortfall was low enough so that it could comfortably be made up 
by transferring excess donations from surrounding branches. The 
relative percentages of the collected blood, according to risk 
category when applying the SABTS 1999 Model, are illustrated 
graphically in Figure 5.13. 
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Figure 5.13: Percentages of whole blood donations by risk category using 
the SABTS 1999 Model 
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As indicated in Chapter 2 the SABTS 1999 Model was based on 
information which indicated that the ethnic group of the donor was 
a strong indicator of HIV exposure risk in the area served by the 
Inland Region of SANBS due to the differing primary modes of 
HIV infection. Tables 5.7 and 5.8 clearly show that this model 
generally fulfilled its purpose.  By the middle of 2004 there had 
been several warnings about the effectiveness of the pre-donation 
screening procedure. If improved effectiveness of the screening 
procedure, using the pre-donation self-exclusion questionnaire 
with its prescribed discussion with the donor, did not bring about 
an improvement in the increasing HIV sero-conversion trend 
among lapsed and new white male donors, the donation risk 
categorization of these subgroups needed to be escalated to a 
higher level. At the time of this study the required improvement 
had not been achieved. This accounts for the fact that in this 
study, the prevalence of HIV-positive donations categorized as 
HIV risk category “A2” exceeded the risk limits for category “A2” 
blood according to the SABTS 1999 Model.  
 
5.3.3.2. The Donation Interval Model 
The Donation Interval Model is extremely dependant on very 
regular donations. Due to the short interval allowed between 
donations, which would allow an improvement on the previous 
donation risk category (up to 121 days) or for the maintenance of 
the previous donation risk category (up to 183 days), the volumes 
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of blood categorized as the safest (“DI1”) is sufficient for the 
provision of platelet concentrates and paediatric red cells at 56% 
of the total whole blood collected subject to quality limitations and 
blood group requirements. The cumulative figure for risk 
categories “DI1” and “DI2” only provides approximately 17800 
donations (almost 67%) for the preparation of the required red cell 
products – almost 8000 donations short of the required 25684 
units of red cell concentrate. Even the additional use of risk 
category “DI3”, whose red cells are intended for use in times of 
extreme shortage, would only provide a total of 20700 donations 
which still leaves a shortfall of approximately 5000 donations. The 
relative percentages of the collected blood according to risk 
category when applying the Donation Interval Model, is illustrated 
graphically in Figure 5.14. 
 
 
 
 111 
P E R C E N T A G E  D O N A T IO N S  P E R  R IS K  C A T E G O R Y :  
D O N A T IO N  IN T E R V A L  M O D E L
D I4 ;  2 2 . 1 4 %
D I2 ;  1 0 . 5 4 % D I1 ;  5 6 . 3 6 %
D I3 ;  1 0 . 9 7 %
D I1
D I2
D I3
D I4
 
Figure 5.14: Percentages of whole blood donations by risk category using 
the Donation Interval Model 
 
As stated in Chapter 2 the Donation Interval Model was 
suggested due to an increasing awareness of the sensitivity of a 
donation risk categorization system, using race as the indicator 
with the greatest influence on the potential usage of the 
donations. This model attempted to apply a completely non-racial 
and non-gender approach as can be seen in Table 2.8. Tables 5.7 
and 5.8 clearly show that this model would have been very 
successful from a blood safety point of view, but most 
unsuccessful from a blood availability point of view. 
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The fact that only one of the sixteen HIV-positive donations was 
“mis-allocated” to risk category “DI1” and the remaining sixteen 
HIV-positive donations were ideally allocated to risk category 
“DI4” gives a strong indication that the interval since the donor’s 
previous donation alone, was a strong predictive indicator of the 
risk of HIV exposure. Given the high number of donations 
allocated to risk category “DI4” and the resulting low percentage 
of HIV-positives, this model’s downfall is over-prediction leading to 
the unnecessary wastage of donated red cells and the inability to 
provide sufficient “low-risk” red cells for transfusion to patients.  
 
Despite the noted difficulties, further research using modifications 
of the interval between donations principle, similar to the Donation 
Interval Model, may well prove valuable. This research would 
have the distinct advantage of possibly being applicable those 
areas in sub-Saharan Africa where blood is collected from 
voluntary donors, since neither race nor gender is used as an 
indicator. The possibility also exists that the use of this principle 
could make the blood transfusion risk management by the use of 
a donation risk hierarchy less susceptible to changes in sexual 
behaviour than would be the case with donor demographics-
based indicators. A likely prerequisite for the successful 
application of any variation of this model would probably be a 
network computer system, which would allow the recording of 
donations made by a donor over an extended geographic area 
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and the easy calculation of each donation’s risk category 
according to the specific parameters of the model variant used. 
 
5.3.3.3. The Combination Model 
A possible solution to the insufficiency of donated blood within the 
two lowest risk categories lies in the application of a combination 
of the SABTS 1999 Model and the Donation Interval Model. As 
mentioned in Chapter 3, one of the shortcomings of the SABTS 
1999 Model is the fact that donations from black and coloured 
donors can only reach an “A3” and “A2” risk category respectively 
at best. The Combination Model applies the SABTS 1999 Model’s 
criteria as a minimum risk category level. In essence this would 
mean that donations from Asian new donors would still enter the 
risk hierarchy at the equivalent of risk category “A2” (being “Cb2”) 
and the next donation, if made within 120 days of the previous 
donation, would be classified as the equivalent of risk category 
“A1” (being “Cb1”). At the opposite end of the spectrum donations 
from black donors would still enter the risk hierarchy at the 
equivalent of risk category “A4” (being ”Cb4”), but if subsequent 
donations are repeatedly made within a 120 day interval, the risk 
classification would successively drop to the equivalent of risk 
category “A1”. The data in Table 5.7 shows that the volumes of 
blood categorized as the safest (“Cb1”) is ample for the provision 
of platelet concentrates and paediatric red cells at 72% of the total 
whole blood collected. The cumulative figure for risk categories 
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“Cb1” and “Cb2” provides approximately 25700 donations (over 
96% of the collections) for the preparation of the required red cell 
products. In terms of availability this model has the potential to 
fulfil the sufficiency requirements. The use of risk category “Cb3”, 
whose red cells are intended for use in extreme shortages, would 
only provide an additional 360 donations since this risk category 
comprises merely 1.35% of the total donations. An additional 
advantage to this model is that risk category “Cb4” donations only 
amount to 2.16%, limiting the number of potentially unusable red 
cells due to risk categorization and therefore also represents a 
more efficient use of the donated blood, even when red cells of 
risk category “Cb3” are not used. The relative percentages of the 
collected blood according to risk category when applying the 
Combination Model, is illustrated graphically in Figure 5.15. 
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Figure 5.15: Percentage of whole blood donations by risk category using the 
Combination Model 
 
The initial opinion that the Donation Interval Model would allow 
insufficient blood to be made available under routine conditions 
when compared with the SABTS 1999 Model, proved well 
founded. This opinion prompted the investigation of a model 
combining the unlimited progression down the risk category scale 
for donations from very regular donors irrespective of race or 
gender as propagated in the Donation Interval Model, with the 
race- and gender-based upper risk category limits defined by the 
SABTS 1999 Model. This approach, while allowing an even better 
availability of blood for routine transfusions than the SABTS 1999 
Model, proved less than satisfactory from a blood safety point of 
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view for reasons due to the higher prevalence of HIV-positive 
donations in the “Cb2” category than in the “Cb3” category. This 
model would be as non-viable outside South Africa as the SABTS 
1999 Model. The implementation of this model, had it been 
suggested at an earlier stage prior to the negative publicity 
generated by the SABTS 1999 Model, may have forestalled the 
worst of the negative publicity and allowed more time to develop a 
more suitable model without recourse to race as an indicator.  
 
5.3.3.4. The SANBS 2005 Model 
The SANBS 2005 Model is also a donation frequency-based 
model similar to the Donation Interval Model. It is, however, a 
more “lenient” model in respect of the regularity of the donations 
and an attempt is also made to make better use of donations from 
new donors through an age-based sub-categorization, than was 
the case with the SABTS 1999 Model as shown in Table 2.10. As 
shown in Table 5.7 the relative amount of risk category “C” blood 
available for the preparation of platelet concentrates and 
paediatric red cell concentrates amounts to just over 62% of the 
blood collected. This compares with the 12.5% demand for these 
products in the area served by the Bloemfontein branch of 
SANBS. As mentioned previously, subject to quality limitations 
and blood group requirements, this allows a very easy choice of 
donated whole blood for the preparation of these products with 
the remainder being available for the preparation of other blood 
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products requiring less stringent selection criteria in respect of HIV 
risk management. The cumulative percentage of risk category “C” 
and “R” blood which amounts to almost 88% is about 2300 
donations short of the number needed to serve the demands of 
the patients for all the red cell requirements of 25684 units of red 
cells during 2005. The relative percentages of the collected blood 
according to risk category when applying the SANBS 2005 Model, 
are illustrated graphically in Figure 5.16. 
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Figure 5.16: Percentage of whole blood donations by risk category using the 
SANBS 2005 Model 
 
The model is based on a donation interval format, but also 
attempts to make better use of donations from new donors. The 
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more liberal donation intervals allowed by this model, has allowed 
an increase in the number of donations when compared to the 
Donation Interval Model. The use of selected donations from new 
donors has further helped to provide more red cells in times of 
extreme shortage. In terms of the blood safety aspect, this model 
shows similar performance to the SABTS 1999 Model when the 
red cells for routine use are considered. It is noticeable that the 
increased “leniency” in terms of the donation interval, when 
compared to the Donation Interval Model, has resulted in a 
considerable deterioration of the safety of the blood for routine 
use. The safety of the categories of blood which can be used in 
times of extreme shortage shows an illogical trend with regard to 
the donations collected by the Bloemfontein Branch. It is clear that 
the age parameters applied to the donations from new donors are 
not suited to their intended task in the geographic area and time 
period covered by this study. This is a particularly serious 
situation, given the fact that blood categorized as “PLR1” is 
presently (in 2007) almost routinely transfused to patients in the 
area served by SANBS. This is due to the growth in the need for 
blood far outstripping the growth in the number of “C” and “R” 
blood donations collected since the implementation of this model. 
Further research into this aspect is therefore necessary, and the 
results obtained during the analysis of HIV-positive donations 
during the first phase of this study, may give an indication of 
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possible modifications which could be investigated in respect of 
donations obtained from new donors. 
 
5.3.3.5. The Age-based Model 
The Age-based Model seeks to exploit the donor age in regular 
donors who have made at least one donation in the preceding 24 
months, as an indicator of HIV risk. Unpublished data undertaken 
in a pilot study, which prompted the study discussed in 5.1 above, 
suggested that the donor’s age possibly played a role in the 
likelihood of the donor being exposed to HIV.  As discussed in 5.1 
a clear relationship can be identified in terms of “recent” exposure. 
This has lead to this study’s suggestion of a 5-level risk 
categorization hierarchy as indicated in Table 5.7. The data in 
Table 5.10 shows that the volumes of blood categorized as the 
safest (“AC1”) is sufficient for the provision of platelet 
concentrates and paediatric red cells, at almost 47% of the total 
whole blood collected. The cumulative figure for risk categories 
“AC1” and “AC2” only provides approximately 16000 donations 
(just over 60% of the collections) for the preparation of the 
required red cell products. In terms of availability this model has a 
shortfall of almost 10000 donations needed for routine use for the 
preparation of the 25684 red cell concentrates required in 2005. 
The use of donations from risk categories “AC3” and “AC4” whose 
red cells are intended for use in times of extreme shortage would 
only provide an additional almost 7300 donations, since these risk 
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categories comprise almost 22% and a little more than 5% of the 
total donations, respectively. It is therefore clear that this model 
does not provide any advantages over the SANBS 2005 Model as 
far as red cell sufficiency is concerned. The relative percentages 
of the collected blood according to risk category when applying 
the Age-based Model, is illustrated graphically in Figure 5.17. 
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Figure 5.17: Percentage of whole blood donations by risk category using the 
Age-based Model 
 
At first glance the Age-based Model imparts a good impression. 
Further analysis, however, shows that its success is purely due to 
the fact that the donations from all new donors and lapsed donors 
are considered high risk donations of which only the plasma is 
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suitable for use. Two of the three donations collected from regular 
donors were categorized as being suitable for paediatric and 
immune-compromised patients, which is most unsatisfactory when 
compared with the SABTS 1999 Model, the Donation Interval 
Model and the Combination Model, but equivalent to the 
performance of the SANBS 2005 Model. A much larger study, 
encompassing a more statistically significant number of HIV-
positive donations, may still validate this model, since the results 
obtained from the second phase of the study, in respect of the 
donations made during the study period, do not appear to 
correlate very well with the results obtained in the first phase of 
the study to determine the criteria for the Age-based Model. 
 
This study centred on the HIV prevalence of each risk category within 
different models and on the availability of “safe” blood for transfusion when 
these models are applied. Two further aspects, not included in this study, 
should be recognized as also playing an important role in the choice of a 
suitable model. Firstly, the ethical consideration of collecting blood from 
voluntary donors when the likelihood of using the blood as intended by the 
donor is minimal. Secondly, the financial implication of collecting blood from 
donors with a high likelihood of the blood being discarded.  
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CHAPTER 6: CONCLUSIONS AND RECOMMENDATIONS 
 
This study has highlighted the dilemma facing blood transfusion services 
across the world and is particularly exacerbated in sub-Saharan Africa due 
to the high prevalence of HIV, a scarcity of resources and insufficient regular 
voluntary non-remunerated donors. This dilemma calls for a balance 
between patients being fatally infected by HIV through the transfused blood, 
or patients losing their lives because blood considered safe enough for 
transfusion was not available. 
 
6.1. Conclusions 
The analysis of these five models strengthens the notion that the 
greater the level of safety sought, the smaller the pool of suitably 
categorized donations available for use will be. This is emphasized 
more if the specific indicators used only partially contribute to the HIV 
risk status of the donor, and therefore to the likelihood of the donations 
being correctly categorized. Changes in social behaviour over time, 
particularly sexual behaviours in the case of HIV, also play a strong 
role in the changes to the effectiveness of any mix of indicators of 
increased risk of HIV exposure at any given time. This study has 
shown some promising avenues for further investigation, and also 
some dead-ends, in terms of the availability of sufficient blood. From 
the blood safety point of view, it is rather more difficult to draw 
conclusions since the numbers of HIV-positive donations received in 
the course of the study were very few, only seventeen in total, due to 
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the low prevalence of HIV among blood donors during the period 
covered by the second phase of this study. This is in keeping with a 
world-wide phenomenon where blood for transfusion to patients is 
collected from voluntary non-remunerated blood donors. The 
differences in the percentages could therefore not be considered 
statistically significant. The limited geographic area of the study vis-à-
vis the geographic area served by SANBS also places constraints on 
the direct extrapolation of any of the findings contained in this study 
without similar research covering other geographic areas. 
 
In spite of these limitations, this study can still serve as a guide 
regarding the applicability of these models, Some of the models show 
sufficient potential warranting further corroboration on a national basis. 
At the same time, this study also provides a good indication of potential 
risk categorization models which do not warrant further investigation. 
 
Over the time period covered by this study it is particularly noticeable 
(from Appendix 3 and Figures 5.3, 5.4, 5.6 and 5.8) that the prevalence 
of HIV-positive donations in the lower HIV risk categories was far from 
ideal when the SABTS 1999 Model and the Combination model was 
applied, while these two models provided the best availability of “low 
HIV risk” blood for patient use (as indicated in Table 5.8 and Figures 
5.13 and 5.15). In contrast it is clear that the Donation Interval Model, 
and to a slightly lesser extent the Age-based Model, can successfully 
be used to relegate HIV-positive donations to the highest HIV risk 
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category (as can be seen in Appendix 3 and Figures 5.5, 5.7, 5.10 and 
5.12). This improvement would unfortunately be at the cost of blood 
availability, which outweighs the gains achieved in terms of blood 
safety. 
 
The results of this study have shown that each of the models studied 
has advantages and disadvantages. Given all the factors, stated in 
Chapters 2 and 5, the SANBS 2005 Model probably remains the most 
useful choice at this time, since the other alternatives without a racial 
indicator proved unsuccessful at providing an improved model in terms 
of the balance between blood safety and availability.  
 
This study has highlighted the possible avenues of investigation using 
modifications to the donation regularity criteria as well as the donor 
age criteria. Geographical indicators were not considered, since the 
study is limited to blood donations received in the geographical area 
served by the Bloemfontein Branch of SANBS, and different 
geographic areas show differences in HIV prevalence in donated 
blood. The impact of these differences on the application of the model 
could therefore not be assessed. 
 
Although doubt has been expressed regarding the feasibility of donor 
screening in countries with a high HIV prevalence and per implication 
possibly also donation risk categorization, this tool may provide a 
measure of safety for patients receiving blood transfusions at a 
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relatively low operational cost. Most sub-Saharan African countries are 
unable to provide sufficient blood for transfusion from voluntary blood 
donors. Because the times of peak supply and peak demand of blood 
of certain ABO and Rhesus groups seldom coincide, the value of the 
risk categorization system would lie in the ability to ensure that if units 
of blood should expire due to insufficient demand at any particular 
point in time, they should ideally be the donations from the group of 
donors exhibiting indicators of the highest risk of possible window-
period HIV transmission. In those African countries where the blood 
transfusion services are under-funded, to the extent that the efficacy of 
donation testing for HIV is compromised, assistance programmes such 
as PEPFAR could be engaged to provide the funding for the required 
expertise, research and computer infrastructure, allowing the effective 
risk categorization of the voluntary blood donations collected for 
transfusion. By visibly enhancing the safety of voluntarily donated 
blood, public awareness of the inherent safety and extent of the need 
for regular voluntary blood donations may be improved. Model 
variations based on the SANBS 2005 Model, Donation Interval Model 
and the Age-based Model could be investigated in other areas of Africa 
for possible implementation, together with any existing or improved 
donor education and screening processes.  
 
6.2. Recommendations 
As the socio-political situation and life-style norms and behaviours on 
the ground level change in Africa and particularly in South Africa, so 
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the demographics of the blood donor base can be expected to change. 
This study can therefore not be the final word on the issue of donation 
risk categorization in countries with a high HIV prevalence. 
 
For as long as the window period of infectivity remains a problem, 
further research in this direction will remain necessary until one or 
more indicators are identified which are minimally affected by changing 
social norms and behaviours in the communities providing the blood 
donations. The successful implementation of a model will also be 
determined by the use of indicators which are not considered 
prejudicial by the communities. 
 
It should be stressed that the management of the risk of HIV 
transmission through blood donation risk categorization is only one tool 
in the risk management arsenal. Other tools must include processes 
such as donor education, effective pre-donation screening by 
appropriate questions and education regarding evidence-based, 
clinically appropriate transfusions. 
 
The impact of NAT has not been considered in this study. It has been 
the premise of SANBS since the implementation of NAT in October 
2005, concurrently with the implementation of the SANBS 2005 
Model, that the reduction in the window period would play a major 
role in mitigating the possible deficiencies of the SANBS 2005 Model, 
as subsequently highlighted in this study, through the increased 
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sensitivity of the test procedure. Continuous monitoring of the test 
results of the collected blood and additional research will determine 
the validity of this premise. 
 
The following specific recommendations based on the results of this 
study can be made: 
 The SANBS 2005 Model is the most useful choice for SANBS at 
this time, and should therefore be used until a better model is 
developed, or NAT has proven sufficiently effective to allow the 
discontinuation of donation risk categorization of donations from 
regular donors. 
 The parameters for the “PLR1”, “PLR2” and “PLR3” risk categories 
in the SANBS 2005 Model need to be investigated to re-assess 
their validity throughout the area served by SANBS. 
 Further investigation using modifications to the donation regularity 
criteria and the donor age criteria should be undertaken by SANBS 
in respect of the SANBS 2005 Model. 
 The effect of changes in the demographic composition of the 
SANBS donor base, emanating from the changed recruitment and 
recall criteria, should be investigated to determine the continued 
validity of the findings of this study. 
 Any modification of the models considered to have promising 
results, should be investigated in all the geographical areas served 
by SANBS (or any other area where implementation is considered) 
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to ensure effectiveness of the model when applied to the donations 
obtained from the specific local donor cohorts. 
 Due to resource constraints in sub-Saharan Africa, initiatives such 
as PEPFAR could be encouraged to provide the funding for the 
initial research to determine the parameters of a suitable blood risk 
categorization model for those countries which cannot implement 
NAT testing of all their donations. 
 Assistance programmes such as PEPFAR could also play an 
invaluable role in the provision of suitable computer infra-structure 
for recording all the appropriate donor and donation details and 
allocation of a risk category to each donation based on the 
recorded donor and donation information. 
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Appendix 1: Ethics Committee letter of approval 
 
 
APPENDIX 2: 
Ethnic* Sex**
Age 
HIV 
Pos
8th Prev. 
Test Date
7th Prev. 
Test Date
6th Prev. 
Test Date
5th Prev. 
Test Date
4th Prev. 
Test Date
3rd Prev. 
Test Date
2nd Prev. 
Test Date
Prev. Test 
Date
Date HIV 
Pos. 
Donation
H001 W M 37 1994/12/29 1995/03/02 1995/05/31 1995/08/07 1995/10/17 1995/12/13 1996/04/10 1997/02/10 1997/06/18
H002 W M 32 1995/11/10 1996/01/09 1996/03/14 1996/05/04 1996/07/26 1996/11/06 1997/04/17 1997/06/19 1997/08/01
H003 W M 36 1995/06/13 1995/08/08 1995/10/10 1996/02/21 1996/08/20 1996/10/22 1996/12/17 1997/04/22 1997/08/19
H004 B M 53 1996/03/26 1996/05/21 1996/07/16 1996/11/05 1997/01/07 1997/03/04 1997/04/29 1997/07/08 1997/11/11
H005 W M 38 1993/06/18 1995/08/17 1995/10/27 1996/01/10 1996/03/13 1996/05/10 1996/07/29 1996/11/05 1997/12/09
H006 B F 30 #N/A #N/A #N/A #N/A #N/A 0 1996/12/05 1997/04/24 1997/12/24
H007 B M 30 #N/A #N/A #N/A #N/A #N/A #N/A 0 1997/02/28 1998/01/08
H008 B M 23 1995/10/20 1996/02/09 1996/04/12 1996/06/07 1996/08/02 1997/01/20 1997/04/11 1997/08/15 1998/01/19
H009 B F 19 #N/A 0 1995/10/20 1996/02/09 1996/04/12 1996/08/02 1997/08/15 1997/10/17 1998/02/06
H010 B M 27 #N/A 0 1996/05/30 1996/09/19 1996/11/21 1997/02/26 1997/04/30 1997/06/25 1998/02/11
H011 B M 34 0 1996/07/08 1997/02/17 1997/04/14 1997/06/11 1997/08/13 1997/10/29 1998/01/21 1998/03/25
H012 B F 29 #N/A 0 1994/08/31 1996/12/05 1997/02/17 1997/04/21 1997/08/25 1997/10/27 1998/04/20
H013 B M 29 #N/A #N/A #N/A #N/A #N/A #N/A 0 1997/08/12 1998/04/29
H014 B M 31 #N/A #N/A #N/A #N/A #N/A #N/A 0 1992/08/28 1998/04/29
H015 B M 41 #N/A #N/A #N/A #N/A #N/A 0 1992/12/02 1993/11/10 1998/04/29
H016 B F 22 #N/A #N/A #N/A #N/A #N/A 0 1995/08/24 1996/02/08 1998/05/21
H017 B F 22 #N/A #N/A 0 1997/01/21 1997/05/20 1997/09/16 1997/11/18 1998/04/07 1998/06/09
H018 B M 21 #N/A #N/A #N/A 0 1997/01/17 1997/12/05 1998/02/06 1998/04/21 1998/06/19
H019 B M 33 1996/11/04 1997/01/22 1997/03/25 1997/05/21 1997/07/23 1997/09/17 1997/11/21 1998/03/24 1998/07/15
H020 B M 44 #N/A #N/A #N/A #N/A #N/A 0 1997/05/28 1997/07/28 1998/08/27
H021 B F 26 #N/A #N/A #N/A 0 1994/11/22 1995/07/04 1997/06/23 1997/12/15 1998/09/02
H022 B F 29 #N/A #N/A #N/A #N/A 0 1995/03/01 1995/04/26 1995/06/21 1998/09/10
H023 B M 31 1996/03/13 1996/11/13 1997/04/22 1997/08/12 1997/10/21 1998/02/24 1998/04/29 1998/07/07 1998/09/29
H024 B M 32 #N/A 0 1993/02/26 1996/05/15 1996/09/11 1996/11/13 1997/04/22 1998/04/29 1998/09/29
H025 W M 24 1995/08/24 1997/02/26 1997/04/29 1997/07/04 1997/09/01 1997/12/03 1998/01/28 1998/04/24 1998/09/30
H026 B F 24 #N/A #N/A #N/A #N/A #N/A 0 1995/07/20 1995/11/13 1998/10/07
H027 B M 23 #N/A #N/A #N/A #N/A 0 1998/02/26 1998/05/07 1998/07/23 1998/10/13
H028 B F 21 #N/A #N/A #N/A #N/A #N/A #N/A 0 1997/07/24 1998/10/19
H029 B F 33 #N/A #N/A #N/A #N/A #N/A 0 1996/03/20 1996/07/24 1998/11/04
DEMOGRAPHICS TEST / DONATION DATES
DONATION CATEGORIZATION STUDY: SANBS, INLAND REGION CONFIRMED HIV-POSITIVE DONATIONS: 1997 - 2006
HIV-positive donations received by SANBS, Inland Region between 1997 and 2006
Donation 
Serial No
Ethnic* Sex**
Age 
HIV 
Pos
8th Prev. 
Test Date
7th Prev. 
Test Date
6th Prev. 
Test Date
5th Prev. 
Test Date
4th Prev. 
Test Date
3rd Prev. 
Test Date
2nd Prev. 
Test Date
Prev. Test 
Date
Date HIV 
Pos. 
Donation
DEMOGRAPHICS TEST / DONATION DATES
Donation 
Serial No
H030 B M 32 1997/05/28 1997/07/23 1997/09/17 1997/11/12 1998/01/08 1998/03/05 1998/06/04 1998/08/27 1998/11/05
H031 W M 34 1996/04/03 1996/11/29 1997/04/17 1997/06/26 1997/09/04 1997/11/07 1998/06/19 1998/08/21 1998/11/20
H032 B F 22 #N/A #N/A #N/A #N/A 0 1997/04/18 1997/06/13 1997/08/08 1998/11/27
H033 B M 34 #N/A #N/A 0 1993/11/18 1994/01/14 1994/03/15 1994/06/13 1994/10/18 1999/02/19
H034 B F 20 #N/A #N/A #N/A #N/A #N/A 0 1998/09/03 1998/12/05 1999/02/26
H035 B F 16 #N/A #N/A #N/A #N/A #N/A #N/A 0 1998/08/06 1999/03/11
H036 B F 24 #N/A #N/A #N/A #N/A #N/A #N/A 0 1993/02/03 1999/04/01
H037 B F 25 #N/A #N/A 0 1997/02/21 1997/04/18 1997/06/17 1997/08/15 1997/10/15 1999/04/13
H038 C F 47 #N/A 0 1997/05/12 1997/11/24 1998/01/26 1998/03/23 1998/07/13 1998/09/08 1999/04/29
H039 B F 18 #N/A #N/A #N/A #N/A #N/A 0 1998/03/11 1999/02/19 1999/04/30
H040 B F 18 #N/A #N/A #N/A #N/A #N/A 0 1998/03/23 1998/08/26 1999/05/12
H041 B F 25 #N/A #N/A #N/A #N/A 0 1998/08/26 1998/10/08 1998/12/03 1999/05/20
H042 B F 17 #N/A #N/A #N/A #N/A #N/A #N/A 0 1998/05/25 1999/05/26
H043 B F 23 1996/04/11 1996/07/25 1996/10/07 1997/01/23 1997/04/17 1997/07/14 1997/09/11 1997/11/10 1999/07/09
H044 C F 33 #N/A #N/A #N/A #N/A #N/A #N/A 0 1999/04/04 1999/08/15
H045 B M 24 #N/A #N/A #N/A #N/A #N/A #N/A 0 1996/12/13 1999/09/14
H046 B M 20 1996/04/11 1996/06/06 1996/10/03 1997/04/10 1997/06/05 1997/10/02 1998/01/29 1998/07/16 1999/10/07
H047 B F 17 #N/A #N/A #N/A #N/A #N/A #N/A 0 1999/02/12 1999/10/22
H048 B M 26 #N/A #N/A 0 1998/11/06 1999/01/14 1999/03/19 1999/05/14 1999/08/28 1999/10/28
H049 B F 57 0 1992/11/16 1993/03/04 1993/10/20 1993/12/31 1994/03/02 1994/05/02 1997/01/31 1999/11/05
H050 B M 39 #N/A #N/A #N/A #N/A #N/A #N/A 0 1999/10/07 1999/12/02
H051 B F 33 #N/A #N/A #N/A #N/A #N/A #N/A 0 1994/01/31 2000/01/04
H052 B F 21 #N/A #N/A #N/A #N/A #N/A 0 1998/03/10 1998/05/18 2000/01/06
H053 B F 28 #N/A #N/A #N/A #N/A #N/A #N/A 0 1994/08/10 2000/01/07
H054 B F 29 1997/04/01 1997/05/30 1997/08/13 1997/10/27 1997/12/22 1998/03/31 1999/01/22 1999/07/20 2000/01/10
H055 W M 33 1998/06/17 1998/08/17 1998/10/12 1998/12/11 1999/02/17 1999/06/18 1999/08/18 1999/10/11 2000/01/10
H056 W M 23 #N/A #N/A #N/A #N/A #N/A #N/A 0 1993/07/29 2000/01/12
H057 B M 43 #N/A #N/A 0 1993/01/19 1993/04/22 1998/02/09 1999/01/11 1999/08/10 2000/01/12
H058 W F 56 #N/A #N/A #N/A #N/A #N/A 0 1995/11/24 1996/01/25 2000/01/12
H059 W F 31 #N/A #N/A #N/A #N/A #N/A #N/A 0 1992/06/04 2000/01/18
H060 B F 45 1998/01/20 1998/03/24 1998/05/19 1998/07/21 1998/09/29 1999/02/09 1999/04/13 1999/06/15 2000/01/18
H061 B F 19 #N/A #N/A #N/A #N/A #N/A #N/A 0 1998/07/28 2000/01/19
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H062 B F 30 #N/A #N/A #N/A 0 1994/11/03 1995/01/26 1995/11/09 1996/05/02 2000/01/25
H063 B F 40 0 1997/06/10 1997/08/06 1997/10/01 1997/12/30 1999/01/12 1999/04/01 1999/11/30 2000/01/26
H064 B M 23 1996/04/25 1996/08/05 1997/05/27 1998/02/23 1998/05/11 1998/08/19 1999/01/27 1999/08/26 2000/01/28
H065 B F 19 #N/A #N/A 0 1998/02/16 1998/05/04 1998/07/22 1998/09/14 1999/05/05 2000/02/01
H066 B F 34 #N/A #N/A #N/A #N/A 0 1996/03/20 1996/07/17 1999/04/01 2000/02/03
H067 B F 49 1998/08/27 1998/10/22 1998/12/17 1999/02/17 1999/04/14 1999/06/21 1999/08/17 1999/12/08 2000/02/03
H068 B F 18 #N/A #N/A #N/A 0 1998/08/20 1998/10/20 1999/02/26 1999/05/04 2000/02/07
H069 W M 41 1997/11/18 1998/01/14 1998/03/13 1998/05/27 1998/07/22 1998/10/29 1998/12/23 1999/02/27 2000/02/07
H070 C F 18 #N/A #N/A #N/A #N/A #N/A #N/A 0 1999/05/24 2000/02/08
H071 B F 20 #N/A #N/A #N/A #N/A 0 1999/03/02 1999/06/08 1999/10/05 2000/02/08
H072 B M 30 #N/A #N/A #N/A #N/A 0 1998/07/14 1998/09/08 1998/11/03 2000/02/08
H073 B M 49 1996/05/20 1996/07/22 1997/05/15 1997/07/17 1997/09/18 1997/11/12 1998/03/11 1998/09/22 2000/02/08
H074 B M 21 #N/A #N/A #N/A #N/A 0 1999/02/03 1999/10/14 1999/12/07 2000/02/10
H075 B M 31 #N/A #N/A #N/A #N/A #N/A #N/A 0 1997/01/25 2000/02/10
H076 B F 40 #N/A #N/A 0 1992/12/03 1993/03/18 1993/06/21 1993/08/17 1993/10/25 2000/02/10
H077 B F 21 #N/A #N/A #N/A #N/A #N/A 0 1999/05/10 1999/08/31 2000/02/11
H078 B M 23 0 1997/04/10 1997/06/06 1997/08/12 1997/10/16 1998/01/15 1998/10/23 1999/04/09 2000/02/11
H079 B F 18 #N/A #N/A #N/A #N/A #N/A #N/A 0 1998/09/02 2000/02/14
H080 B M 20 #N/A #N/A #N/A #N/A 0 1999/02/19 1999/04/30 1999/09/03 2000/02/14
H081 B M 29 #N/A #N/A #N/A #N/A #N/A #N/A 0 1999/02/16 2000/02/15
H082 B M 32 1995/09/06 1996/05/02 1996/10/15 1997/11/07 1998/08/21 1998/10/13 1999/08/05 1999/09/16 2000/02/15
H083 B M 16 #N/A #N/A #N/A #N/A #N/A #N/A 0 1999/02/18 2000/02/16
H084 C M 25 #N/A #N/A #N/A #N/A #N/A #N/A 0 1996/03/13 2000/02/16
H085 B F 41 #N/A #N/A #N/A #N/A #N/A #N/A 0 1999/02/19 2000/02/17
H086 W M 44 #N/A 0 1992/11/12 1997/01/26 1998/01/11 1998/03/16 1998/06/07 1999/04/27 2000/02/18
H087 C F 21 0 1996/02/13 1996/07/24 1997/04/01 1997/07/08 1997/11/14 1998/03/24 1998/12/08 2000/02/22
H088 B F 24 #N/A #N/A #N/A #N/A #N/A #N/A 0 1999/08/23 2000/02/23
H089 W F 36 1993/02/26 1993/05/24 1993/09/03 1994/04/25 1995/10/21 1998/04/27 1998/07/20 1998/10/06 2000/02/23
H090 B M 41 1995/01/30 1995/12/18 1996/06/13 1996/11/13 1997/02/18 1997/07/03 1997/11/17 1998/02/16 2000/02/24
H091 W M 21 1995/05/03 1997/07/31 1997/10/01 1998/01/08 1999/01/21 1999/04/06 1999/06/01 1999/10/22 2000/02/28
H092 W M 45 1998/02/04 1998/09/02 1998/12/02 1999/02/03 1999/04/07 1999/07/07 1999/09/01 1999/11/03 2000/03/01
H093 B F 27 #N/A #N/A #N/A #N/A #N/A #N/A 0 1998/12/10 2000/03/02
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H094 B M 33 1993/04/05 1994/10/26 1998/07/30 1999/04/07 1999/06/01 1999/07/29 1999/09/30 1999/11/26 2000/03/02
H095 B M 24 #N/A #N/A #N/A #N/A 0 1999/02/17 1999/05/12 1999/08/26 2000/03/07
H096 B F 32 #N/A #N/A #N/A #N/A #N/A 0 1998/06/30 1998/08/25 2000/03/07
H097 W M 25 1998/05/09 1998/07/04 1998/08/29 1998/10/24 1998/12/24 1999/04/01 1999/06/01 1999/11/27 2000/03/13
H098 C M 30 #N/A #N/A 0 1995/10/25 1995/12/20 1996/02/20 1996/05/16 1996/08/02 2000/03/13
H099 B F 33 #N/A #N/A 0 1998/04/09 1999/02/25 1999/06/25 1999/10/11 1999/12/29 2000/03/13
H100 B M 28 #N/A #N/A 0 1998/12/07 1999/02/03 1999/04/07 1999/06/11 1999/08/10 2000/03/14
H101 B M 30 #N/A #N/A #N/A 0 1993/01/26 1993/03/30 1993/05/25 1996/03/11 2000/03/15
H102 B F 20 #N/A #N/A #N/A #N/A #N/A #N/A 0 1999/02/25 2000/03/20
H103 B F 20 #N/A #N/A #N/A #N/A #N/A 0 1998/05/28 1998/09/03 2000/03/20
H104 B M 31 #N/A #N/A 0 1995/03/13 1996/05/04 1996/06/14 1998/09/04 1999/09/13 2000/03/20
H105 B M 21 #N/A #N/A 0 1998/12/09 1999/03/02 1999/04/28 1999/08/23 1999/11/15 2000/03/22
H106 B M 28 0 1998/05/18 1998/07/21 1998/09/22 1999/01/21 1999/05/25 1999/07/27 1999/09/28 2000/03/23
H107 B M 35 1998/11/30 1999/01/25 1999/03/29 1999/05/24 1999/07/19 1999/09/28 1999/11/25 2000/01/20 2000/03/23
H108 B F 25 #N/A #N/A #N/A #N/A #N/A #N/A 0 1999/04/06 2000/03/24
H109 B F 22 #N/A #N/A #N/A 0 1996/05/13 1997/06/05 1998/03/02 1998/11/12 2000/03/27
H110 B M 33 #N/A #N/A #N/A #N/A 0 1993/07/15 1993/09/09 1996/06/20 2000/03/30
H111 B F 39 #N/A #N/A #N/A #N/A #N/A 0 1992/12/21 1993/10/16 2000/03/31
H112 B F 29 #N/A #N/A #N/A #N/A 0 1998/08/21 1999/05/18 1999/07/14 2000/04/04
H113 B M 34 #N/A #N/A #N/A #N/A #N/A #N/A 0 1996/04/11 2000/04/12
H114 B M 30 #N/A #N/A #N/A #N/A #N/A 0 1997/07/23 1997/11/03 2000/04/13
H115 C M 36 #N/A 0 1993/05/10 1993/09/28 1993/11/25 1994/05/26 1995/01/25 1999/10/26 2000/04/13
H116 W M 21 #N/A 0 1998/09/01 1999/03/10 1999/05/05 1999/07/01 1999/09/18 1999/12/09 2000/04/14
H117 B F 33 0 1998/07/10 1998/09/07 1998/12/28 1999/03/03 1999/05/10 1999/08/10 2000/02/18 2000/04/14
H118 B M 32 #N/A #N/A #N/A #N/A #N/A 0 1992/12/22 1993/02/24 2000/04/17
H119 B M 25 1996/06/18 1996/08/12 1997/08/14 1998/01/20 1998/04/21 1998/10/27 1999/03/29 1999/07/21 2000/04/18
H120 W M 19 #N/A #N/A #N/A #N/A #N/A #N/A 0 1998/11/16 2000/04/19
H121 B F 17 #N/A #N/A #N/A #N/A #N/A 0 1999/04/29 1999/08/19 2000/04/20
H122 C F 24 1994/03/01 1995/04/26 1996/02/07 1996/05/08 1996/08/21 1997/08/29 1997/11/01 1998/04/24 2000/04/29
H123 B F 33 1995/09/04 1995/10/31 1996/01/02 1996/02/27 1996/04/23 1996/08/18 1996/12/22 1997/02/22 2000/05/02
H124 B F 16 #N/A #N/A #N/A #N/A #N/A #N/A 0 2000/01/21 2000/05/05
H125 B F 23 #N/A #N/A #N/A #N/A #N/A 0 1999/10/12 1999/12/08 2000/05/05
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H126 B F 19 #N/A #N/A #N/A 0 1998/08/25 1998/11/23 1999/02/23 1999/04/29 2000/05/11
H127 B F 36 #N/A #N/A #N/A #N/A #N/A #N/A 0 2000/04/19 2000/05/11
H128 B M 37 1998/10/26 1998/12/14 1999/02/09 1999/04/13 1999/09/01 1999/11/10 2000/01/13 2000/03/11 2000/05/11
H129 W F 28 1998/05/06 1998/07/02 1998/08/27 1998/10/22 1998/12/18 1999/04/01 1999/06/08 1999/08/19 2000/05/12
H130 B F 30 #N/A #N/A #N/A #N/A #N/A #N/A 0 1999/04/30 2000/05/12
H131 B F 19 #N/A #N/A #N/A #N/A 0 1999/03/09 1999/05/11 1999/08/17 2000/05/16
H132 B F 20 #N/A #N/A #N/A #N/A 0 1999/02/11 1999/04/22 1999/08/27 2000/05/16
H133 B M 34 1995/09/29 1996/03/23 1996/05/17 1996/11/02 1997/08/29 1997/10/31 1998/08/28 1998/10/23 2000/05/17
H134 B M 34 #N/A #N/A 0 1997/10/03 1999/06/30 1999/08/25 1999/10/27 2000/02/23 2000/05/22
H135 B F 23 #N/A #N/A 0 1996/03/07 1996/05/27 1996/09/12 1997/03/13 1997/06/03 2000/05/27
H136 W M 38 1999/02/17 1999/04/14 1999/06/10 1999/08/05 1999/10/04 1999/12/08 2000/02/07 2000/04/04 2000/05/31
H137 B M 25 #N/A #N/A #N/A #N/A 0 1996/09/18 1997/04/23 1997/10/29 2000/06/05
H138 B M 43 1999/03/12 1999/05/04 1999/06/30 1999/08/25 1999/10/19 1999/12/15 2000/02/14 2000/04/10 2000/06/05
H139 B M 44 1998/01/15 1998/04/08 1998/06/03 1999/01/19 1999/03/16 1999/05/11 1999/07/21 1999/11/24 2000/06/05
H140 W F 23 #N/A #N/A #N/A 0 1996/03/05 1996/07/23 1996/10/22 1997/02/06 2000/06/06
H141 B F 46 1995/09/02 1995/11/18 1996/04/24 1996/09/21 1996/12/19 1998/06/02 1998/08/01 1999/12/13 2000/06/06
H142 C F 23 #N/A #N/A #N/A 0 1994/02/18 1994/07/27 1994/10/24 1995/05/05 2000/06/10
H143 W F 26 1996/08/14 1996/10/16 1997/04/09 1997/10/25 1998/02/11 1999/04/10 1999/11/13 2000/01/15 2000/06/10
H144 B M 31 1995/07/03 1995/09/05 1995/12/05 1996/03/14 1997/01/30 1997/05/06 1997/07/04 1997/09/05 2000/06/15
H145 B M 51 1997/10/29 1997/12/27 1998/02/21 1998/04/18 1998/06/13 1998/08/08 1998/10/03 2000/04/12 2000/06/15
H146 B F 28 #N/A #N/A #N/A #N/A #N/A #N/A 0 1998/05/28 2000/06/23
H147 B F 31 #N/A #N/A #N/A #N/A #N/A #N/A 0 1994/04/22 2000/06/23
H148 B M 34 #N/A #N/A #N/A #N/A #N/A #N/A 0 2000/03/30 2000/06/27
H149 B M 25 #N/A #N/A #N/A #N/A #N/A #N/A 0 1995/08/22 2000/07/03
H150 B M 38 0 1997/09/29 1997/11/26 1998/04/06 1998/11/10 1999/06/07 1999/11/08 2000/01/11 2000/07/04
H151 B F 44 #N/A #N/A #N/A #N/A 0 1993/11/18 1994/11/02 1995/07/25 2000/07/05
H152 B M 24 1997/11/14 1998/02/23 1998/05/11 1998/08/19 1998/10/16 1998/12/03 1999/02/23 2000/04/07 2000/07/07
H153 B F 35 #N/A #N/A #N/A 0 1998/09/16 1999/02/08 1999/04/23 1999/07/12 2000/07/11
H154 B M 52 #N/A #N/A #N/A #N/A #N/A 0 1993/08/04 1994/04/13 2000/07/12
H155 B M 42 #N/A #N/A #N/A #N/A 0 1993/03/18 1993/07/08 1997/07/03 2000/07/13
H156 B F 25 #N/A #N/A #N/A #N/A #N/A #N/A 0 2000/05/10 2000/07/14
H157 B M 46 #N/A #N/A #N/A #N/A #N/A #N/A 0 1995/01/12 2000/07/14
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H158 B F 19 #N/A #N/A #N/A #N/A #N/A #N/A 0 1999/07/20 2000/07/17
H159 B F 19 0 1998/08/27 1999/04/14 1999/07/05 1999/09/21 1999/11/16 2000/02/22 2000/04/12 2000/07/19
H160 B F 29 #N/A #N/A #N/A #N/A 0 1999/04/28 1999/08/17 1999/10/13 2000/07/19
H161 W M 44 1998/01/15 1998/03/12 1998/07/16 1998/09/17 1998/11/19 2000/01/08 2000/03/09 2000/05/25 2000/07/20
H162 B F 30 #N/A #N/A #N/A #N/A #N/A 0 1999/05/27 1999/11/03 2000/07/21
H163 B M 32 #N/A #N/A #N/A #N/A #N/A #N/A 0 1997/04/07 2000/07/21
H164 B F 19 #N/A #N/A #N/A #N/A #N/A 0 1999/05/24 2000/02/21 2000/07/26
H165 W M 21 #N/A #N/A #N/A 0 1996/11/01 1997/07/18 1997/12/01 1998/04/30 2000/07/26
H166 B F 23 #N/A #N/A #N/A #N/A #N/A 0 1994/06/13 1996/02/21 2000/07/28
H167 W M 24 #N/A #N/A #N/A #N/A #N/A 0 1993/03/31 1994/07/01 2000/07/29
H168 B F 30 #N/A #N/A #N/A #N/A #N/A #N/A 0 1996/01/05 2000/07/31
H169 B M 20 #N/A #N/A #N/A #N/A #N/A #N/A 0 1998/08/13 2000/08/10
H170 W M 34 1998/02/14 1998/08/01 1998/09/25 1998/12/11 1999/03/27 1999/09/06 1999/12/29 2000/04/22 2000/08/12
H171 B F 19 #N/A #N/A #N/A #N/A #N/A #N/A 0 1998/03/27 2000/08/16
H172 C F 23 #N/A #N/A 0 1994/02/25 1994/07/22 1994/10/13 1995/02/20 1995/09/05 2000/08/16
H173 B M 42 #N/A #N/A #N/A #N/A #N/A #N/A 0 1996/09/23 2000/08/17
H174 B M 27 #N/A 0 1997/06/18 1997/08/13 1998/01/21 1998/03/20 1998/08/18 1998/10/14 2000/08/18
H175 W F 39 #N/A 0 1997/01/07 1998/12/10 1999/04/23 1999/06/30 1999/09/14 1999/11/29 2000/08/23
H176 B M 29 #N/A #N/A #N/A 0 1999/06/29 1999/10/26 1999/12/28 2000/02/24 2000/08/24
H177 B M 29 #N/A #N/A #N/A 0 1996/10/02 1997/11/14 2000/04/25 2000/06/27 2000/08/29
H178 B M 30 1997/08/21 1997/12/11 1998/04/16 1998/08/20 1998/10/22 1998/12/17 1999/04/22 1999/10/28 2000/08/29
H179 W M 36 1996/05/13 1997/08/18 1997/12/01 1998/04/06 1998/09/28 1999/07/21 1999/09/22 2000/02/16 2000/08/30
H180 B M 37 #N/A #N/A #N/A #N/A 0 1994/08/16 1995/02/02 1996/02/22 2000/08/30
H181 B F 25 #N/A #N/A #N/A #N/A 0 1995/08/04 1995/10/06 1996/02/21 2000/08/31
H182 B M 36 #N/A #N/A #N/A #N/A #N/A 0 1993/10/27 1993/12/22 2000/08/31
H183 B M 47 #N/A #N/A #N/A #N/A #N/A #N/A 0 1999/02/23 2000/09/06
H184 B M 27 #N/A #N/A #N/A #N/A #N/A #N/A 0 2000/04/19 2000/09/07
H185 B M 26 #N/A #N/A 0 1996/09/19 1996/11/21 1997/05/14 1997/09/17 1998/01/15 2000/09/12
H186 W M 25 #N/A 0 1994/07/14 1995/02/21 1997/09/27 1997/12/19 1998/03/20 1998/07/04 2000/09/16
H187 B F 23 #N/A #N/A #N/A #N/A #N/A #N/A 0 1997/06/10 2000/09/18
H188 B F 20 #N/A #N/A 0 1998/08/26 1999/02/17 1999/05/12 1999/08/26 2000/03/07 2000/09/20
H189 B M 32 0 1993/10/28 1994/11/25 1995/07/12 1996/06/18 1996/12/05 1997/11/28 1998/09/11 2000/09/20
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H190 B M 27 #N/A #N/A #N/A #N/A 0 1996/11/11 1997/08/29 1997/10/31 2000/09/21
H191 W F 24 #N/A #N/A #N/A 0 1995/01/30 1995/03/27 1995/05/29 1998/03/03 2000/09/26
H192 W M 43 1995/06/28 1997/03/26 1998/01/29 1999/04/07 1999/12/01 2000/01/26 2000/03/22 2000/06/07 2000/09/27
H193 W M 22 1997/12/13 1998/02/25 1998/05/09 1998/10/12 1998/12/29 1999/06/08 2000/01/21 2000/06/06 2000/09/28
H194 B M 37 #N/A #N/A #N/A #N/A #N/A #N/A 0 1993/04/03 2000/09/30
H195 B F 17 #N/A #N/A #N/A #N/A #N/A 0 2000/04/13 2000/07/25 2000/10/03
H196 B M 39 #N/A #N/A #N/A #N/A #N/A #N/A 0 1998/07/29 2000/10/11
H197 C M 32 1996/07/30 1996/09/25 1996/11/21 1997/01/20 1997/11/04 1999/08/30 2000/02/22 2000/05/11 2000/10/13
H198 B F 21 0 1998/03/11 1998/09/02 1999/04/30 1999/09/03 1999/11/26 2000/01/21 2000/06/23 2000/10/20
H199 W M 60 1999/05/28 1999/07/23 1999/09/17 1999/11/12 2000/01/10 2000/03/10 2000/05/12 2000/07/28 2000/10/20
H200 B F 18 #N/A #N/A #N/A #N/A #N/A #N/A 0 2000/03/20 2000/10/23
H201 B M 34 #N/A #N/A #N/A #N/A #N/A #N/A 0 2000/08/11 2000/10/24
H202 B M 35 #N/A #N/A #N/A #N/A #N/A #N/A 0 2000/02/03 2000/10/25
H203 C M 21 1997/06/19 1997/08/21 1997/10/16 1997/12/11 1998/02/19 1998/04/23 1999/04/29 1999/06/24 2000/10/26
H204 B F 57 #N/A #N/A #N/A #N/A 0 1994/04/13 2000/02/17 2000/04/17 2000/10/26
H205 B M 30 0 1992/09/10 1992/11/27 1993/02/11 1993/07/28 1993/09/27 1995/07/13 1998/04/25 2000/10/27
H206 C M 27 1993/07/26 1993/09/28 1994/01/19 1994/03/16 1994/05/11 1994/07/13 1994/11/09 1995/02/11 2000/10/28
H207 W M 33 #N/A #N/A #N/A #N/A #N/A #N/A 0 1992/04/07 2000/10/30
H208 B F 23 #N/A #N/A #N/A #N/A #N/A #N/A 0 1995/08/21 2000/11/04
H209 C M 36 #N/A #N/A #N/A #N/A #N/A #N/A 0 2000/01/11 2000/11/04
H210 B F 44 #N/A #N/A #N/A #N/A #N/A #N/A 0 1999/05/14 2000/11/06
H211 B F 30 #N/A #N/A #N/A #N/A 0 1998/06/23 1999/02/19 1999/06/11 2000/11/07
H212 B M 30 #N/A #N/A #N/A #N/A #N/A 0 1997/01/15 1997/06/02 2000/11/08
H213 B F 40 #N/A #N/A #N/A #N/A 0 1999/06/17 1999/10/21 2000/02/24 2000/11/09
H214 B F 25 #N/A #N/A #N/A #N/A #N/A #N/A 0 1998/10/09 2000/11/10
H215 C F 24 0 1995/10/26 1996/10/30 1998/10/29 1999/05/14 1999/08/12 1999/10/12 2000/09/07 2000/11/17
H216 B F 27 #N/A #N/A #N/A 0 1997/07/24 1998/03/19 1998/07/09 1998/09/03 2000/11/17
H217 B M 33 #N/A #N/A #N/A 0 1998/10/08 1999/04/08 1999/06/03 1999/08/04 2000/11/20
H218 B M 29 #N/A #N/A #N/A #N/A #N/A #N/A 0 1993/11/19 2000/11/27
H219 B F 19 1998/09/03 1999/02/25 1999/05/05 1999/08/25 1999/11/22 2000/01/21 2000/03/17 2000/05/12 2000/11/29
H220 B M 40 #N/A #N/A #N/A #N/A #N/A #N/A 0 1994/03/30 2000/11/29
H221 C M 28 1998/12/04 1999/02/05 1999/08/06 1999/10/08 1999/12/03 2000/06/02 2000/08/04 2000/10/06 2000/12/01
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H222 B M 45 1998/10/09 1998/12/04 1999/02/05 1999/04/09 1999/06/04 1999/10/08 2000/04/07 2000/08/04 2000/12/01
H223 W M 24 1997/08/12 1997/10/22 1998/01/08 1998/04/06 1998/06/09 1998/08/05 2000/05/18 2000/07/14 2000/12/02
H224 W F 54 #N/A #N/A #N/A 0 1994/05/18 1998/07/03 1999/07/31 1999/11/29 2000/12/02
H225 B M 25 #N/A #N/A #N/A #N/A #N/A #N/A 0 1998/03/13 2000/12/06
H226 C F 23 #N/A #N/A 0 1994/08/11 1995/05/16 1995/08/31 1996/04/26 2000/06/14 2000/12/13
H227 B F 25 #N/A #N/A #N/A #N/A #N/A #N/A 0 1995/06/19 2000/12/13
H228 W M 47 #N/A #N/A #N/A #N/A #N/A #N/A 0 1996/10/10 2000/12/13
H229 B F 36 #N/A #N/A #N/A #N/A #N/A 0 1992/09/12 1998/08/24 2000/12/14
H230 W M 35 1994/01/11 1994/03/09 1994/05/14 1994/08/15 1994/10/17 1995/01/03 1995/03/13 1995/07/13 2000/12/18
H231 C F 26 #N/A #N/A #N/A #N/A #N/A #N/A 0 2000/10/25 2000/12/20
H232 W M 25 #N/A #N/A #N/A #N/A #N/A #N/A 0 1997/07/31 2000/12/28
H233 B F 22 1998/08/21 1998/12/03 1999/03/16 1999/08/16 2000/03/10 2000/05/05 2000/07/28 2000/11/03 2000/12/29
H234 W F 22 1999/08/27 1999/10/22 1999/12/14 2000/02/07 2000/05/30 2000/07/24 2000/09/18 2000/11/10 2001/01/04
H235 B F 22 #N/A #N/A #N/A #N/A #N/A 0 1999/02/13 1999/05/04 2001/01/04
H236 B M 31 #N/A #N/A #N/A #N/A #N/A #N/A 0 1998/04/17 2001/01/04
H237 W M 52 1998/08/26 1998/10/23 1998/12/18 1999/02/12 1999/04/09 1999/06/04 1999/08/06 1999/10/01 2001/01/05
H238 B F 25 #N/A #N/A #N/A 0 1997/07/07 1998/01/12 1998/07/06 1999/03/08 2001/01/08
H239 B F 27 #N/A #N/A #N/A #N/A #N/A 0 1993/03/29 2000/05/08 2001/01/08
H240 B F 28 #N/A #N/A #N/A #N/A #N/A 0 1994/02/16 1996/05/21 2001/01/08
H241 B M 40 #N/A #N/A #N/A #N/A #N/A #N/A 0 1996/08/14 2001/01/10
H242 B F 20 0 1997/11/10 1998/05/13 1998/07/15 1998/09/09 1998/11/06 1999/02/11 2000/06/26 2001/01/11
H243 B M 23 #N/A #N/A #N/A #N/A #N/A 0 2000/05/02 2000/06/27 2001/01/16
H244 B F 18 #N/A #N/A #N/A #N/A #N/A 0 1999/07/26 2000/01/13 2001/01/18
H245 B F 32 #N/A 0 1999/03/04 1999/08/26 1999/10/21 2000/02/24 2000/05/04 2000/07/06 2001/01/18
H246 B M 29 1998/05/04 1998/11/02 1999/01/30 1999/08/28 1999/11/01 2000/07/26 2000/09/26 2000/11/13 2001/01/19
H247 B M 38 #N/A #N/A #N/A #N/A 0 1994/04/25 1994/08/10 1994/11/28 2001/01/19
H248 B F 41 #N/A #N/A #N/A #N/A #N/A 0 1995/08/17 1995/10/19 2001/01/25
H249 B M 25 #N/A #N/A #N/A #N/A #N/A #N/A 0 1995/02/22 2001/01/31
H250 B M 27 #N/A #N/A #N/A 0 1998/12/01 1999/02/26 1999/07/27 1999/11/10 2001/02/01
H251 B F 41 #N/A #N/A #N/A #N/A #N/A #N/A 0 1999/06/06 2001/02/04
H252 B F 19 #N/A #N/A #N/A #N/A 0 1999/03/17 1999/05/20 2000/08/29 2001/02/06
H253 B F 53 #N/A #N/A #N/A #N/A #N/A #N/A 0 1996/04/09 2001/02/07
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H254 B F 24 #N/A #N/A 0 1998/11/23 1999/01/18 1999/03/15 1999/10/25 1999/12/20 2001/02/10
H255 B F 29 1998/05/18 1998/07/20 1998/09/21 1998/11/16 1999/04/19 1999/11/15 2000/03/13 2000/07/10 2001/02/12
H256 C F 35 #N/A #N/A #N/A #N/A 0 1996/10/30 1997/03/05 1997/06/20 2001/02/15
H257 B M 33 #N/A #N/A #N/A #N/A #N/A #N/A 0 1996/02/28 2001/02/19
H258 B M 19 #N/A #N/A #N/A #N/A #N/A 0 1998/03/19 2000/02/22 2001/02/20
H259 B M 24 #N/A #N/A #N/A 0 1998/05/05 1998/10/05 1999/02/15 1999/04/22 2001/02/20
H260 B F 30 #N/A #N/A #N/A #N/A 0 1997/02/03 1997/09/17 1998/02/24 2001/02/21
H261 C F 35 #N/A #N/A #N/A #N/A 0 1996/04/16 1996/06/21 1996/09/27 2001/02/21
H262 B F 19 #N/A #N/A #N/A #N/A #N/A 0 1999/01/25 1999/04/14 2001/02/23
H263 B F 17 #N/A #N/A #N/A #N/A #N/A #N/A 0 2000/03/16 2001/02/27
H264 B F 19 #N/A #N/A #N/A #N/A #N/A #N/A 0 1999/02/16 2001/02/27
H265 W M 19 #N/A #N/A #N/A #N/A #N/A #N/A 0 2000/06/30 2001/03/02
H266 W M 61 #N/A #N/A #N/A #N/A #N/A #N/A 0 1996/08/07 2001/03/02
H267 C F 44 0 1998/04/14 1998/06/23 1998/11/03 1999/01/12 1999/07/06 1999/09/07 2000/05/16 2001/03/06
H268 B F 23 #N/A #N/A #N/A 0 1999/02/17 1999/04/14 1999/08/04 2000/10/18 2001/03/08
H269 W M 27 #N/A #N/A 0 1993/10/11 1993/12/10 1994/02/18 1994/05/09 1995/04/06 2001/03/08
H270 W M 41 1998/12/30 1999/02/26 1999/04/24 1999/08/13 1999/10/13 2000/03/09 2000/05/23 2000/08/01 2001/03/08
H271 C M 26 #N/A #N/A #N/A #N/A 0 1997/10/21 1998/03/04 1999/06/10 2001/03/12
H272 B F 39 #N/A #N/A #N/A #N/A #N/A #N/A 0 2000/11/13 2001/03/13
H273 B M 19 #N/A #N/A #N/A #N/A 0 1999/03/04 1999/05/10 1999/07/28 2001/03/14
H274 B F 21 #N/A #N/A 0 1997/05/07 1998/03/20 1998/05/29 1999/02/01 1999/04/16 2001/03/14
H275 B M 23 #N/A #N/A #N/A #N/A #N/A 0 2000/08/21 2000/10/16 2001/03/15
H276 W F 18 #N/A #N/A #N/A #N/A #N/A #N/A 0 2000/11/20 2001/03/16
H277 B M 29 #N/A #N/A 0 1998/12/30 2000/04/14 2000/08/14 2000/10/20 2001/01/15 2001/03/16
H278 B M 32 #N/A #N/A #N/A #N/A #N/A 0 1992/09/17 1993/02/01 2001/03/19
H279 B M 36 1997/10/29 1998/08/12 1998/10/07 1999/03/24 1999/05/19 1999/07/14 1999/09/08 1999/12/29 2001/03/22
H280 B M 44 0 1993/04/15 1998/05/13 1998/07/17 1998/09/11 1998/11/10 1999/01/19 1999/03/11 2001/03/24
H281 B F 32 #N/A #N/A #N/A #N/A #N/A #N/A 0 2000/08/07 2001/03/26
H282 B M 34 #N/A #N/A #N/A #N/A #N/A 0 1997/03/03 1997/10/28 2001/03/26
H283 B F 19 #N/A #N/A #N/A #N/A 0 1999/03/08 1999/05/25 2000/08/07 2001/03/27
H284 B M 21 #N/A #N/A #N/A #N/A 0 1999/09/10 2000/01/21 2000/07/15 2001/03/28
H285 B M 22 #N/A #N/A #N/A #N/A 0 2000/03/02 2000/05/31 2000/11/14 2001/03/28
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H286 B F 24 #N/A #N/A #N/A #N/A #N/A 0 2000/12/06 2001/02/01 2001/03/29
H287 B F 23 0 1995/03/09 1996/02/21 1996/04/16 1996/08/13 1997/02/07 1997/08/06 1999/01/06 2001/04/02
H288 W M 42 1994/12/03 1995/02/15 1995/05/11 1995/06/30 1995/09/02 1995/10/28 1995/11/30 1996/02/24 2001/04/04
H289 B M 27 #N/A #N/A #N/A #N/A #N/A 0 1995/02/21 1996/10/09 2001/04/10
H290 C F 24 #N/A 0 1993/03/16 1993/07/13 1993/09/14 1997/02/18 1997/04/15 1997/06/24 2001/04/17
H291 W M 40 #N/A #N/A #N/A 0 1993/09/25 1994/09/13 1994/11/15 1997/02/14 2001/04/18
H292 B M 23 1999/07/16 1999/09/09 1999/11/13 2000/02/02 2000/04/01 2000/07/07 2000/09/26 2001/01/29 2001/04/26
H293 B F 20 #N/A #N/A #N/A #N/A 0 1999/04/14 1999/10/20 2000/10/18 2001/05/03
H294 B M 31 #N/A #N/A #N/A 0 1998/12/21 1999/03/19 1999/07/14 2000/07/27 2001/05/04
H295 B M 41 #N/A #N/A #N/A #N/A #N/A #N/A 0 2000/11/06 2001/05/09
H296 B M 19 1999/01/28 1999/04/20 1999/09/21 2000/01/27 2000/04/13 2000/07/20 2000/09/14 2001/02/06 2001/05/10
H297 W M 26 1994/05/19 1994/09/02 1994/10/31 1995/01/12 1996/09/03 1997/05/06 1997/10/13 2001/01/05 2001/05/10
H298 B M 38 1999/08/02 1999/12/09 2000/02/10 2000/04/06 2000/06/15 2000/10/05 2000/11/30 2001/02/08 2001/05/10
H299 W M 22 1999/05/17 1999/07/06 1999/08/30 1999/10/25 1999/12/20 2000/02/16 2000/05/17 2000/11/27 2001/05/11
H300 B F 24 #N/A #N/A #N/A #N/A #N/A 0 1999/10/21 2000/05/15 2001/05/11
H301 B M 26 #N/A #N/A #N/A #N/A #N/A 0 1992/09/14 1997/05/27 2001/05/12
H302 B M 27 0 1995/04/04 2000/01/20 2000/03/20 2000/08/07 2000/11/14 2001/01/23 2001/03/20 2001/05/15
H303 W M 25 #N/A #N/A #N/A #N/A #N/A #N/A 0 1994/08/27 2001/05/22
H304 C M 46 1999/08/04 1999/12/08 2000/02/09 2000/04/05 2000/06/07 2000/08/02 2000/12/06 2001/01/31 2001/05/23
H305 B F 41 #N/A #N/A #N/A #N/A #N/A #N/A 0 2000/12/18 2001/05/25
H306 W M 47 #N/A #N/A #N/A #N/A #N/A #N/A 0 1993/01/13 2001/05/25
H307 C M 35 #N/A #N/A #N/A #N/A #N/A #N/A 0 1999/06/18 2001/05/26
H308 B F 35 0 1994/07/15 1994/09/14 1994/11/16 1995/01/18 1995/05/31 1995/08/02 1995/10/04 2001/05/26
H309 B F 19 #N/A #N/A #N/A #N/A 0 2000/10/09 2001/01/22 2001/03/26 2001/05/29
H310 W M 48 1999/08/02 1999/10/11 2000/02/08 2000/05/03 2000/08/25 2000/10/20 2000/12/27 2001/04/09 2001/06/05
H311 B F 32 1998/05/27 1998/09/16 1998/11/11 1999/06/23 1999/08/18 1999/10/22 1999/12/17 2000/10/18 2001/06/12
H312 C F 26 #N/A #N/A #N/A #N/A #N/A 0 1995/03/24 1995/05/19 2001/06/24
H313 W F 21 1996/09/30 1996/12/12 1997/03/20 1997/06/11 1997/08/28 1998/11/09 1999/02/18 1999/05/11 2001/06/26
H314 W M 64 #N/A #N/A #N/A #N/A #N/A 0 1997/12/08 1998/02/02 2001/06/30
H315 B M 30 #N/A #N/A #N/A #N/A 0 1996/04/10 1997/04/04 1998/11/30 2001/07/04
H316 B M 30 #N/A #N/A 0 2000/02/22 2000/06/13 2000/08/08 2000/11/28 2001/01/23 2001/07/10
H317 B F 58 1997/04/16 1997/07/09 1997/11/06 1998/04/09 1998/07/09 1998/10/02 1999/03/03 1999/05/04 2001/07/10
Ethnic* Sex**
Age 
HIV 
Pos
8th Prev. 
Test Date
7th Prev. 
Test Date
6th Prev. 
Test Date
5th Prev. 
Test Date
4th Prev. 
Test Date
3rd Prev. 
Test Date
2nd Prev. 
Test Date
Prev. Test 
Date
Date HIV 
Pos. 
Donation
DEMOGRAPHICS TEST / DONATION DATES
Donation 
Serial No
H318 B M 29 1998/10/23 1998/12/18 1999/04/16 1999/06/11 1999/08/06 1999/12/03 2000/02/04 2000/06/20 2001/07/12
H319 A M 31 #N/A #N/A #N/A #N/A 0 2000/03/24 2000/06/14 2000/12/13 2001/07/15
H320 B M 23 0 2000/01/17 2000/03/15 2000/05/10 2000/07/17 2000/10/27 2001/01/19 2001/03/16 2001/07/17
H321 B F 24 #N/A #N/A #N/A #N/A 0 2000/05/17 2000/07/13 2000/09/13 2001/07/17
H322 B F 17 #N/A #N/A #N/A 0 2000/02/07 2000/04/13 2000/07/25 2000/10/03 2001/07/26
H323 B M 25 2000/02/22 2000/04/18 2000/06/13 2000/08/08 2000/10/23 2001/01/15 2001/04/09 2001/06/04 2001/07/30
H324 W M 51 2000/03/08 2000/05/04 2000/07/12 2000/09/19 2000/11/21 2001/01/16 2001/03/19 2001/05/17 2001/07/31
H325 B F 26 #N/A 0 1999/09/09 2000/02/01 2000/04/14 2000/10/17 2001/02/22 2001/05/29 2001/08/01
H326 B F 23 #N/A #N/A #N/A #N/A #N/A #N/A 0 1996/03/11 2001/08/10
H327 B M 27 #N/A #N/A #N/A #N/A #N/A #N/A 0 2000/12/06 2001/08/15
H328 W F 33 #N/A #N/A #N/A #N/A #N/A 0 1994/11/22 1995/09/18 2001/08/15
H329 C F 36 #N/A #N/A #N/A #N/A #N/A 0 2000/07/03 2000/11/14 2001/08/16
H330 B M 25 #N/A #N/A #N/A #N/A #N/A #N/A 0 1995/03/23 2001/08/18
H331 B M 40 1995/03/27 1995/07/12 1996/03/25 1996/09/20 1998/01/16 1998/07/08 1998/09/11 1998/11/23 2001/08/20
H332 B M 28 1996/03/01 1996/05/16 1997/04/03 1998/09/08 1999/06/24 1999/08/19 1999/12/09 2000/04/10 2001/08/21
H333 A F 26 1999/11/17 2000/01/12 2000/03/08 2000/06/09 2000/08/07 2000/10/17 2000/12/13 2001/03/07 2001/08/27
H334 B F 26 #N/A #N/A #N/A #N/A #N/A #N/A 0 1995/02/22 2001/08/28
H335 W F 43 #N/A #N/A #N/A #N/A 0 1993/04/21 1993/09/06 1994/01/25 2001/08/30
H336 B F 34 #N/A #N/A #N/A #N/A #N/A 0 1992/11/05 1995/05/09 2001/08/31
H337 B M 21 #N/A #N/A #N/A #N/A #N/A #N/A 0 1996/09/02 2001/09/08
H338 C M 29 #N/A #N/A #N/A #N/A #N/A 0 1999/11/18 2001/07/12 2001/09/13
H339 B F 19 #N/A #N/A #N/A #N/A #N/A #N/A 0 2001/05/03 2001/09/17
H340 B F 31 0 1999/11/15 2000/03/20 2000/05/29 2000/07/24 2000/09/18 2001/03/19 2001/05/14 2001/09/17
H341 B M 54 1999/04/06 1999/06/09 2000/01/25 2000/05/30 2000/08/22 2000/10/24 2001/03/13 2001/05/21 2001/09/17
H342 A M 58 1999/09/20 1999/12/04 2000/01/29 2000/06/24 2000/10/14 2001/01/06 2001/03/10 2001/05/05 2001/09/17
H343 B M 32 1996/06/05 1996/09/25 1997/08/13 1997/11/19 1999/02/25 1999/07/26 1999/10/05 2000/05/08 2001/09/19
H344 B F 25 #N/A #N/A #N/A 0 1994/10/21 1995/03/24 1996/05/06 1997/07/11 2001/09/27
H345 B M 24 #N/A #N/A #N/A #N/A 0 2001/03/22 2001/05/25 2001/07/25 2001/10/11
H346 W M 34 #N/A #N/A 0 1992/11/07 1993/07/24 1995/08/08 1996/11/07 1997/02/19 2001/10/11
H347 B F 18 #N/A #N/A #N/A #N/A #N/A #N/A 0 2001/01/26 2001/10/12
H348 B M 22 #N/A #N/A 0 1996/08/28 2000/04/17 2001/02/27 2001/04/24 2001/07/04 2001/10/16
H349 B F 17 #N/A #N/A #N/A #N/A 0 2000/05/22 2000/07/20 2000/09/14 2001/10/18
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H350 B F 30 #N/A #N/A #N/A #N/A #N/A #N/A 0 1995/04/06 2001/10/18
H351 B F 31 #N/A #N/A #N/A 0 1995/08/03 1996/01/11 1996/04/23 1997/03/18 2001/10/27
H352 B F 17 #N/A #N/A #N/A #N/A #N/A #N/A 0 2001/04/20 2001/10/29
H353 B F 26 #N/A #N/A 0 1996/10/02 1998/03/19 1998/07/23 1998/09/17 1998/11/12 2001/10/30
H354 B M 39 #N/A #N/A #N/A #N/A #N/A 0 1992/04/14 1994/05/27 2001/10/30
H355 B F 24 #N/A #N/A #N/A 0 1993/12/23 1997/06/18 1997/08/13 1997/10/11 2001/11/02
H356 W M 25 #N/A #N/A #N/A #N/A 0 1994/08/06 1995/02/06 1996/09/09 2001/11/14
H357 B F 36 #N/A 0 1999/07/14 1999/11/18 2000/05/17 2000/09/13 2000/11/15 2001/05/10 2001/11/20
H358 W M 34 #N/A #N/A #N/A #N/A #N/A #N/A 0 1991/10/01 2001/11/21
H359 B M 43 1995/08/22 1996/03/19 1996/07/04 1997/06/18 1998/04/08 1999/02/10 1999/10/13 2000/04/12 2001/11/21
H360 B F 32 1995/09/19 1996/02/20 1996/05/10 1996/09/04 1996/12/31 1997/06/04 1997/08/22 1997/11/04 2001/11/22
H361 B M 46 1997/04/01 1997/06/04 1997/10/24 1998/02/19 1998/04/17 1998/07/27 1998/12/03 1999/01/28 2001/11/22
H362 B F 30 #N/A #N/A #N/A #N/A #N/A 0 1999/07/06 1999/12/14 2001/11/25
H363 B F 46 #N/A #N/A 0 1996/11/12 1997/10/02 1999/02/03 1999/06/17 2000/10/19 2001/11/28
H364 B M 30 #N/A #N/A #N/A #N/A 0 1998/11/27 2000/10/02 2000/11/27 2001/12/03
H365 B F 27 1997/01/30 1997/04/30 1997/12/22 1998/02/12 1998/05/22 1998/07/06 1998/09/15 1999/03/02 2001/12/12
H366 B M 35 #N/A #N/A #N/A 0 1993/11/19 1995/03/25 1998/12/30 1999/11/13 2001/12/15
H367 C M 25 1998/07/21 1998/10/02 1998/12/09 1999/06/19 2000/09/28 2001/04/18 2001/07/04 2001/10/05 2001/12/19
H368 C M 28 #N/A #N/A #N/A #N/A #N/A 0 1998/09/20 1999/03/07 2001/12/21
H369 B M 42 #N/A #N/A #N/A 0 1992/09/08 1993/04/15 1993/08/16 1993/10/11 2001/12/23
H370 B F 24 1997/04/22 1997/10/14 1998/06/11 1998/12/07 1999/05/06 1999/09/06 2000/01/19 2000/12/01 2001/12/28
H371 B F 32 #N/A #N/A #N/A 0 1999/03/09 1999/05/04 1999/08/03 1999/10/26 2001/12/31
H372 W M 36 2000/07/11 2000/09/14 2000/11/16 2001/02/05 2001/04/04 2001/05/30 2001/07/26 2001/10/08 2002/01/07
H373 B F 38 2000/04/28 2000/08/07 2000/10/20 2000/12/20 2001/02/21 2001/04/20 2001/06/22 2001/08/10 2002/01/11
H374 W F 20 0 1997/08/28 1998/08/20 1998/11/18 1999/11/27 2000/09/16 2001/01/13 2001/06/02 2002/01/12
H375 B M 29 #N/A #N/A #N/A #N/A 0 1996/04/03 1997/07/16 1998/03/18 2002/01/15
H376 W M 35 #N/A #N/A #N/A #N/A 0 2001/05/03 2001/07/02 2001/08/30 2002/01/15
H377 B F 36 #N/A #N/A #N/A #N/A #N/A #N/A 0 2001/06/09 2002/01/19
H378 B M 24 1999/09/22 1999/11/17 2000/01/19 2000/03/15 2000/07/19 2000/09/20 2001/03/20 2001/09/19 2002/01/23
H379 B F 37 #N/A #N/A #N/A #N/A #N/A #N/A 0 1997/07/24 2002/01/23
H380 B M 24 1997/08/04 1997/10/16 1998/12/03 1999/02/08 1999/06/07 1999/10/09 2000/06/29 2001/02/15 2002/01/24
H381 W M 21 #N/A 0 1997/05/27 1997/08/27 1997/10/29 1998/11/16 1999/04/28 1999/11/19 2002/01/26
Ethnic* Sex**
Age 
HIV 
Pos
8th Prev. 
Test Date
7th Prev. 
Test Date
6th Prev. 
Test Date
5th Prev. 
Test Date
4th Prev. 
Test Date
3rd Prev. 
Test Date
2nd Prev. 
Test Date
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Date HIV 
Pos. 
Donation
DEMOGRAPHICS TEST / DONATION DATES
Donation 
Serial No
H382 W M 35 #N/A 0 1993/10/01 1999/05/19 2001/01/18 2001/05/07 2001/08/06 2001/10/05 2002/01/29
H383 B F 29 #N/A #N/A #N/A #N/A #N/A 0 2001/01/03 2001/04/25 2002/01/30
H384 B M 18 #N/A #N/A #N/A #N/A #N/A #N/A 0 2001/10/10 2002/02/05
H385 B F 19 #N/A #N/A #N/A #N/A #N/A 0 2001/02/05 2001/04/21 2002/02/05
H386 B F 35 1996/04/24 1996/07/31 1997/02/26 1997/05/12 1999/02/08 2001/01/19 2001/04/23 2001/07/17 2002/02/07
H387 B F 30 #N/A #N/A #N/A #N/A #N/A #N/A 0 1993/06/08 2002/02/12
H388 W M 36 1994/05/19 1995/01/21 1995/04/12 1996/08/31 1997/07/09 1997/09/23 1997/12/31 1999/01/19 2002/02/15
H389 B F 38 1997/04/23 1998/07/03 1998/06/24 1998/11/04 1999/01/20 1999/03/31 1999/07/21 1999/09/29 2002/02/20
H390 C M 61 1993/09/08 1994/05/18 1994/09/07 1995/01/04 1995/06/21 1995/10/18 1996/08/07 1997/01/09 2002/02/21
H391 B F 19 #N/A #N/A #N/A #N/A 0 2001/04/19 2001/07/19 2001/11/06 2002/02/25
H392 B F 21 #N/A #N/A 0 1998/10/04 1998/12/13 1999/03/28 2000/01/23 2001/02/18 2002/02/25
H393 B M 38 1996/09/02 1996/12/13 1997/04/14 1997/06/09 1997/08/13 1997/10/14 1998/02/18 1998/09/03 2002/02/25
H394 W F 18 1999/04/26 1999/07/23 1999/09/17 1999/12/07 2000/02/26 2000/06/20 2001/03/19 2001/05/28 2002/02/26
H395 B F 22 #N/A #N/A #N/A #N/A #N/A #N/A 0 2001/05/14 2002/02/27
H396 B F 27 #N/A #N/A #N/A #N/A 0 1999/11/22 2000/01/17 2000/07/26 2002/03/01
H397 W F 21 #N/A #N/A #N/A #N/A #N/A 0 2001/01/15 2001/03/12 2002/03/04
H398 A M 22 1999/04/09 1999/06/04 1999/10/08 1999/12/03 2000/02/04 2000/08/04 2001/10/05 2002/01/08 2002/03/05
H399 B F 17 #N/A #N/A #N/A #N/A #N/A #N/A 0 2001/08/22 2002/03/06
H400 B F 33 #N/A #N/A #N/A 0 1999/02/10 1999/04/07 1999/06/11 2000/02/16 2002/03/13
H401 B F 24 #N/A #N/A #N/A #N/A #N/A #N/A 0 1995/10/23 2002/03/14
H402 C M 31 #N/A #N/A #N/A #N/A 0 1994/07/12 1995/04/03 2001/10/18 2002/03/14
H403 B M 32 #N/A #N/A #N/A #N/A 0 1993/05/13 1993/08/12 1994/02/03 2002/03/21
H404 B F 23 #N/A #N/A #N/A 0 1998/05/11 1998/08/19 1998/10/16 1998/12/04 2002/03/24
H405 B M 24 #N/A #N/A #N/A #N/A #N/A #N/A 0 2002/01/25 2002/03/25
H406 B F 28 #N/A 0 1994/05/27 1994/10/01 1994/11/26 1995/03/27 1996/07/17 1996/10/28 2002/03/25
H407 W M 31 0 1992/07/03 1994/04/05 1994/08/24 1994/10/26 1995/02/01 1995/04/12 1995/10/30 2002/03/27
H408 C F 23 #N/A #N/A 0 1999/11/27 2000/12/02 2001/09/27 2001/11/29 2002/01/31 2002/03/28
H409 B F 26 #N/A #N/A #N/A #N/A #N/A 0 1996/02/02 1996/10/25 2002/04/01
H410 B F 36 #N/A #N/A #N/A #N/A #N/A #N/A 0 1994/03/29 2002/04/01
H411 B M 37 1996/09/03 1997/01/29 1997/04/18 1997/06/23 1997/08/19 1998/02/25 1998/04/23 1998/06/17 2002/04/01
H412 B F 20 0 2000/05/23 2000/08/08 2000/10/03 2000/11/28 2001/05/09 2001/11/14 2002/01/09 2002/04/03
H413 B F 25 #N/A #N/A #N/A #N/A #N/A #N/A 0 1998/04/04 2002/04/04
Ethnic* Sex**
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HIV 
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Test Date
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H414 B M 30 #N/A #N/A #N/A #N/A 0 1998/03/27 1998/05/22 1999/06/22 2002/04/04
H415 B F 29 1993/07/20 1993/12/21 1994/05/06 1995/09/07 1996/09/16 1996/11/18 1997/09/30 1998/11/20 2002/04/06
H416 W M 43 1998/02/09 1998/04/08 1998/06/11 1998/08/22 1998/10/28 2000/08/29 2000/10/25 2001/04/18 2002/04/10
H417 B M 36 #N/A #N/A 0 1998/10/16 2001/02/22 2001/05/04 2001/09/05 2001/11/07 2002/04/11
H418 B F 16 #N/A #N/A #N/A #N/A #N/A #N/A 0 2002/02/07 2002/04/17
H419 C F 25 1996/02/27 1996/05/02 1996/08/22 1997/01/30 1997/04/29 1997/08/12 1997/10/23 1998/09/05 2002/04/17
H420 B M 28 #N/A #N/A #N/A #N/A #N/A #N/A 0 1996/07/30 2002/04/18
H421 B F 27 #N/A #N/A #N/A #N/A #N/A 0 1993/02/10 1993/03/03 2002/04/19
H422 W M 24 #N/A #N/A #N/A 0 2000/03/08 2000/07/12 2000/09/13 2001/08/22 2002/04/23
H423 B F 28 #N/A #N/A #N/A #N/A #N/A 0 1992/09/16 1993/02/26 2002/04/24
H424 W M 34 1993/04/08 1993/10/22 1997/08/21 1997/12/22 1998/03/31 1998/06/30 2000/10/24 2001/02/24 2002/04/24
H425 B M 36 2000/02/25 2000/05/05 2000/07/28 2000/09/21 2001/01/10 2001/04/25 2001/08/31 2001/12/19 2002/04/24
H426 B F 17 #N/A #N/A #N/A 0 2000/09/15 2001/02/07 2001/05/02 2001/09/14 2002/04/25
H427 B M 23 #N/A #N/A #N/A #N/A 0 1996/08/27 1997/04/08 1998/09/05 2002/04/25
H428 W F 31 2000/12/18 2001/02/21 2001/04/18 2001/06/14 2001/08/10 2001/10/05 2001/12/01 2002/02/26 2002/05/03
H429 W M 28 1994/11/08 1994/12/28 1995/05/02 1995/07/26 1995/12/04 1996/01/31 1996/05/22 1997/01/03 2002/05/06
H430 C F 27 #N/A 0 1999/10/01 2000/10/09 2001/01/09 2001/03/13 2001/05/08 2001/09/11 2002/05/07
H431 B F 35 #N/A #N/A #N/A #N/A #N/A 0 1995/06/14 1997/07/16 2002/05/07
H432 W M 40 #N/A #N/A #N/A #N/A #N/A #N/A 0 1993/11/25 2002/05/07
H433 B F 22 #N/A #N/A #N/A #N/A #N/A #N/A 0 1999/02/03 2002/05/10
H434 B M 24 #N/A #N/A #N/A #N/A #N/A 0 1997/09/25 1998/04/28 2002/05/13
H435 B F 45 1999/02/23 2001/02/20 2001/04/25 2001/07/04 2001/09/12 2001/11/07 2002/01/24 2002/03/22 2002/05/17
H436 B F 29 #N/A #N/A #N/A #N/A #N/A 0 1997/03/18 1998/03/04 2002/05/18
H437 W F 42 #N/A #N/A 0 1997/09/03 2000/05/21 2000/07/16 2000/09/10 2000/12/31 2002/05/18
H438 B F 17 #N/A #N/A #N/A #N/A #N/A 0 2001/08/02 2001/10/16 2002/05/24
H439 B F 30 #N/A #N/A #N/A #N/A #N/A #N/A 0 2001/06/09 2002/05/31
H440 B M 27 #N/A #N/A 0 2000/02/12 2000/04/08 2000/06/05 2000/08/04 2000/09/29 2002/06/18
H441 W M 32 #N/A #N/A #N/A 0 1993/04/28 1995/01/10 1995/03/06 1995/06/22 2002/06/26
H442 B M 48 #N/A #N/A #N/A #N/A 0 1995/03/22 1995/09/12 1995/11/14 2002/07/02
H443 B M 26 2000/06/14 2000/08/10 2000/10/11 2001/04/11 2001/06/06 2001/08/01 2001/09/16 2002/01/16 2002/07/03
H444 B F 33 #N/A #N/A #N/A #N/A #N/A 0 1995/11/30 1996/07/18 2002/07/03
H445 W F 37 2000/09/27 2000/11/29 2001/03/07 2001/05/02 2001/07/04 2001/09/05 2002/01/09 2002/03/06 2002/07/10
Ethnic* Sex**
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H446 B F 17 #N/A #N/A 0 2001/02/23 2001/06/08 2001/08/14 2001/10/18 2002/01/30 2002/07/19
H447 B F 18 #N/A #N/A #N/A #N/A #N/A #N/A 0 2002/03/04 2002/07/23
H448 W M 46 #N/A #N/A 0 2000/06/22 2000/10/26 2001/02/22 2001/04/19 2001/06/21 2002/07/24
H449 C F 23 1996/02/15 1997/02/18 1997/04/23 1997/07/29 1997/10/22 1998/01/27 1998/05/12 1998/07/27 2002/07/30
H450 B M 26 1999/04/08 1999/08/05 1999/10/14 2000/02/10 2000/04/13 2000/12/07 2001/02/01 2001/04/05 2002/08/01
H451 W F 55 1997/04/21 1997/09/04 1998/11/07 1999/02/11 1999/11/15 2000/01/10 2000/03/16 2000/05/25 2002/08/01
H452 B M 30 #N/A #N/A #N/A #N/A #N/A #N/A 0 1995/10/31 2002/08/07
H453 B M 32 1999/05/25 1999/09/28 1999/11/23 2000/01/25 2000/07/24 2000/09/27 2001/09/06 2002/02/05 2002/08/07
H454 B M 28 2000/09/14 2000/11/16 2001/02/15 2001/04/18 2001/10/24 2002/01/11 2002/04/04 2002/06/06 2002/08/08
H455 W M 25 #N/A #N/A #N/A 0 1993/12/14 1994/04/11 1994/07/04 1994/09/30 2002/08/10
H456 B M 25 #N/A #N/A #N/A #N/A #N/A #N/A 0 2002/04/18 2002/08/19
H457 B M 30 #N/A #N/A #N/A #N/A #N/A #N/A 0 1994/08/16 2002/08/23
H458 B M 40 0 1995/07/03 1998/08/04 2000/10/10 2000/12/20 2001/05/24 2002/01/11 2002/03/26 2002/09/02
H459 B M 32 2000/08/08 2000/10/03 2001/03/27 2001/05/29 2001/07/31 2001/09/25 2002/01/29 2002/05/22 2002/09/18
H460 W M 30 1996/12/14 1997/04/24 1997/07/23 1997/09/17 1997/12/02 1998/02/25 1998/05/26 1999/01/18 2002/09/23
H461 B M 31 1996/12/05 1997/03/18 1997/07/15 1997/09/16 1998/02/10 1998/10/07 1998/12/02 1999/09/29 2002/09/26
H462 B F 50 #N/A 0 2001/04/26 2001/06/22 2001/10/26 2002/01/25 2002/04/05 2002/05/31 2002/09/27
H463 W M 47 0 1997/11/07 1998/12/07 2001/03/05 2001/06/04 2001/10/31 2002/01/19 2002/03/28 2002/09/28
H464 B F 20 #N/A #N/A #N/A #N/A #N/A #N/A 0 2000/03/23 2002/10/04
H465 W M 24 2001/01/02 2001/03/27 2001/07/03 2001/09/03 2001/11/05 2002/01/15 2002/03/12 2002/07/16 2002/10/09
H466 W F 33 1998/06/10 1998/08/12 1999/02/10 1999/04/14 1999/08/11 1999/12/08 2000/06/14 2000/10/11 2002/10/09
H467 B M 19 #N/A #N/A #N/A #N/A #N/A #N/A 0 2002/03/14 2002/10/10
H468 B M 36 #N/A #N/A #N/A #N/A #N/A #N/A 0 1997/08/28 2002/10/10
H469 B M 23 #N/A #N/A #N/A #N/A #N/A #N/A 0 1994/03/15 2002/10/11
H470 B F 29 1995/11/10 1996/05/10 1996/09/13 1996/11/08 1997/01/10 1997/07/11 1997/11/14 1998/03/06 2002/10/21
H471 B M 41 1995/06/07 1996/08/07 1996/12/04 1997/04/30 1997/06/25 1998/01/14 1998/03/11 1998/05/13 2002/10/23
H472 W F 24 1999/08/26 1999/10/21 1999/12/28 2000/02/22 2000/06/29 2001/02/14 2001/08/16 2001/12/06 2002/10/24
H473 B M 46 #N/A 0 1993/09/02 2000/05/17 2000/07/21 2000/10/10 2002/02/08 2002/04/11 2002/10/24
H474 B F 19 #N/A #N/A #N/A #N/A #N/A #N/A 0 1999/03/11 2002/11/11
H475 B M 27 #N/A #N/A #N/A #N/A #N/A #N/A 0 1995/02/07 2002/11/11
H476 B M 47 #N/A #N/A #N/A #N/A #N/A 0 1998/03/02 1998/04/28 2002/11/12
H477 B M 27 #N/A #N/A #N/A #N/A #N/A 0 2001/09/13 2001/11/08 2002/11/14
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H478 W M 61 #N/A #N/A #N/A #N/A #N/A #N/A 0 1997/11/06 2002/11/26
H479 B F 29 #N/A #N/A #N/A #N/A 0 2000/02/03 2000/06/08 2000/08/10 2002/11/27
H480 B M 26 #N/A #N/A #N/A #N/A #N/A #N/A 0 2002/09/02 2002/12/02
H481 B M 29 1996/07/02 1996/11/19 1997/01/15 1997/05/07 1997/07/09 1997/09/03 1998/07/14 1998/09/15 2002/12/03
H482 B F 35 0 1998/08/26 1998/10/28 2000/03/03 2001/01/31 2001/09/27 2002/02/13 2002/04/17 2002/12/04
H483 B F 21 #N/A #N/A #N/A #N/A #N/A #N/A 0 1998/02/17 2002/12/05
H484 B M 38 2001/07/25 2001/09/20 2001/12/04 2002/01/29 2002/03/26 2002/05/24 2002/07/24 2002/09/18 2002/12/05
H485 W M 45 2001/07/02 2001/09/11 2001/11/14 2002/01/08 2002/02/18 2002/04/22 2002/06/20 2002/08/21 2002/12/10
H486 A F 31 1996/11/08 1997/01/13 1998/01/14 2000/04/14 2000/06/30 2000/10/10 2001/11/17 2002/01/15 2002/12/14
H487 C M 21 1996/08/08 1997/02/03 1997/05/05 1998/03/03 1998/05/05 1999/05/05 1999/08/18 1999/11/02 2002/12/21
H488 B M 31 #N/A #N/A #N/A #N/A #N/A #N/A 0 1993/04/01 2002/12/21
H489 B M 40 #N/A #N/A #N/A #N/A #N/A 0 1999/03/02 2001/07/05 2002/12/28
H490 B F 26 2000/03/29 2000/06/09 2000/08/10 2000/12/14 2001/07/09 2002/04/15 2002/06/11 2002/09/19 2002/12/31
H491 W M 19 0 2001/08/28 2001/10/22 2001/12/18 2002/02/15 2002/04/26 2002/06/21 2002/09/18 2003/01/02
H492 W M 52 2001/07/24 2001/09/18 2001/11/15 2002/01/25 2002/03/28 2002/05/28 2002/07/30 2002/10/02 2003/01/06
H493 C F 39 #N/A #N/A #N/A 0 1994/04/12 1994/07/13 1994/10/27 1995/08/10 2003/01/08
H494 W M 32 2000/01/26 2000/03/22 2000/05/24 2000/07/26 2002/04/04 2002/05/30 2002/07/29 2002/09/23 2003/01/15
H495 W M 49 #N/A 0 1998/12/05 1999/03/19 2001/10/01 2001/12/31 2002/03/01 2002/05/15 2003/01/15
H496 W M 24 #N/A #N/A #N/A #N/A #N/A #N/A 0 1994/11/26 2003/01/23
H497 W M 23 2001/02/26 2001/05/17 2001/07/12 2001/11/26 2002/02/23 2002/05/03 2002/06/28 2002/08/23 2003/01/27
H498 B M 40 2001/04/02 2001/06/25 2001/09/12 2001/11/19 2002/01/28 2002/04/29 2002/07/18 2002/09/12 2003/02/01
H499 B M 50 2001/07/05 2001/08/30 2001/10/25 2001/12/20 2002/02/28 2002/04/25 2002/06/27 2002/08/29 2003/02/07
H500 B F 27 #N/A #N/A #N/A #N/A 0 2002/02/17 2002/05/26 2002/07/28 2003/02/09
H501 B F 22 #N/A #N/A #N/A #N/A 0 1998/02/20 1998/08/14 2000/03/04 2003/02/12
H502 B F 23 #N/A #N/A 0 1999/01/26 1999/04/14 1999/06/10 1999/08/26 1999/10/22 2003/02/12
H503 B M 29 #N/A #N/A #N/A 0 1999/02/02 1999/08/03 1999/10/05 2000/11/07 2003/02/14
H504 B M 24 #N/A #N/A #N/A #N/A #N/A 0 2000/10/04 2001/01/31 2003/02/17
H505 W M 33 2001/06/11 2001/08/06 2001/10/01 2001/11/26 2002/01/21 2002/03/18 2002/09/02 2002/10/18 2003/02/17
H506 B F 17 #N/A #N/A #N/A #N/A #N/A 0 2002/03/06 2002/05/21 2003/02/27
H507 B F 17 #N/A #N/A #N/A #N/A 0 2001/07/20 2002/03/01 2002/05/10 2003/02/28
H508 B M 29 2001/06/29 2001/09/19 2001/11/14 2002/01/10 2002/03/13 2002/05/15 2002/08/23 2002/11/28 2003/02/28
H509 B M 39 2001/01/22 2001/08/22 2001/10/19 2001/12/14 2002/02/14 2002/04/11 2002/06/06 2002/08/19 2003/03/03
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H510 B M 30 2001/05/02 2001/06/27 2001/08/27 2001/11/30 2002/02/11 2002/04/15 2002/06/24 2002/10/08 2003/03/05
H511 W M 46 2001/07/18 2001/09/05 2001/11/07 2002/02/13 2002/04/24 2002/08/10 2002/10/09 2002/12/11 2003/03/05
H512 B F 36 #N/A 0 1998/12/10 2000/03/25 2001/04/21 2001/06/30 2001/09/01 2002/04/12 2003/03/25
H513 B F 35 #N/A #N/A #N/A #N/A #N/A 0 2002/08/28 2002/10/30 2003/03/26
H514 B M 32 #N/A #N/A #N/A 0 1997/03/05 1997/05/06 1997/07/01 1998/02/10 2003/03/27
H515 B F 44 2000/09/07 2000/11/09 2001/01/18 2001/03/22 2001/05/17 2001/07/12 2001/12/06 2002/04/11 2003/03/27
H516 B F 36 #N/A 0 1999/03/11 2001/02/08 2001/04/12 2002/02/14 2002/04/11 2002/10/10 2003/04/03
H517 W M 35 #N/A #N/A #N/A #N/A 0 1996/05/14 1997/03/14 2003/02/11 2003/04/08
H518 B F 24 #N/A #N/A #N/A #N/A 0 1999/02/26 2000/05/17 2000/07/12 2003/04/09
H519 B F 35 1999/01/21 1999/04/26 1999/10/02 1999/11/27 2000/03/04 2000/05/13 2000/12/29 2001/03/07 2003/04/09
H520 B F 43 #N/A #N/A #N/A 0 1993/11/11 1994/04/11 1994/09/28 1994/11/30 2003/04/09
H521 C F 19 #N/A #N/A #N/A #N/A #N/A #N/A 0 2002/05/07 2003/04/15
H522 W M 20 2001/12/19 2002/02/15 2002/04/15 2002/06/18 2002/08/13 2002/10/10 2002/12/05 2003/01/30 2003/04/21
H523 W M 32 2001/07/11 2001/09/08 2001/11/07 2002/01/22 2002/03/30 2002/05/30 2002/07/25 2002/11/26 2003/04/22
H524 W M 50 #N/A #N/A #N/A #N/A #N/A #N/A 0 1992/04/07 2003/05/02
H525 W M 23 0 1998/02/23 1998/05/04 1998/10/26 1999/01/25 1999/04/26 1999/07/26 1999/12/20 2003/05/05
H526 C F 16 #N/A #N/A #N/A #N/A #N/A #N/A 0 2003/03/12 2003/05/07
H527 W F 28 #N/A #N/A #N/A #N/A #N/A #N/A 0 1992/09/01 2003/05/09
H528 W M 43 #N/A #N/A #N/A 0 1993/04/08 1993/08/05 1993/09/30 1993/11/25 2003/05/09
H529 B F 30 #N/A #N/A #N/A #N/A #N/A 0 2002/07/16 2002/11/19 2003/05/13
H530 W M 25 1997/08/07 1997/12/15 2000/07/26 2000/10/05 2002/08/05 2002/10/25 2002/12/18 2003/02/13 2003/05/19
H531 W F 25 2000/11/28 2001/03/22 2001/07/31 2001/09/25 2002/01/22 2002/03/26 2002/11/20 2003/01/20 2003/05/19
H532 B M 36 2002/03/11 2002/04/29 2002/06/21 2002/08/12 2002/10/03 2002/11/28 2003/01/27 2003/03/24 2003/05/21
H533 B F 42 #N/A #N/A #N/A #N/A #N/A 0 1993/11/18 2002/11/30 2003/05/30
H534 W M 26 2002/01/10 2002/03/07 2002/05/27 2002/07/25 2002/09/23 2002/11/25 2003/02/05 2003/04/07 2003/06/02
H535 B M 44 2001/08/21 2001/10/16 2001/12/11 2005/02/05 2002/04/18 2002/06/12 2002/09/25 2002/11/20 2003/06/04
H536 B F 31 1998/01/02 1998/02/27 1998/04/24 1998/06/20 1999/02/23 1999/04/20 1999/06/15 1999/09/27 2003/06/06
H537 W M 42 1993/12/07 1996/11/26 2001/04/17 2001/07/03 2001/09/03 2001/11/07 2002/03/05 2002/07/19 2003/06/06
H538 B M 37 #N/A #N/A #N/A #N/A #N/A #N/A 0 1996/05/10 2003/06/09
H539 B M 34 1998/08/04 1998/10/13 1999/01/19 1999/03/19 1999/12/02 2000/03/06 2001/08/07 2002/02/07 2003/06/13
H540 W M 42 #N/A 0 1993/08/05 1997/04/03 1997/11/14 1998/03/18 1998/06/09 1998/08/19 2003/06/28
H541 B M 53 2001/10/31 2002/01/17 2002/03/13 2002/05/15 2002/07/10 2002/09/11 2002/11/13 2003/01/15 2003/07/02
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H542 W M 42 #N/A #N/A #N/A #N/A #N/A #N/A 0 2002/08/20 2003/07/08
H543 W M 66 2002/01/02 2002/02/27 2002/06/26 2002/08/21 2002/10/16 2002/12/19 2003/02/17 2003/05/09 2003/07/09
H544 B F 38 #N/A 0 2001/11/06 2002/02/05 2002/06/13 2002/08/07 2002/11/27 2003/02/05 2003/07/10
H545 B F 19 #N/A #N/A #N/A 0 2001/04/20 2001/07/20 2002/02/01 2002/07/26 2003/07/18
H546 B M 40 1997/10/30 1998/06/09 1998/10/23 1998/12/29 1999/07/16 2000/06/29 2000/10/16 2001/05/14 2003/07/18
H547 W F 30 1998/03/28 1998/11/11 1999/01/11 1999/03/06 1999/05/08 1999/07/03 1999/08/28 1999/10/23 2003/07/23
H548 W M 66 2002/01/30 2002/04/05 2002/06/07 2002/08/07 2002/10/09 2003/01/22 2003/03/20 2003/05/24 2003/07/28
H549 C F 19 2001/05/10 2001/07/30 2001/09/25 2002/02/18 2002/05/16 2002/07/25 2002/09/26 2003/01/23 2003/08/05
H550 B M 27 2001/01/15 2001/03/26 2001/05/25 2001/10/22 2002/01/14 2002/05/06 2002/07/24 2002/10/14 2003/08/05
H551 B M 28 #N/A #N/A #N/A #N/A 0 1999/01/21 1999/11/25 2000/05/11 2003/08/08
H552 B F 22 #N/A #N/A #N/A #N/A #N/A 0 1997/08/29 1999/06/17 2003/08/11
H553 B M 48 1997/08/19 1997/10/20 1998/07/04 1998/08/30 1998/10/29 1999/01/21 1999/07/02 1999/08/19 2003/08/19
H554 B F 39 #N/A #N/A #N/A #N/A #N/A #N/A 0 2001/06/21 2003/08/20
H555 C M 39 2002/01/04 2002/03/01 2002/05/03 2002/07/05 2002/09/06 2002/11/01 2003/01/10 2003/03/07 2003/08/22
H556 B F 28 #N/A #N/A #N/A #N/A #N/A #N/A 0 1994/08/19 2003/09/02
H557 C M 30 #N/A #N/A #N/A #N/A #N/A #N/A 0 1996/12/11 2003/09/03
H558 B F 56 1999/10/12 1999/12/21 2000/04/03 2000/07/03 2000/10/07 2000/12/04 2001/04/12 2002/04/26 2003/09/04
H559 B F 45 #N/A #N/A #N/A #N/A 0 1996/10/09 1999/07/13 2000/01/17 2003/09/29
H560 W F 45 1993/08/30 1993/11/17 1994/05/27 1994/09/26 1995/05/22 1995/10/06 1998/01/26 1998/05/25 2003/09/29
H561 W F 19 2001/12/19 2002/02/20 2002/04/29 2002/06/25 2002/08/21 2002/12/19 2003/03/10 2003/06/26 2003/09/30
H562 B F 42 #N/A 0 2001/05/07 2001/07/31 2001/10/15 2003/02/17 2003/05/16 2003/07/17 2003/10/02
H563 B M 34 #N/A #N/A #N/A #N/A #N/A 0 1994/08/11 1994/12/08 2003/10/03
H564 B M 39 #N/A 0 1992/10/23 1993/03/10 1994/10/06 2002/09/12 2003/01/23 2003/03/27 2003/10/08
H565 B F 23 #N/A #N/A #N/A #N/A #N/A #N/A 0 1999/02/23 2003/10/09
H566 C F 52 2000/12/02 2001/03/17 2001/05/12 2001/12/21 2002/02/16 2002/06/22 2002/08/17 2002/10/19 2003/10/11
H567 W M 68 2001/09/12 2002/01/15 2002/04/04 2002/06/06 2002/08/01 2002/10/21 2002/12/31 2003/03/03 2003/10/16
H568 B M 38 2001/11/02 2002/01/04 2002/03/01 2002/05/03 2002/11/01 2003/03/07 2003/05/02 2003/08/22 2003/10/17
H569 B M 40 #N/A #N/A #N/A #N/A #N/A #N/A 0 1997/05/20 2003/10/24
H570 B M 37 1995/06/26 1995/09/13 1996/03/18 1999/05/11 1999/07/20 1999/09/23 1999/11/25 2000/11/02 2003/11/05
H571 B F 39 2001/12/24 2002/02/25 2002/04/23 2002/07/02 2002/09/30 2003/01/11 2003/04/03 2003/05/29 2003/11/06
H572 B M 36 #N/A #N/A #N/A #N/A #N/A #N/A 0 1998/11/25 2003/11/12
H573 B M 38 #N/A #N/A #N/A #N/A #N/A 0 1995/06/07 1996/03/13 2003/11/21
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H574 B M 28 #N/A #N/A #N/A #N/A 0 1993/03/09 1993/08/06 1994/02/15 2003/11/24
H575 W M 32 2002/06/25 2002/09/16 2002/12/02 2003/01/31 2003/04/08 2003/06/03 2003/07/29 2003/09/25 2003/11/25
H576 B M 30 2001/01/21 2002/04/03 2002/06/12 2002/08/14 2002/10/23 2003/01/15 2003/03/19 2003/05/21 2003/11/26
H577 W M 25 #N/A #N/A #N/A #N/A #N/A #N/A 0 1997/04/25 2003/11/27
H578 B F 35 #N/A #N/A #N/A #N/A #N/A 0 1993/03/26 1994/09/23 2003/11/27
H579 W F 29 #N/A 0 1993/04/07 1993/06/21 1993/08/16 1993/10/25 1993/12/20 2001/11/01 2003/11/28
H580 W F 31 #N/A #N/A #N/A 0 2003/02/26 2003/04/24 2003/07/07 2003/09/06 2003/11/29
H581 W F 26 #N/A #N/A #N/A 0 1994/03/05 1998/02/28 1998/11/20 2000/07/28 2003/12/05
H582 B F 30 #N/A #N/A #N/A #N/A #N/A #N/A 0 1998/07/31 2003/12/07
H583 C M 43 #N/A #N/A #N/A #N/A #N/A #N/A 0 2000/06/22 2003/12/10
H584 W M 56 2002/07/13 2002/09/16 2002/11/13 2003/01/18 2003/03/15 2003/05/10 2003/07/05 2003/08/30 2003/12/13
H585 W F 24 #N/A 0 1994/09/09 1995/02/16 1995/05/11 1996/05/22 1997/01/24 2002/07/22 2003/12/17
H586 C F 22 #N/A #N/A #N/A #N/A 0 2001/03/14 2001/11/22 2002/12/19 2003/12/18
H587 W M 25 2001/05/04 2001/07/18 2001/10/31 2002/08/02 2002/11/20 2003/01/16 2003/03/17 2003/10/25 2004/01/12
H588 W M 29 2001/10/27 2002/01/24 2002/07/09 2002/11/21 2003/02/05 2003/04/03 2003/06/19 2003/09/05 2004/01/19
H589 W M 31 1995/05/13 1995/07/26 1997/09/29 1999/02/27 1999/08/28 2000/09/02 2000/11/07 2001/01/02 2004/01/21
H590 B F 20 2000/05/11 2000/08/11 2000/10/05 2000/12/01 2001/09/27 2001/12/07 2002/02/14 2002/04/26 2004/01/30
H591 B F 23 1999/04/13 1999/06/28 1999/09/30 2000/04/19 2000/08/01 2001/09/06 2001/11/08 2003/12/02 2004/02/03
H592 B M 19 #N/A #N/A #N/A 0 2003/02/06 2003/05/06 2003/08/07 2003/12/05 2004/02/10
H593 B M 36 #N/A #N/A 0 2000/05/09 2001/10/09 2002/02/05 2002/06/13 2002/10/24 2004/02/10
H594 B F 37 #N/A #N/A #N/A #N/A #N/A 0 2002/06/19 2003/02/09 2004/02/10
H595 B M 58 #N/A #N/A #N/A #N/A #N/A #N/A 0 1992/09/29 2004/02/14
H596 B F 44 #N/A #N/A #N/A #N/A #N/A #N/A 0 1995/06/30 2004/02/27
H597 B M 46 #N/A #N/A #N/A 0 1995/06/19 1995/08/28 1996/04/22 1996/08/19 2004/03/01
H598 B F 24 1997/06/06 1997/08/19 1998/01/30 1998/04/17 1998/08/14 1998/10/16 1999/02/19 1999/06/12 2004/03/03
H599 B F 37 1999/07/22 1999/09/16 1999/11/18 2000/05/18 2001/01/11 2001/05/10 2001/07/12 2001/09/06 2004/03/04
H600 B M 42 1995/05/11 1995/12/21 1996/04/11 1996/06/06 1996/08/01 1997/01/16 1999/02/18 2001/03/15 2004/03/04
H601 B M 36 #N/A #N/A #N/A #N/A 0 1995/12/11 1996/06/28 1997/08/08 2004/03/06
H602 C F 24 #N/A #N/A #N/A 0 1996/03/13 1997/08/14 1998/10/14 2000/02/24 2004/03/10
H603 W M 22 2002/10/19 2002/12/17 2003/04/08 2003/06/03 2003/07/29 2003/09/23 2003/11/18 2004/01/19 2004/03/15
H604 W M 25 2002/07/04 2002/10/17 2003/01/20 2003/04/14 2003/06/19 2003/09/04 2003/11/13 2004/01/12 2004/03/15
H605 B M 28 #N/A #N/A #N/A #N/A #N/A #N/A 0 2000/03/22 2004/03/17
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H606 B F 23 #N/A #N/A #N/A #N/A #N/A #N/A 0 2001/07/16 2004/03/20
H607 W M 18 2002/07/17 2002/09/11 2002/11/06 2003/03/12 2003/05/14 2003/08/20 2003/11/19 2004/01/15 2004/03/23
H608 B M 41 #N/A #N/A #N/A 0 1992/01/23 1994/02/17 1994/12/14 1995/07/06 2004/03/27
H609 B F 35 0 1996/10/30 1997/05/14 1997/11/12 1998/03/11 1998/11/11 1999/08/04 2001/05/18 2004/03/30
H610 W M 39 2002/08/08 2003/02/26 2003/04/23 2003/06/18 2003/08/13 2003/10/08 2003/12/03 2004/01/28 2004/04/01
H611 W F 23 #N/A #N/A 0 2002/04/08 2002/06/03 2002/10/07 2003/10/06 2003/12/01 2004/04/05
H612 W M 32 1999/04/16 1999/09/21 1999/12/15 2000/02/15 2000/06/02 2000/08/19 2001/08/04 2001/10/07 2004/04/06
H613 B M 28 2001/08/21 2001/10/23 2002/02/19 2002/04/23 2002/06/25 2002/08/20 2002/12/17 2003/02/25 2004/04/20
H614 W F 62 1997/01/30 1997/05/29 1997/07/31 1997/09/25 2003/03/20 2003/05/22 2003/09/18 2003/11/20 2004/04/21
H615 W F 44 1994/05/06 1996/12/21 2000/02/09 2000/04/11 2001/09/28 2001/11/26 2002/08/31 2003/07/18 2004/04/27
H616 B F 25 #N/A 0 1999/04/21 1999/08/11 2000/02/15 2000/04/19 2001/05/17 2001/08/14 2004/05/11
H617 B F 29 #N/A #N/A #N/A 0 2002/02/18 2002/08/19 2002/10/17 2003/11/07 2004/05/11
H618 C M 32 2002/11/12 2003/01/07 2003/03/04 2003/04/30 2003/06/25 2003/08/26 2003/10/22 2003/12/23 2004/05/12
H619 B M 31 #N/A #N/A #N/A #N/A #N/A #N/A 0 2004/03/15 2004/05/17
H620 W M 69 2002/07/24 2002/09/18 2002/11/20 2003/01/22 2003/03/19 2003/05/21 2003/07/23 2003/12/17 2004/05/19
H621 B F 37 #N/A #N/A #N/A #N/A #N/A #N/A 0 2000/01/27 2004/05/25
H622 B M 38 #N/A #N/A #N/A #N/A #N/A #N/A 0 1992/03/19 2004/06/01
H623 B F 31 2001/02/04 2001/04/01 2001/05/27 2001/11/25 2002/04/07 2002/06/02 2002/10/06 2002/12/15 2004/06/06
H624 B F 34 0 2002/10/09 2002/12/05 2003/02/11 2003/04/15 2003/06/10 2003/10/14 2004/02/10 2004/06/08
H625 B F 28 #N/A #N/A #N/A #N/A #N/A 0 2002/02/16 2003/12/05 2004/06/09
H626 W M 43 2001/04/04 2001/06/06 2001/09/17 2001/11/21 2002/02/05 2002/07/24 2003/06/05 2003/08/15 2004/06/09
H627 W F 43 2002/07/10 2002/09/04 2002/11/05 2003/03/13 2003/05/09 2003/07/09 2003/11/17 2004/02/06 2004/06/14
H628 C M 29 1997/04/29 1997/10/23 1997/12/18 1998/05/06 1998/08/13 1999/04/24 2000/05/26 2000/08/04 2004/06/15
H629 B M 30 1997/12/02 1998/06/22 1998/11/04 1999/01/06 1999/06/14 2001/12/01 2002/12/07 2003/03/06 2004/06/15
H630 B F 35 #N/A 0 1999/05/23 1999/07/21 1999/09/15 1999/11/10 2000/01/28 2000/04/07 2004/06/17
H631 B F 28 #N/A #N/A #N/A #N/A #N/A 0 2004/02/23 2004/04/21 2004/06/22
H632 C M 32 1998/02/02 1998/07/03 1998/08/25 1998/12/08 2001/02/22 2001/11/03 2002/10/03 2003/03/01 2004/06/26
H633 B F 23 #N/A #N/A #N/A #N/A #N/A #N/A 0 2004/05/07 2004/07/02
H634 C F 32 #N/A #N/A #N/A #N/A 0 1998/11/05 1999/01/07 1999/09/09 2004/07/02
H635 W M 25 #N/A #N/A #N/A #N/A #N/A #N/A 0 2000/03/06 2004/07/05
H636 W M 39 2002/11/28 2003/02/12 2003/04/09 2003/06/04 2003/09/23 2003/11/19 2004/03/10 2004/05/05 2004/07/05
H637 W F 39 2002/10/17 2002/12/12 2003/02/06 2003/04/03 2003/06/12 2003/07/31 2003/10/02 2004/05/10 2004/07/06
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H638 C F 34 #N/A #N/A #N/A #N/A #N/A #N/A 0 2004/03/05 2004/07/12
H639 B M 30 #N/A #N/A #N/A #N/A #N/A #N/A 0 1999/08/19 2004/07/13
H640 C F 34 #N/A 0 1994/04/15 1994/06/17 1994/08/19 1994/10/24 1994/12/19 1995/10/18 2004/07/21
H641 B F 17 #N/A #N/A #N/A #N/A #N/A #N/A 0 2004/02/27 2004/07/22
H642 C F 38 #N/A #N/A #N/A #N/A 0 1998/01/31 1998/03/28 1998/09/26 2004/07/24
H643 W M 42 1996/04/18 1999/04/26 1999/11/11 2000/02/01 2000/04/07 2000/07/07 2000/10/04 2001/02/07 2004/07/26
H644 B F 21 0 1998/09/02 1999/05/17 1999/07/28 1999/10/20 2000/04/10 2001/01/29 2003/07/22 2004/07/28
H645 B F 32 #N/A #N/A #N/A #N/A #N/A #N/A 0 2001/08/16 2004/07/29
H646 C F 16 #N/A #N/A #N/A #N/A #N/A #N/A 0 2003/02/18 2004/07/30
H647 B M 19 #N/A #N/A #N/A #N/A #N/A 0 2003/02/18 2003/10/31 2004/07/30
H648 B M 19 0 2002/02/12 2002/05/10 2002/10/11 2003/02/11 2003/04/23 2003/07/31 2003/12/05 2004/08/03
H649 B F 20 #N/A #N/A #N/A 0 2001/03/06 2001/05/08 2002/02/19 2002/04/16 2004/08/03
H650 B M 32 #N/A #N/A #N/A #N/A #N/A 0 1993/03/19 1998/08/21 2004/08/05
H651 C F 30 #N/A #N/A 0 1999/05/08 2001/07/22 2001/09/16 2001/11/11 2002/06/18 2004/08/07
H652 W M 41 2003/05/07 2003/07/02 2003/08/27 2003/10/27 2003/12/22 2004/02/16 2004/04/15 2004/06/12 2004/08/07
H653 C M 18 #N/A #N/A #N/A #N/A #N/A 0 2004/01/29 2004/04/29 2004/08/11
H654 B F 21 #N/A #N/A #N/A #N/A #N/A #N/A 0 1999/07/29 2004/08/11
H655 B M 20 #N/A #N/A #N/A #N/A #N/A 0 2000/02/29 2004/06/17 2004/08/13
H656 B F 36 0 1999/03/09 1999/07/02 1999/11/02 2000/02/18 2000/06/21 2000/08/15 2002/03/31 2004/08/16
H657 W M 66 2000/08/23 2001/01/10 2001/03/28 2001/09/05 2001/10/31 2002/01/16 2002/05/29 2002/09/25 2004/08/17
H658 B F 21 #N/A #N/A #N/A 0 2002/03/12 2002/05/17 2002/07/12 2003/02/20 2004/08/23
H659 B M 34 #N/A #N/A 0 1992/10/23 1994/10/28 1997/08/21 2000/01/22 2000/11/13 2004/08/24
H660 W F 27 1995/10/10 1998/03/03 1998/05/05 1999/03/09 2001/07/10 2001/12/12 2003/01/07 2003/07/31 2004/08/25
H661 B F 19 #N/A #N/A #N/A #N/A #N/A 0 2004/02/18 2004/05/12 2004/08/26
H662 B F 17 #N/A #N/A #N/A #N/A #N/A #N/A 0 2004/05/21 2004/08/27
H663 W F 41 2002/01/10 2002/03/12 2002/06/03 2002/07/29 2003/01/20 2003/05/12 2003/07/15 2004/04/20 2004/08/29
H664 B M 24 #N/A #N/A #N/A #N/A #N/A #N/A 0 2004/02/27 2004/09/02
H665 B M 32 #N/A #N/A #N/A #N/A #N/A #N/A 0 1993/10/22 2004/09/02
H666 B M 40 2002/10/18 2003/02/07 2003/04/25 2003/07/18 2003/09/12 2004/01/30 2004/03/26 2004/05/21 2004/09/03
H667 W F 46 #N/A #N/A #N/A #N/A #N/A #N/A 0 1999/02/02 2004/09/08
H668 B M 42 1998/12/05 1999/02/01 1999/03/29 1999/06/01 1999/07/27 1999/09/21 1999/11/25 2000/03/02 2004/09/13
H669 C M 37 #N/A #N/A #N/A #N/A #N/A #N/A 0 1994/11/07 2004/09/19
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H670 B F 39 #N/A #N/A #N/A #N/A #N/A #N/A 0 2000/12/14 2004/09/22
H671 B M 33 #N/A #N/A #N/A #N/A #N/A 0 1992/08/10 1993/02/18 2004/09/28
H672 A M 28 0 1997/08/19 1997/10/21 1997/12/19 1998/02/24 1998/05/05 1998/07/21 2001/08/18 2004/10/06
H673 B M 24 2002/02/15 2002/05/03 2002/07/29 2002/10/08 2003/02/04 2003/05/08 2003/08/01 2003/09/26 2004/10/18
H674 B M 38 #N/A #N/A #N/A #N/A #N/A #N/A 0 1999/05/28 2004/10/19
H675 B F 24 #N/A #N/A #N/A #N/A #N/A 0 2003/10/31 2004/03/12 2004/10/22
H676 W F 38 1995/07/15 1995/09/25 1995/12/04 1996/02/05 1996/04/02 1996/08/06 1997/02/12 1997/11/17 2004/10/29
H677 B F 32 #N/A #N/A #N/A 0 1994/04/25 1995/05/25 1995/09/21 1995/11/23 2004/10/31
H678 W M 26 1995/09/28 1998/05/13 1998/07/10 1998/09/12 1998/11/26 1999/01/13 1999/03/12 2001/02/06 2004/11/09
H679 B F 30 #N/A 0 1995/03/03 1996/02/05 2000/07/05 2001/03/26 2002/04/02 2003/06/09 2004/11/13
H680 A M 23 #N/A #N/A 0 2002/01/31 2002/04/09 2002/09/17 2002/11/14 2003/01/28 2004/11/18
H681 B F 46 2001/03/18 2001/05/20 2001/08/12 2002/02/02 2002/12/07 2003/02/15 2003/07/19 2003/12/20 2004/11/20
H682 B F 28 2000/01/06 2000/04/06 2000/06/08 2000/08/10 2000/11/09 2001/03/15 2001/08/16 2003/09/11 2004/11/22
H683 W M 28 1998/05/22 1998/08/24 1998/12/14 1999/07/13 2000/03/01 2003/03/29 2004/01/29 2004/03/29 2004/11/23
H684 B M 27 1998/03/03 1998/05/05 1998/08/04 1998/09/29 1999/02/23 1999/05/04 1999/08/10 2001/10/03 2004/12/03
H685 B M 38 #N/A #N/A #N/A #N/A 0 1992/07/28 1994/08/26 1994/10/06 2004/12/06
H686 B F 41 #N/A #N/A 0 1999/05/13 1999/09/16 1999/11/18 2000/03/16 2000/09/20 2004/12/06
H687 B M 30 #N/A #N/A #N/A #N/A #N/A #N/A 0 1999/09/21 2004/12/08
H688 W M 57 1995/02/02 1995/11/13 1996/04/01 1996/07/23 1996/09/23 1996/12/06 1997/07/03 1997/10/06 2005/01/24
H689 C F 45 1999/10/11 1999/12/30 2000/06/29 2000/10/12 2001/01/29 2002/05/08 2004/05/11 2004/08/05 2005/02/04
H690 W M 23 1999/02/13 1999/05/25 1999/08/02 2002/09/21 2004/05/24 2004/07/27 2004/09/21 2004/11/23 2005/02/11
H691 C F 35 1994/01/20 1994/03/24 1994/05/19 1994/09/22 1996/06/19 1996/08/21 1996/10/16 1997/02/19 2005/02/16
H692 B M 30 0 2002/05/13 2002/06/07 2002/08/08 2002/09/11 2002/12/23 2003/07/21 2003/10/06 2005/02/22
H693 W F 67 #N/A #N/A #N/A #N/A #N/A 0 2003/03/07 2004/08/12 2005/02/22
H694 B F 17 #N/A #N/A #N/A #N/A #N/A 0 2004/08/17 2004/10/20 2005/02/23
H695 B F 31 #N/A #N/A #N/A #N/A 0 2000/11/09 2001/06/28 2001/08/30 2005/02/24
H696 B F 18 #N/A #N/A #N/A #N/A 0 2004/01/21 2004/05/17 2004/09/09 2005/03/01
H697 B M 30 1998/09/17 1999/03/29 1999/06/11 1999/08/17 1999/10/12 2000/03/06 2000/05/11 2000/07/10 2005/03/04
H698 B F 22 #N/A #N/A #N/A #N/A #N/A #N/A 0 1999/10/07 2005/03/07
H699 W M 54 2003/09/03 2003/10/29 2003/12/24 2004/02/18 2004/04/15 2004/06/23 2004/08/18 2004/12/29 2005/03/10
H700 B M 51 2003/04/24 2003/11/07 2004/01/05 2004/03/10 2004/05/19 2004/07/23 2004/10/04 2005/01/10 2005/03/11
H701 B M 44 2002/11/20 2003/03/26 2003/05/21 2003/07/23 2003/09/17 2004/03/17 2004/05/19 2004/11/17 2005/03/16
Ethnic* Sex**
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HIV 
Pos
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Test Date
7th Prev. 
Test Date
6th Prev. 
Test Date
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Test Date
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Test Date
3rd Prev. 
Test Date
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Test Date
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Pos. 
Donation
DEMOGRAPHICS TEST / DONATION DATES
Donation 
Serial No
H702 W M 17 0 2003/07/01 2003/09/02 2003/11/04 2004/03/02 2004/05/04 2004/07/06 2004/09/07 2005/03/30
H703 C M 27 1998/08/17 1998/10/12 1998/12/07 1999/02/19 1999/04/22 1999/07/27 1999/10/08 2000/11/24 2005/04/02
H704 W F 33 #N/A #N/A #N/A #N/A 0 2004/10/13 2004/12/09 2005/02/07 2005/04/05
H705 B F 17 #N/A #N/A #N/A #N/A #N/A #N/A 0 2004/07/23 2005/04/08
H706 W M 68 2000/07/18 2003/05/20 2003/06/20 2003/07/18 2003/08/20 2003/10/30 2004/10/13 2004/12/08 2005/04/13
H707 W M 38 1995/10/31 1996/05/28 1996/09/17 1997/03/11 1997/05/06 1997/09/02 1997/11/04 1998/03/03 2005/04/20
H708 B F 29 #N/A #N/A #N/A #N/A 0 1994/10/28 1995/05/08 1996/02/02 2005/04/21
H709 C M 23 1998/08/11 1999/03/05 1999/05/31 1999/10/04 2001/02/01 2001/07/03 2001/09/13 2003/05/21 2005/04/28
H710 C M 18 #N/A #N/A #N/A 0 2004/01/30 2004/04/30 2004/10/27 2005/01/28 2005/04/29
H711 W F 19 2002/03/05 2002/05/03 2002/07/01 2003/03/17 2003/05/07 2003/07/23 2003/10/09 2004/01/24 2005/05/04
H712 B M 37 1998/10/05 1998/12/31 1999/07/19 1999/11/03 2000/04/07 2000/06/12 2001/05/18 2001/11/20 2005/05/07
H713 C F 19 #N/A #N/A #N/A #N/A #N/A #N/A 0 2003/05/05 2005/05/11
H714 W M 31 2001/04/09 2001/06/19 2001/08/16 2001/10/11 2001/12/11 2002/02/15 2002/05/15 2004/02/09 2005/05/12
H715 B M 48 1998/09/02 1998/11/04 1999/01/13 1999/03/10 1999/05/05 1999/09/01 1999/11/03 2000/01/20 2005/05/18
H716 W F 49 #N/A 0 1995/11/07 2003/10/10 2004/08/25 2004/10/20 2004/12/29 2005/03/03 2005/05/19
H717 B F 17 #N/A #N/A #N/A #N/A #N/A 0 2004/03/17 2004/08/06 2005/05/27
H718 C F 24 #N/A #N/A 0 2000/11/03 2001/11/30 2002/05/25 2003/07/19 2005/03/28 2005/05/28
H719 W M 34 1996/09/10 1996/12/30 1997/02/27 1997/11/27 1998/03/11 1998/05/13 1998/07/08 1998/09/18 2005/05/28
H720 B F 33 #N/A 0 1997/02/04 1997/04/22 1998/02/17 1998/09/10 1999/06/24 2000/04/19 2005/07/05
H721 C F 28 #N/A #N/A #N/A #N/A #N/A #N/A 0 1993/08/19 2005/07/06
H722 W F 30 1997/03/27 1999/10/26 1999/12/22 2000/03/20 2003/07/10 2003/11/12 2004/09/01 2004/12/01 2005/07/06
H723 W M 52 2003/08/06 2003/11/05 2004/01/07 2004/04/07 2004/06/02 2004/09/01 2004/12/14 2005/03/09 2005/07/06
H724 B M 54 #N/A #N/A #N/A #N/A #N/A #N/A 0 2001/01/18 2005/07/07
H725 B M 42 #N/A 0 1995/05/17 1995/07/12 1995/09/06 1996/03/06 1996/05/09 1996/09/04 2005/07/08
H726 B M 33 0 1993/01/26 1993/10/11 1994/06/20 1994/08/25 1996/03/19 1997/12/04 1998/03/24 2005/07/15
H727 B M 28 #N/A #N/A #N/A #N/A #N/A #N/A 0 1997/01/24 2005/07/18
H728 W M 33 #N/A #N/A #N/A #N/A 0 1993/12/28 1997/08/05 1997/08/12 2005/07/23
H729 W M 60 #N/A #N/A #N/A #N/A #N/A #N/A 0 1993/02/03 2005/08/06
H730 C M 32 #N/A #N/A #N/A #N/A #N/A 0 1996/09/06 1997/01/14 2005/08/07
H731 C M 24 #N/A #N/A #N/A #N/A #N/A #N/A 0 1999/05/13 2005/08/09
H732 W M 44 2003/06/04 2003/07/30 2004/08/25 2004/10/20 2004/12/16 2005/02/09 2005/04/06 2005/06/01 2005/08/10
H733 W M 56 2004/04/06 2004/06/01 2004/07/27 2004/09/28 2004/11/23 2005/01/25 2005/03/29 2005/05/31 2005/08/16
Ethnic* Sex**
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H734 B F 17 #N/A #N/A #N/A #N/A 0 2004/08/02 2005/01/18 2005/04/05 2005/08/18
H735 B M 35 #N/A #N/A #N/A #N/A #N/A 0 1994/01/27 1994/05/26 2005/08/19
H736 B M 36 2002/10/11 2002/12/06 2003/02/19 2003/04/16 2003/06/13 2003/08/13 2003/10/08 2003/12/03 2005/08/19
H737 B M 36 #N/A #N/A #N/A #N/A #N/A #N/A 0 1999/05/07 2005/08/22
H738 W M 42 #N/A #N/A #N/A #N/A #N/A 0 1995/01/03 1995/07/03 2005/08/24
H739 B F 35 #N/A #N/A #N/A #N/A #N/A #N/A 0 1995/02/23 2005/08/27
H740 B M 38 #N/A #N/A #N/A #N/A #N/A #N/A 0 1995/11/24 2005/08/27
H741 B F 20 #N/A #N/A #N/A #N/A #N/A #N/A 0 2004/04/15 2005/08/30
H742 B M 27 2002/09/05 2003/01/03 2003/12/17 2004/02/16 2004/04/15 2004/06/15 2004/08/30 2005/01/17 2005/08/30
H743 W M 39 1997/12/23 2000/07/29 2000/12/10 2001/02/15 2001/06/29 2001/09/01 2001/11/03 2002/01/02 2005/09/02
H744 B M 29 #N/A #N/A 0 1993/03/25 1993/09/09 1999/08/18 2000/09/08 2001/12/18 2005/09/03
H745 W M 35 #N/A #N/A #N/A #N/A #N/A #N/A 0 1993/03/08 2005/09/03
H746 W M 22 #N/A #N/A #N/A #N/A 0 1998/05/13 1998/09/09 1999/11/25 2005/09/10
H747 B F 48 1997/12/02 1998/01/27 1998/03/24 1998/07/07 1998/09/08 1998/11/10 1999/03/02 1999/08/03 2005/09/22
H748 B M 46 2001/11/15 2002/11/04 2003/02/17 2003/05/12 2003/11/17 2004/01/26 2004/03/29 2004/06/07 2005/10/03
H749 B F 16 #N/A #N/A #N/A #N/A #N/A #N/A 0 2005/04/12 2005/10/04
H750 W M 50 2004/05/27 2004/07/22 2004/09/16 2004/11/11 2005/01/06 2005/04/28 2005/06/23 2005/08/18 2005/10/13
H751 B F 52 #N/A #N/A #N/A #N/A #N/A #N/A 0 2005/07/20 2005/10/14
H752 W F 38 2004/04/20 2004/06/15 2004/08/17 2004/12/06 2005/02/15 2005/04/19 2005/06/14 2005/08/16 2005/10/18
H753 B F 31 #N/A #N/A #N/A 0 1997/03/20 1999/04/17 2000/11/29 2001/10/04 2005/10/19
H754 B M 45 #N/A #N/A #N/A #N/A #N/A 0 1998/09/03 1999/02/09 2005/10/19
H755 B M 22 #N/A #N/A #N/A 0 1999/05/28 1999/07/28 1999/10/20 2000/10/04 2005/10/21
H756 C M 32 #N/A #N/A #N/A #N/A 0 1997/10/16 1998/10/13 1999/04/13 2005/10/21
H757 A F 35 #N/A #N/A #N/A #N/A 0 2002/04/24 2002/06/20 2002/10/23 2005/10/25
H758 B M 30 #N/A #N/A #N/A #N/A #N/A #N/A 0 2005/07/13 2005/10/26
H759 B M 48 2001/07/27 2002/09/27 2002/11/29 2003/01/31 2003/05/30 2003/07/25 2004/10/01 2005/02/25 2005/10/28
H760 W M 62 1999/01/06 1999/04/19 1999/11/08 2000/02/07 2000/04/10 2000/05/22 2000/09/18 2001/01/16 2005/11/03
H761 B M 40 1996/07/09 1996/09/10 1997/03/18 1997/05/13 1997/07/07 1998/03/26 1998/07/06 1998/10/26 2005/11/08
H762 W F 37 #N/A #N/A #N/A #N/A #N/A #N/A 0 1997/05/22 2005/11/11
H763 B M 48 #N/A #N/A #N/A #N/A #N/A #N/A 0 1998/01/12 2005/11/17
H764 C F 32 #N/A #N/A #N/A #N/A #N/A 0 1996/08/22 2005/05/15 2005/11/18
H765 W F 38 2001/05/28 2014/07/30 2001/10/01 2004/04/01 2004/11/20 2005/01/15 2005/03/12 2005/06/20 2005/11/19
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H766 B F 28 #N/A #N/A #N/A #N/A #N/A #N/A 0 2002/11/09 2005/11/26
H767 W M 41 1997/12/02 1998/02/03 1998/05/19 1998/12/15 2001/02/03 2001/04/29 2001/09/19 2002/09/03 2005/11/27
H768 W F 16 #N/A #N/A #N/A #N/A #N/A 0 2005/05/12 2005/08/12 2005/11/28
H769 B M 28 #N/A #N/A #N/A #N/A #N/A 0 1995/02/24 1996/05/02 2005/11/30
H770 W M 31 2002/06/19 2002/08/21 2002/09/18 2002/11/20 2003/01/22 2003/03/19 2003/05/21 2003/07/23 2005/12/07
H771 W F 37 2002/07/23 2003/01/28 2003/05/27 2003/09/23 2004/05/25 2004/07/21 2004/12/22 2005/02/16 2005/12/07
H772 C M 52 2003/01/17 2003/03/22 2003/08/02 2003/11/15 2004/05/17 2004/10/22 2004/12/18 2005/02/12 2005/12/07
H773 C F 33 #N/A #N/A #N/A #N/A #N/A #N/A 0 2001/05/28 2005/12/10
H774 B F 25 #N/A #N/A #N/A #N/A #N/A #N/A 0 2005/04/19 2005/12/14
H775 W M 28 2001/04/09 2002/01/04 2002/03/18 2002/07/10 2002/09/17 2002/11/25 2003/01/22 2003/04/29 2005/12/16
H776 B M 38 0 1999/09/01 1999/11/18 2000/01/18 2000/08/26 2000/10/31 2001/02/13 2001/04/11 2005/12/23
H777 W M 23 2003/07/30 2003/10/01 2003/11/26 2004/06/02 2004/08/18 2004/11/03 2004/12/29 2005/04/13 2006/01/03
H778 W M 50 #N/A #N/A #N/A #N/A #N/A #N/A 0 2005/10/19 2006/01/04
H779 W M 45 1994/05/30 1994/11/15 1995/05/09 1995/07/11 1997/06/01 1999/02/07 1999/05/25 1999/10/15 2006/01/12
H780 B F 49 #N/A #N/A #N/A #N/A #N/A 0 2004/04/05 2004/05/31 2006/01/23
H781 W F 44 #N/A #N/A #N/A #N/A #N/A 0 2000/11/17 2001/01/12 2006/01/24
H782 W M 28 2004/08/26 2004/10/28 2005/01/27 2005/03/31 2005/05/26 2005/07/28 2005/09/29 2005/11/24 2006/01/26
H783 B F 35 #N/A 0 2000/04/20 2003/10/02 2004/01/22 2004/03/18 2004/07/08 2004/09/23 2006/01/26
H784 C M 38 2002/01/18 2002/03/15 2002/09/20 2002/11/15 2003/01/17 2003/03/14 2003/05/16 2003/07/18 2006/01/27
H785 W F 28 2004/05/13 2004/09/03 2004/11/11 2005/01/13 2005/04/10 2005/07/27 2005/10/03 2005/12/01 2006/01/28
H786 B M 40 #N/A #N/A #N/A #N/A #N/A 0 2005/09/29 2005/11/28 2006/02/02
H787 B F 35 #N/A #N/A #N/A #N/A #N/A 0 1999/03/03 1999/04/28 2006/02/07
H788 C M 27 #N/A #N/A #N/A 0 1995/02/09 1995/05/11 1995/08/23 1996/02/06 2006/02/09
H789 B F 26 #N/A #N/A #N/A #N/A #N/A #N/A 0 2000/05/08 2006/02/13
H790 W M 23 1999/07/01 1999/08/27 1999/11/25 2000/01/31 2000/03/28 2000/07/28 2001/07/01 2001/12/22 2006/02/14
H791 B M 26 2004/05/24 2004/07/19 2004/09/14 2005/01/03 2005/03/10 2005/05/31 2005/06/27 2005/12/19 2006/02/14
H792 B F 39 2002/08/23 2003/02/07 2003/10/10 2004/01/30 2004/05/21 2004/07/16 2004/09/17 2004/11/23 2006/02/17
H793 W M 43 #N/A #N/A 0 2001/08/27 2001/10/15 2001/12/10 2002/02/11 2002/04/15 2006/02/20
H794 B M 36 #N/A #N/A #N/A #N/A 0 2003/10/07 2005/02/21 2005/10/11 2006/02/21
H795 B F 19 #N/A #N/A #N/A #N/A #N/A 0 2005/01/27 2005/04/06 2006/02/22
H796 B F 24 #N/A #N/A #N/A #N/A #N/A 0 2004/10/15 2005/12/08 2006/02/23
H797 W M 38 1992/09/15 1993/01/19 1993/03/16 1993/09/25 1994/02/22 1994/11/15 1995/02/10 1995/04/18 2006/02/25
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H798 W M 51 1993/06/24 1993/08/20 1993/11/18 1994/02/14 1994/06/28 1994/11/15 1995/05/03 1995/07/11 2006/02/25
H799 B F 19 #N/A #N/A #N/A #N/A 0 2005/02/10 2005/05/10 2005/10/19 2006/02/28
H800 B F 44 #N/A #N/A 0 1999/12/03 2000/01/28 2000/03/31 2001/08/03 2001/11/13 2006/03/07
H801 C F 24 #N/A #N/A #N/A #N/A #N/A 0 1998/02/03 1998/04/06 2006/03/10
H802 B F 30 2000/04/12 2000/06/14 2000/10/13 2002/08/15 2002/11/06 2004/09/02 2004/11/02 2005/04/22 2006/03/11
H803 B F 23 #N/A #N/A #N/A 0 2000/09/19 2001/04/12 2003/10/08 2004/01/30 2006/03/13
H804 C F 28 #N/A #N/A #N/A #N/A #N/A #N/A 0 1994/12/28 2006/03/17
H805 W M 27 2001/01/17 2001/03/17 2001/07/02 2001/08/27 2001/10/24 2002/02/11 2002/04/08 2002/06/03 2006/03/23
H806 B F 34 #N/A #N/A #N/A #N/A #N/A 0 1996/02/27 1996/10/01 2006/03/26
H807 B M 18 #N/A #N/A #N/A #N/A 0 2004/04/30 2005/04/08 2005/07/22 2006/03/29
H808 W M 23 2001/10/10 2002/02/11 2002/07/25 2002/10/28 2003/01/22 2003/05/29 2003/10/16 2005/08/29 2006/04/05
H809 B M 29 #N/A #N/A #N/A #N/A #N/A 0 2004/11/25 2005/02/09 2006/04/12
H810 B M 35 #N/A 0 1995/05/12 1995/07/07 1996/01/12 1996/03/14 1996/05/16 1997/04/05 2006/04/20
H811 B F 33 #N/A #N/A #N/A 0 1998/01/22 1998/05/21 1998/07/23 1998/09/17 2006/04/21
H812 B F 32 #N/A #N/A 0 1996/02/16 1996/04/13 1996/07/30 1998/02/21 1998/04/25 2006/04/23
H813 C F 24 #N/A #N/A #N/A #N/A #N/A #N/A 0 1999/09/23 2006/04/26
H814 B M 39 #N/A #N/A #N/A #N/A 0 1996/08/02 1998/02/04 1999/02/02 2006/04/28
H815 W M 57 2002/05/02 2002/08/23 2002/10/18 2002/12/13 2003/06/12 2004/05/14 2004/08/06 2005/07/08 2006/04/29
H816 B F 33 #N/A #N/A #N/A #N/A #N/A #N/A 0 1993/04/30 2006/05/12
H817 W F 42 1997/12/03 1998/02/12 1998/04/14 1998/06/25 1998/08/28 1998/12/01 1999/03/24 2003/09/16 2006/05/19
H818 B M 36 #N/A #N/A #N/A #N/A #N/A 0 2003/11/29 2005/08/30 2006/06/01
H819 B M 34 #N/A #N/A #N/A #N/A #N/A #N/A 0 2006/02/09 2006/06/08
H820 W M 53 #N/A #N/A #N/A #N/A #N/A #N/A 0 1997/11/21 2006/06/09
H821 B F 52 1996/10/19 1997/05/06 1997/07/01 1997/08/26 1998/01/08 1998/03/05 1998/05/29 1998/09/03 2006/06/12
H822 C F 34 #N/A 0 1996/12/30 1998/04/02 1998/06/29 1998/09/30 1998/11/30 2006/01/16 2006/06/16
H823 C F 35 2002/07/04 2004/03/30 2004/12/09 2005/03/31 2005/05/26 2005/09/15 2006/02/22 2006/04/19 2006/06/20
H824 B M 53 #N/A #N/A #N/A #N/A #N/A #N/A 0 2006/02/01 2006/06/20
H825 B M 42 #N/A #N/A #N/A #N/A #N/A #N/A 0 1996/09/25 2006/06/22
H826 W M 27 2002/06/14 2002/10/18 2002/12/13 2003/02/14 2003/06/20 2004/02/04 2004/04/07 2004/06/08 2006/06/24
H827 C M 53 #N/A #N/A 0 1995/10/12 2002/11/14 2003/07/17 2003/11/06 2004/03/18 2006/07/08
H828 W F 39 #N/A #N/A #N/A #N/A #N/A 0 1999/03/05 1999/03/30 2006/07/13
H829 B M 49 #N/A #N/A #N/A #N/A #N/A #N/A 0 1997/07/09 2006/07/18
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H830 B M 50 #N/A #N/A #N/A #N/A #N/A 0 1994/10/05 1995/09/06 2006/07/18
H831 B F 29 1996/02/16 1997/02/05 1997/04/08 1997/06/25 1997/12/04 1998/02/05 2001/01/26 2001/03/29 2006/07/20
H832 B F 18 #N/A #N/A #N/A #N/A #N/A 0 2005/07/15 2006/04/28 2006/07/21
H833 B F 21 #N/A #N/A #N/A #N/A #N/A #N/A 0 2006/04/24 2006/07/21
H834 B F 52 #N/A #N/A #N/A #N/A #N/A #N/A 0 1994/04/16 2006/07/25
H835 W M 30 #N/A #N/A #N/A #N/A 0 1994/05/07 1999/11/26 2000/09/15 2006/07/29
H836 W M 44 2004/03/12 2004/09/21 2004/12/21 2005/02/15 2005/06/21 2005/09/20 2005/11/15 2006/01/24 2006/07/29
H837 B F 18 #N/A #N/A #N/A #N/A #N/A 0 2005/08/25 2005/10/20 2006/07/31
H838 W M 36 2000/10/29 2001/04/23 2001/07/10 2001/12/20 2002/01/31 2002/03/28 2003/01/29 2004/02/19 2006/07/31
H839 B M 61 0 1993/03/30 1993/06/17 1994/12/13 1995/03/29 1995/09/27 1996/09/04 1997/06/24 2006/07/31
H840 C F 17 #N/A #N/A #N/A #N/A #N/A #N/A 0 2005/03/09 2006/08/01
H841 B M 30 #N/A #N/A #N/A 0 2005/06/28 2005/09/05 2005/11/07 2006/02/27 2006/08/07
H842 C M 39 1993/11/03 1994/05/25 1994/10/07 1995/02/08 1995/05/03 1996/01/02 1996/03/22 1996/07/15 2006/08/14
H843 B M 18 #N/A #N/A #N/A #N/A 0 2006/01/11 2006/03/08 2006/05/05 2006/08/18
H844 B M 24 #N/A #N/A #N/A #N/A #N/A 0 2001/09/08 2002/05/21 2006/08/18
H845 B M 35 1997/11/17 1998/01/12 1998/03/16 1998/05/11 1998/07/13 1998/09/14 1998/11/16 1999/03/16 2006/08/18
H846 B M 27 #N/A #N/A #N/A #N/A 0 1998/12/18 1999/02/20 1999/04/17 2006/08/19
H847 B M 57 #N/A #N/A #N/A #N/A #N/A #N/A 0 1996/08/14 2006/08/21
H848 B M 28 #N/A #N/A #N/A #N/A #N/A 0 2005/08/19 2005/11/16 2006/08/25
H849 B F 34 #N/A #N/A #N/A #N/A #N/A 0 2005/08/29 2005/10/24 2006/08/28
H850 C F 31 1999/01/14 1999/03/12 1999/05/24 1999/08/18 2002/02/18 2002/04/15 2002/09/18 2003/02/14 2006/09/05
H851 W F 34 2003/02/08 2003/06/11 2003/09/10 2003/11/06 2004/01/02 2004/03/25 2004/05/27 2004/07/30 2006/09/05
H852 B M 33 #N/A #N/A #N/A #N/A #N/A #N/A 0 1995/11/20 2006/09/07
H853 W M 48 #N/A #N/A #N/A #N/A #N/A 0 2006/03/11 2006/06/07 2006/09/09
H854 B F 16 #N/A #N/A #N/A #N/A #N/A #N/A 0 2005/10/11 2006/09/12
H855 C F 29 #N/A #N/A #N/A #N/A #N/A 0 2002/08/01 2005/10/15 2006/09/14
H856 B M 41 #N/A #N/A #N/A #N/A #N/A #N/A 0 2005/03/13 2006/09/15
H857 W M 30 2001/04/09 2001/06/06 2001/12/14 2002/08/30 2003/03/07 2003/08/13 2004/04/02 2004/11/03 2006/09/25
H858 B M 41 #N/A #N/A #N/A #N/A #N/A #N/A 0 1997/10/30 2006/09/26
H859 W F 33 1995/06/05 1995/10/23 1996/09/04 1997/08/04 1997/10/07 1997/12/02 2004/10/04 2006/06/12 2006/10/02
H860 W M 43 #N/A #N/A #N/A #N/A #N/A #N/A 0 2002/07/19 2006/10/03
H861 B M 36 #N/A #N/A #N/A #N/A #N/A #N/A 0 2006/04/28 2006/10/04
Ethnic* Sex**
Age 
HIV 
Pos
8th Prev. 
Test Date
7th Prev. 
Test Date
6th Prev. 
Test Date
5th Prev. 
Test Date
4th Prev. 
Test Date
3rd Prev. 
Test Date
2nd Prev. 
Test Date
Prev. Test 
Date
Date HIV 
Pos. 
Donation
DEMOGRAPHICS TEST / DONATION DATES
Donation 
Serial No
H862 B M 37 2003/02/13 2003/04/10 2004/02/05 2004/08/05 2004/10/07 2006/02/09 2006/06/08 2006/08/10 2006/10/05
H863 B F 37 #N/A #N/A #N/A #N/A #N/A 0 1998/05/15 1999/01/20 2006/10/05
H864 W F 33 #N/A #N/A #N/A #N/A #N/A 0 1996/03/27 1996/07/24 2006/10/11
H865 B M 25 #N/A #N/A #N/A #N/A 0 2005/08/07 2006/02/19 2006/06/25 2006/10/15
B = Black / African
C = Coloured
W = White / Caucasian
Ethnic* Sex** F = Female
M = Male
A = Asian
APPENDIX 3: HIV-positive donations received by SANBS, Bloemfontein between October 2004 and September 2005
Ethnic* Sex** Age Blood Group
8th Prev. 
Test Date
7th Prev. 
Test Date
6th Prev. 
Test Date
5th Prev. 
Test Date
4th Prev. 
Test Date
3rd Prev. 
Test Date
2nd Prev. 
Test Date
Prev. Test 
Date
Present 
Donation 
Date
SABTS 
1999 
Model
Donation 
Interval 
Model
Combination 
Model
SANBS 
2005 
Model
Age-
based 
Model
01501 B M 24 ABPos 2002/02/15 2002/05/03 2002/07/29 2002/10/08 2003/02/04 2003/05/08 2003/08/01 2003/09/26 2004/10/18 A4 DI4 Cb4 C AC3 Pos
03228 C M 37 APos #N/A #N/A #N/A #N/A #N/A #N/A #N/A 0 2004/11/09 A3 DI4 Cb3 P AC5 Pos
03562 B M 30 APos #N/A #N/A #N/A #N/A #N/A #N/A #N/A 0 2004/11/12 A4 DI4 Cb4 P AC5 Pos
06142 W M 23 OPos #N/A #N/A #N/A #N/A #N/A #N/A #N/A 0 2004/12/11 A2 DI4 Cb2 PLR2 AC5 Pos
08643 W M 57 ABPos 1995/02/02 1995/11/13 1996/04/01 1996/07/23 1996/09/23 1996/12/06 1997/07/03 1997/10/06 2005/01/24 A2 DI4 Cb2 PLR1 AC5 Pos
09730 C F 45 ONeg 1999/10/11 1999/12/30 2000/06/29 2000/10/12 2001/01/29 2002/05/08 2004/05/11 2004/08/05 2005/02/04 A2 DI4 Cb3 R AC1 Pos
10565 C F 35 OPos 1994/01/20 1994/03/24 1994/05/19 1994/09/22 1996/06/19 1996/08/21 1996/10/16 1997/02/19 2005/02/16 A3 DI4 Cb3 PLR1 AC5 Pos
11076 B F 31 OPos #N/A #N/A #N/A #N/A 0 2000/11/09 2001/06/28 2001/08/30 2005/02/24 A4 DI4 Cb4 PLR1 AC5 Pos
11758 B F 22 OPos #N/A #N/A #N/A #N/A #N/A #N/A 0 1999/10/07 2005/03/07 A4 DI4 Cb4 PLR1 AC5 Pos
12107 B M 51 OPos 2003/04/24 2003/11/07 2004/01/05 2004/03/10 2004/05/19 2004/07/23 2004/10/04 2005/01/10 2005/03/11 A3 DI1 Cb1 C AC1 Pos
15305 W M 38 APos 1995/10/31 1996/05/28 1996/09/17 1997/03/11 1997/05/06 1997/09/02 1997/11/04 1998/03/03 2005/04/20 A2 DI4 Cb2 PLR1 AC5 Pos
16342 B M 37 APos 1998/10/05 1998/12/31 1999/07/19 1999/11/03 2000/04/07 2000/06/12 2001/05/18 2001/11/20 2005/05/07 A4 DI4 Cb4 PLR1 AC5 Pos
17114 B M 48 APos 1998/09/02 1998/11/04 1999/01/13 1999/03/10 1999/05/05 1999/09/01 1999/11/03 2000/01/20 2005/05/18 A4 DI4 Cb4 PLR1 AC5 Pos
21654 W M 23 OPos #N/A #N/A #N/A #N/A #N/A #N/A #N/A 0 2005/07/27 A2 DI4 Cb2 PLR2 AC5 Pos
24205 B M 28 APos #N/A #N/A #N/A #N/A #N/A #N/A #N/A 0 2005/08/30 A4 DI4 Cb4 P AC5 Pos
24482 W F 30 OPos #N/A #N/A #N/A #N/A #N/A #N/A #N/A 0 2005/08/31 A2 DI4 Cb2 P AC5 Pos
26416 B M 60 BPos #N/A #N/A #N/A #N/A #N/A #N/A #N/A 0 2005/09/29 A4 DI4 Cb4 P AC5 Pos
W = White / Caucasian
Donation 
Serial No
DEMOGRAPHICS TEST / DONATION DATES Conf. 
HIV 
Result
DONATION CATEGORIZATION STUDY: BLOEMFONTEIN VOLUNTARY DONATIONS - Confirmed HIV-positive donations: Oct 2004 - Sept 2005
Ethnic* A = Asian Sex** F = Female
B = Black / African M = Male
C = Coloured
MODEL RISK CATEGORIZATIONS
APPENDIX 4: Risk categorization of the last donations prior to the HIV-positive donations received by SANBS, Bloemfontein between October 2004 and September 2005
Ethnic* Sex** Age Blood Group
8th Prev. 
Test Date
7th Prev. 
Test Date
6th Prev. 
Test Date
5th Prev. 
Test Date
4th Prev. 
Test Date
3rd Prev. 
Test Date
2nd Prev. 
Test Date
Prev. Test 
Date
Present 
Donation 
Date
SABTS 
1999 
Model
Donation 
Interval 
Model
Combination 
Model
SANBS 
2005 
Model
Age-
based 
Model
01501 B M 23 ABPos 2001/11/16 2002/02/15 2002/05/03 2002/07/29 2002/10/08 2003/02/04 2003/05/08 2003/08/01 2003/09/26 A3 DI1 Cb1 C AC3
08643 W M 50 ABPos 1994/11/15 1995/02/02 1995/11/13 1996/04/01 1996/07/23 1996/09/23 1996/12/06 1997/07/03 1997/10/06 A1 DI1 Cb1 C AC1
09730 C F 45 ONeg 1998/12/03 1999/10/11 1999/12/30 2000/06/29 2000/10/12 2001/01/29 2002/05/08 2004/05/11 2004/08/05 A2 DI3 Cb2 R AC1
10565 C F 27 OPos 1993/09/16 1994/01/20 1994/03/24 1994/05/19 1994/09/22 1996/06/19 1996/08/21 1996/10/16 1997/02/19 A2 DI2 Cb1 R AC3
11076 B F 28 OPos #N/A #N/A #N/A #N/A #N/A 0 2000/11/09 2001/06/28 2001/08/30 A3 DI3 Cb3 R AC2
11758 B F 16 OPos #N/A #N/A #N/A #N/A #N/A #N/A #N/A 0 1999/10/07 A4 DI4 Cb4 PLR3 AC5
12107 B M 51 OPos 2003/02/20 2003/04/24 2003/11/07 2004/01/05 2004/03/10 2004/05/19 2004/07/23 2004/10/04 2005/01/10 A3 DI1 Cb1 C AC1
15305 W M 31 APos 1995/09/05 1995/10/31 1996/05/28 1996/09/17 1997/03/11 1997/05/06 1997/09/02 1997/11/04 1998/03/03 A1 DI1 Cb1 C AC3
16342 B M 34 APos 1998/06/29 1998/10/05 1998/12/31 1999/07/19 1999/11/03 2000/04/07 2000/06/12 2001/05/18 2001/11/20 A3 DI3 Cb3 R AC3
17114 B M 42 APos 1998/07/01 1998/09/02 1998/11/04 1999/01/13 1999/03/10 1999/05/05 1999/09/01 1999/11/03 2000/01/20 A3 DI1 Cb1 C AC1
Ethnic* A = Asian Sex** F = Female
B = Black / African M = Male
C = Coloured
W = White / Caucasian
DONATION CATEGORIZATION STUDY: BLOEMFONTEIN HIV POSITIVE DONATIONS 1004 - 0905 - PREVIOUS DONATIONS
Donation 
Serial No
DEMOGRAPHICS TEST / DONATION DATES MODEL RISK CATEGORIZATIONS
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Conf. HIV 
Result
